<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2021v4.2">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2023-02-07T15:59:44-06:00</ReturnTs>
    <TaxPeriodEndDt>2022-03-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>873231666</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>PKF O'CONNOR DAVIES ADVISORY LLC</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>245 PARK AVENUE 12TH FLOOR</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10167</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990PF</ReturnTypeCd>
    <TaxPeriodBeginDt>2021-04-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>137184401</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>THE LEONA M AND HARRY B HELMSLEY</BusinessNameLine1Txt>
        <BusinessNameLine2Txt>CHARITABLE TRUST</BusinessNameLine2Txt>
      </BusinessName>
      <BusinessNameControlTxt>LEON</BusinessNameControlTxt>
      <PhoneNum>2126793600</PhoneNum>
      <USAddress>
        <AddressLine1Txt>230 PARK AVENUE 659</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10169</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>NICHOLAS J SCHIAVO</PersonNm>
      <PersonTitleTxt>CFO</PersonTitleTxt>
      <PhoneNum>2126793600</PhoneNum>
      <SignatureDt>2023-02-01</SignatureDt>
      <DiscussWithPaidPreparerInd>1</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <SigningOfficerGrp>
      <PersonFullName>
        <PersonFirstNm>NICHOLAS</PersonFirstNm>
        <PersonLastNm>SCHIAVO</PersonLastNm>
      </PersonFullName>
      <SSN>XXX-XX-XXXX</SSN>
    </SigningOfficerGrp>
    <PreparerPersonGrp>
      <PreparerPersonNm>THOMAS BLANEY</PreparerPersonNm>
      <PTIN>P00234022</PTIN>
      <PhoneNum>2122862600</PhoneNum>
      <PreparationDt>2023-02-01</PreparationDt>
    </PreparerPersonGrp>
    <AdditionalFilerInformation>
      <TrustedCustomerGrp>
        <TrustedCustomerCd>3</TrustedCustomerCd>
        <AuthenticationAssuranceLevelCd>AAL1</AuthenticationAssuranceLevelCd>
        <IdentityAssuranceLevelCd>IAL1</IdentityAssuranceLevelCd>
      </TrustedCustomerGrp>
    </AdditionalFilerInformation>
    <TaxYr>2021</TaxYr>
    <BuildTS>2023-03-07 01:45:13Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="19">
    <IRS990PF documentId="RetDoc1235000001" referenceDocumentId="RetDoc2258700001">
      <Organization501c3ExemptPFInd>X</Organization501c3ExemptPFInd>
      <FMVAssetsEOYAmt>8221675612</FMVAssetsEOYAmt>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AnalysisOfRevenueAndExpenses>
        <ScheduleBNotRequiredInd>X</ScheduleBNotRequiredInd>
        <InterestOnSavRevAndExpnssAmt>17175</InterestOnSavRevAndExpnssAmt>
        <InterestOnSavNetInvstIncmAmt>17175</InterestOnSavNetInvstIncmAmt>
        <DividendsRevAndExpnssAmt>36631242</DividendsRevAndExpnssAmt>
        <DividendsNetInvstIncmAmt>129538579</DividendsNetInvstIncmAmt>
        <NetGainSaleAstRevAndExpnssAmt>761645902</NetGainSaleAstRevAndExpnssAmt>
        <GrossSalesPriceAmt>1837772977</GrossSalesPriceAmt>
        <CapGainNetIncmNetInvstIncmAmt>713350607</CapGainNetIncmNetInvstIncmAmt>
        <OtherIncomeRevAndExpnssAmt referenceDocumentId="RetDoc2001500001">41198822</OtherIncomeRevAndExpnssAmt>
        <OtherIncomeNetInvstIncmAmt>279081117</OtherIncomeNetInvstIncmAmt>
        <TotalRevAndExpnssAmt>839493141</TotalRevAndExpnssAmt>
        <TotalNetInvstIncmAmt>1121987478</TotalNetInvstIncmAmt>
        <CompOfcrDirTrstRevAndExpnssAmt>4376425</CompOfcrDirTrstRevAndExpnssAmt>
        <CompOfcrDirTrstNetInvstIncmAmt>1691434</CompOfcrDirTrstNetInvstIncmAmt>
        <CompOfcrDirTrstDsbrsChrtblAmt>2196238</CompOfcrDirTrstDsbrsChrtblAmt>
        <OthEmplSlrsWgsRevAndExpnssAmt>15931176</OthEmplSlrsWgsRevAndExpnssAmt>
        <OthEmplSlrsWgsNetInvstIncmAmt>5200197</OthEmplSlrsWgsNetInvstIncmAmt>
        <OthEmplSlrsWgsDsbrsChrtblAmt>10353131</OthEmplSlrsWgsDsbrsChrtblAmt>
        <PensionEmplBnftRevAndExpnssAmt>7356974</PensionEmplBnftRevAndExpnssAmt>
        <PensionEmplBnftNetInvstIncmAmt>1775482</PensionEmplBnftNetInvstIncmAmt>
        <PensionEmplBnftDsbrsChrtblAmt>5487497</PensionEmplBnftDsbrsChrtblAmt>
        <LegalFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002100001">446869</LegalFeesRevAndExpnssAmt>
        <LegalFeesNetInvstIncmAmt>240534</LegalFeesNetInvstIncmAmt>
        <LegalFeesDsbrsChrtblAmt>171108</LegalFeesDsbrsChrtblAmt>
        <AccountingFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002200001">618474</AccountingFeesRevAndExpnssAmt>
        <AccountingFeesNetInvstIncmAmt>288521</AccountingFeesNetInvstIncmAmt>
        <AccountingFeesChrtblPrpsAmt>280539</AccountingFeesChrtblPrpsAmt>
        <OtherProfFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002300001">9031764</OtherProfFeesRevAndExpnssAmt>
        <OtherProfFeesNetInvstIncmAmt>6537533</OtherProfFeesNetInvstIncmAmt>
        <OtherProfFeesDsbrsChrtblAmt>2576991</OtherProfFeesDsbrsChrtblAmt>
        <InterestNetInvstIncmAmt>1565857</InterestNetInvstIncmAmt>
        <TaxesRevAndExpnssAmt referenceDocumentId="RetDoc2002500001">16033503</TaxesRevAndExpnssAmt>
        <TaxesNetInvstIncmAmt>3095765</TaxesNetInvstIncmAmt>
        <TaxesDsbrsChrtblAmt>0</TaxesDsbrsChrtblAmt>
        <DeprecAndDpltnRevAndExpnssAmt>412792</DeprecAndDpltnRevAndExpnssAmt>
        <DeprecAndDpltnNetInvstIncmAmt>23687</DeprecAndDpltnNetInvstIncmAmt>
        <OccupancyRevAndExpnssAmt>1118651</OccupancyRevAndExpnssAmt>
        <OccupancyNetInvstIncmAmt>5163</OccupancyNetInvstIncmAmt>
        <OccupancyDsbrsChrtblAmt>1067322</OccupancyDsbrsChrtblAmt>
        <TravConfMeetingRevAndExpnssAmt>401351</TravConfMeetingRevAndExpnssAmt>
        <TravConfMeetingNetInvstIncmAmt>33206</TravConfMeetingNetInvstIncmAmt>
        <TravConfMeetingDsbrsChrtblAmt>266155</TravConfMeetingDsbrsChrtblAmt>
        <OtherExpensesRevAndExpnssAmt referenceDocumentId="RetDoc2003200001">23083802</OtherExpensesRevAndExpnssAmt>
        <OtherExpensesNetInvstIncmAmt>52769729</OtherExpensesNetInvstIncmAmt>
        <OtherExpensesDsbrsChrtblAmt>2101380</OtherExpensesDsbrsChrtblAmt>
        <TotOprExpensesRevAndExpnssAmt>78811781</TotOprExpensesRevAndExpnssAmt>
        <TotOprExpensesNetInvstIncmAmt>73227108</TotOprExpensesNetInvstIncmAmt>
        <TotOprExpensesDsbrsChrtblAmt>24500361</TotOprExpensesDsbrsChrtblAmt>
        <ContriPaidRevAndExpnssAmt>461305969</ContriPaidRevAndExpnssAmt>
        <ContriPaidDsbrsChrtblAmt>385014429</ContriPaidDsbrsChrtblAmt>
        <TotalExpensesRevAndExpnssAmt>540117750</TotalExpensesRevAndExpnssAmt>
        <TotalExpensesNetInvstIncmAmt>73227108</TotalExpensesNetInvstIncmAmt>
        <TotalExpensesDsbrsChrtblAmt>409514790</TotalExpensesDsbrsChrtblAmt>
        <ExcessRevenueOverExpensesAmt>299375391</ExcessRevenueOverExpensesAmt>
        <NetInvestmentIncomeAmt>1048760370</NetInvestmentIncomeAmt>
      </AnalysisOfRevenueAndExpenses>
      <Form990PFBalanceSheetsGrp>
        <CashBOYAmt>32275203</CashBOYAmt>
        <CashEOYAmt>27238568</CashEOYAmt>
        <CashEOYFMVAmt>27238568</CashEOYFMVAmt>
        <SavAndTempCashInvstBOYAmt>62457618</SavAndTempCashInvstBOYAmt>
        <SavAndTempCashInvstEOYAmt>53717402</SavAndTempCashInvstEOYAmt>
        <SavAndTempCashInvstEOYFMVAmt>53717402</SavAndTempCashInvstEOYFMVAmt>
        <AcctRcvblAmt>449759</AcctRcvblAmt>
        <AcctRcvblEOYAmt>449759</AcctRcvblEOYAmt>
        <AcctRcvblEOYFMVAmt>449759</AcctRcvblEOYFMVAmt>
        <PrepaidExpensesBOYAmt>1132903</PrepaidExpensesBOYAmt>
        <PrepaidExpensesEOYAmt>993143</PrepaidExpensesEOYAmt>
        <PrepaidExpensesEOYFMVAmt>993143</PrepaidExpensesEOYFMVAmt>
        <CorporateStockBOYAmt>736377294</CorporateStockBOYAmt>
        <CorporateStockEOYAmt referenceDocumentId="RetDoc2018900001">591948988</CorporateStockEOYAmt>
        <CorporateStockEOYFMVAmt>591948988</CorporateStockEOYFMVAmt>
        <OtherInvestmentsBOYAmt>7438326657</OtherInvestmentsBOYAmt>
        <OtherInvestmentsEOYAmt referenceDocumentId="RetDoc2018100001">7406511362</OtherInvestmentsEOYAmt>
        <OtherInvestmentsEOYFMVAmt>7406511362</OtherInvestmentsEOYFMVAmt>
        <LandBldgEquipCostOrOtherBssAmt>9637533</LandBldgEquipCostOrOtherBssAmt>
        <LandBldgEquipAccumDeprecAmt>2338162</LandBldgEquipAccumDeprecAmt>
        <LandBOYAmt>2756942</LandBOYAmt>
        <LandEOYAmt referenceDocumentId="RetDoc2059000001">7299371</LandEOYAmt>
        <LandEOYFMVAmt>7299371</LandEOYFMVAmt>
        <OtherAssetsBOYAmt referenceDocumentId="RetDoc2046600001">40261279</OtherAssetsBOYAmt>
        <OtherAssetsEOYAmt referenceDocumentId="RetDoc2046600001">133517019</OtherAssetsEOYAmt>
        <OtherAssetsEOYFMVAmt referenceDocumentId="RetDoc2046600001">133517019</OtherAssetsEOYFMVAmt>
        <TotalAssetsBOYAmt>8313587896</TotalAssetsBOYAmt>
        <TotalAssetsEOYAmt>8221675612</TotalAssetsEOYAmt>
        <TotalAssetsEOYFMVAmt>8221675612</TotalAssetsEOYFMVAmt>
        <AccountsPayableBOYAmt>11454781</AccountsPayableBOYAmt>
        <AccountsPayableEOYAmt>12198129</AccountsPayableEOYAmt>
        <GrantsPayableBOYAmt>385738876</GrantsPayableBOYAmt>
        <GrantsPayableEOYAmt>462030416</GrantsPayableEOYAmt>
        <OtherLiabilitiesBOYAmt referenceDocumentId="RetDoc2065700001">48968356</OtherLiabilitiesBOYAmt>
        <OtherLiabilitiesEOYAmt referenceDocumentId="RetDoc2065700001">42966460</OtherLiabilitiesEOYAmt>
        <TotalLiabilitiesBOYAmt>446162013</TotalLiabilitiesBOYAmt>
        <TotalLiabilitiesEOYAmt>517195005</TotalLiabilitiesEOYAmt>
        <OrganizationFollowsFASB117Ind>X</OrganizationFollowsFASB117Ind>
        <NoDonorRstrNetAssestsBOYAmt>7867425883</NoDonorRstrNetAssestsBOYAmt>
        <NoDonorRstrNetAssestsEOYAmt>7704480607</NoDonorRstrNetAssestsEOYAmt>
        <TotNetAstOrFundBalancesBOYAmt>7867425883</TotNetAstOrFundBalancesBOYAmt>
        <TotNetAstOrFundBalancesEOYAmt>7704480607</TotNetAstOrFundBalancesEOYAmt>
        <TotalLiabilitiesNetAstBOYAmt>8313587896</TotalLiabilitiesNetAstBOYAmt>
        <TotalLiabilitiesNetAstEOYAmt>8221675612</TotalLiabilitiesNetAstEOYAmt>
      </Form990PFBalanceSheetsGrp>
      <ChgInNetAssetsFundBalancesGrp>
        <TotNetAstOrFundBalancesBOYAmt>7867425883</TotNetAstOrFundBalancesBOYAmt>
        <ExcessRevenueOverExpensesAmt>299375391</ExcessRevenueOverExpensesAmt>
        <OtherIncreasesAmt referenceDocumentId="RetDoc2049700001">6516842</OtherIncreasesAmt>
        <SubtotalAmt>8173318116</SubtotalAmt>
        <OtherDecreasesAmt referenceDocumentId="RetDoc2049800001">468837509</OtherDecreasesAmt>
        <TotNetAstOrFundBalancesEOYAmt>7704480607</TotNetAstOrFundBalancesEOYAmt>
      </ChgInNetAssetsFundBalancesGrp>
      <CapGainsLossTxInvstIncmDetail>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SALE OF PUBLICLY TRADED SECURITIES</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>783260325</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>502142463</CostOrOtherBasisAmt>
          <GainOrLossAmt>281117862</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>281117862</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-12</SoldDt>
          <GrossSalesPriceAmt>6043498</GrossSalesPriceAmt>
          <GainOrLossAmt>6043498</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>6043498</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-23</SoldDt>
          <GrossSalesPriceAmt>5256152</GrossSalesPriceAmt>
          <GainOrLossAmt>5256152</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>5256152</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-07</SoldDt>
          <GrossSalesPriceAmt>704849</GrossSalesPriceAmt>
          <GainOrLossAmt>704849</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>704849</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-07</SoldDt>
          <GrossSalesPriceAmt>116909</GrossSalesPriceAmt>
          <GainOrLossAmt>116909</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>116909</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-02</SoldDt>
          <GrossSalesPriceAmt>100187</GrossSalesPriceAmt>
          <GainOrLossAmt>100187</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>100187</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-16</SoldDt>
          <GrossSalesPriceAmt>15765801</GrossSalesPriceAmt>
          <GainOrLossAmt>15765801</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15765801</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-29</SoldDt>
          <GrossSalesPriceAmt>7271558</GrossSalesPriceAmt>
          <GainOrLossAmt>7271558</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>7271558</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-23</SoldDt>
          <GrossSalesPriceAmt>627403</GrossSalesPriceAmt>
          <GainOrLossAmt>627403</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>627403</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-12</SoldDt>
          <GrossSalesPriceAmt>14718858</GrossSalesPriceAmt>
          <GainOrLossAmt>14718858</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>14718858</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-03</SoldDt>
          <GrossSalesPriceAmt>762599</GrossSalesPriceAmt>
          <GainOrLossAmt>762599</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>762599</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-30</SoldDt>
          <GrossSalesPriceAmt>1371954</GrossSalesPriceAmt>
          <GainOrLossAmt>1371954</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1371954</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-01</SoldDt>
          <GrossSalesPriceAmt>1927891</GrossSalesPriceAmt>
          <GainOrLossAmt>1927891</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1927891</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-27</SoldDt>
          <GrossSalesPriceAmt>844748</GrossSalesPriceAmt>
          <GainOrLossAmt>844748</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>844748</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-05</SoldDt>
          <GrossSalesPriceAmt>794475</GrossSalesPriceAmt>
          <GainOrLossAmt>794475</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>794475</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-08</SoldDt>
          <GrossSalesPriceAmt>795456</GrossSalesPriceAmt>
          <GainOrLossAmt>795456</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>795456</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-21</SoldDt>
          <GrossSalesPriceAmt>827150</GrossSalesPriceAmt>
          <GainOrLossAmt>827150</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>827150</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-09</SoldDt>
          <GrossSalesPriceAmt>898054</GrossSalesPriceAmt>
          <GainOrLossAmt>898054</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>898054</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-28</SoldDt>
          <GrossSalesPriceAmt>935520</GrossSalesPriceAmt>
          <GainOrLossAmt>935520</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>935520</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-22</SoldDt>
          <GrossSalesPriceAmt>916349</GrossSalesPriceAmt>
          <GainOrLossAmt>916349</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>916349</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-09</SoldDt>
          <GrossSalesPriceAmt>922445</GrossSalesPriceAmt>
          <GainOrLossAmt>922445</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>922445</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-13</SoldDt>
          <GrossSalesPriceAmt>1678310</GrossSalesPriceAmt>
          <GainOrLossAmt>1678310</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1678310</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-15</SoldDt>
          <GrossSalesPriceAmt>918329</GrossSalesPriceAmt>
          <GainOrLossAmt>918329</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>918329</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-07</SoldDt>
          <GrossSalesPriceAmt>3023197</GrossSalesPriceAmt>
          <GainOrLossAmt>3023197</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3023197</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-07</SoldDt>
          <GrossSalesPriceAmt>1049551</GrossSalesPriceAmt>
          <GainOrLossAmt>1049551</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1049551</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-12</SoldDt>
          <GrossSalesPriceAmt>651714</GrossSalesPriceAmt>
          <GainOrLossAmt>651714</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>651714</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-09</SoldDt>
          <GrossSalesPriceAmt>1519324</GrossSalesPriceAmt>
          <GainOrLossAmt>1519324</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1519324</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-22</SoldDt>
          <GrossSalesPriceAmt>892266</GrossSalesPriceAmt>
          <GainOrLossAmt>892266</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>892266</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-11</SoldDt>
          <GrossSalesPriceAmt>805302</GrossSalesPriceAmt>
          <GainOrLossAmt>805302</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>805302</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-15</SoldDt>
          <GrossSalesPriceAmt>1506581</GrossSalesPriceAmt>
          <GainOrLossAmt>1506581</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1506581</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-14</SoldDt>
          <GrossSalesPriceAmt>193482</GrossSalesPriceAmt>
          <GainOrLossAmt>193482</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>193482</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL INDIA V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-19</SoldDt>
          <GrossSalesPriceAmt>629258</GrossSalesPriceAmt>
          <GainOrLossAmt>629258</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>629258</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-04</SoldDt>
          <GrossSalesPriceAmt>643613</GrossSalesPriceAmt>
          <GainOrLossAmt>643613</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>643613</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-03</SoldDt>
          <GrossSalesPriceAmt>1294558</GrossSalesPriceAmt>
          <GainOrLossAmt>1294558</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1294558</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-10</SoldDt>
          <GrossSalesPriceAmt>861407</GrossSalesPriceAmt>
          <GainOrLossAmt>861407</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>861407</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-22</SoldDt>
          <GrossSalesPriceAmt>490375</GrossSalesPriceAmt>
          <GainOrLossAmt>490375</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>490375</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-08</SoldDt>
          <GrossSalesPriceAmt>1836781</GrossSalesPriceAmt>
          <GainOrLossAmt>1836781</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1836781</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-07</SoldDt>
          <GrossSalesPriceAmt>584066</GrossSalesPriceAmt>
          <GainOrLossAmt>584066</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>584066</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL XI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-08</SoldDt>
          <GrossSalesPriceAmt>549774</GrossSalesPriceAmt>
          <GainOrLossAmt>549774</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>549774</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL XI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-01</SoldDt>
          <GrossSalesPriceAmt>557760</GrossSalesPriceAmt>
          <GainOrLossAmt>557760</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>557760</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL XI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-14</SoldDt>
          <GrossSalesPriceAmt>207655</GrossSalesPriceAmt>
          <GainOrLossAmt>207655</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>207655</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL XI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-07</SoldDt>
          <GrossSalesPriceAmt>250682</GrossSalesPriceAmt>
          <GainOrLossAmt>250682</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>250682</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL XI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-09</SoldDt>
          <GrossSalesPriceAmt>552167</GrossSalesPriceAmt>
          <GainOrLossAmt>552167</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>552167</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL XI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-08</SoldDt>
          <GrossSalesPriceAmt>126456</GrossSalesPriceAmt>
          <GainOrLossAmt>126456</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>126456</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL XI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-17</SoldDt>
          <GrossSalesPriceAmt>199073</GrossSalesPriceAmt>
          <GainOrLossAmt>199073</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>199073</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL XI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-07</SoldDt>
          <GrossSalesPriceAmt>978678</GrossSalesPriceAmt>
          <GainOrLossAmt>978678</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>978678</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL XII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-20</SoldDt>
          <GrossSalesPriceAmt>1225001</GrossSalesPriceAmt>
          <GainOrLossAmt>1225001</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1225001</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL XII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-14</SoldDt>
          <GrossSalesPriceAmt>2092646</GrossSalesPriceAmt>
          <GainOrLossAmt>2092646</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2092646</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-05</SoldDt>
          <GrossSalesPriceAmt>755268</GrossSalesPriceAmt>
          <GainOrLossAmt>755268</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>755268</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-14</SoldDt>
          <GrossSalesPriceAmt>1913779</GrossSalesPriceAmt>
          <GainOrLossAmt>1913779</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1913779</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-14</SoldDt>
          <GrossSalesPriceAmt>96328</GrossSalesPriceAmt>
          <GainOrLossAmt>96328</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>96328</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-21</SoldDt>
          <GrossSalesPriceAmt>1292278</GrossSalesPriceAmt>
          <GainOrLossAmt>1292278</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1292278</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-23</SoldDt>
          <GrossSalesPriceAmt>905039</GrossSalesPriceAmt>
          <GainOrLossAmt>905039</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>905039</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-06</SoldDt>
          <GrossSalesPriceAmt>838046</GrossSalesPriceAmt>
          <GainOrLossAmt>838046</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>838046</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-19</SoldDt>
          <GrossSalesPriceAmt>2040811</GrossSalesPriceAmt>
          <GainOrLossAmt>2040811</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2040811</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-25</SoldDt>
          <GrossSalesPriceAmt>931238</GrossSalesPriceAmt>
          <GainOrLossAmt>931238</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>931238</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-09</SoldDt>
          <GrossSalesPriceAmt>858855</GrossSalesPriceAmt>
          <GainOrLossAmt>858855</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>858855</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-07</SoldDt>
          <GrossSalesPriceAmt>855947</GrossSalesPriceAmt>
          <GainOrLossAmt>855947</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>855947</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-30</SoldDt>
          <GrossSalesPriceAmt>1472731</GrossSalesPriceAmt>
          <GainOrLossAmt>1472731</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1472731</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-12</SoldDt>
          <GrossSalesPriceAmt>141753</GrossSalesPriceAmt>
          <GainOrLossAmt>141753</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>141753</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-25</SoldDt>
          <GrossSalesPriceAmt>1364143</GrossSalesPriceAmt>
          <GainOrLossAmt>1364143</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1364143</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-14</SoldDt>
          <GrossSalesPriceAmt>16413572</GrossSalesPriceAmt>
          <GainOrLossAmt>16413572</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>16413572</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-19</SoldDt>
          <GrossSalesPriceAmt>2984077</GrossSalesPriceAmt>
          <GainOrLossAmt>2984077</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2984077</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-06</SoldDt>
          <GrossSalesPriceAmt>1304066</GrossSalesPriceAmt>
          <GainOrLossAmt>1304066</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1304066</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-23</SoldDt>
          <GrossSalesPriceAmt>407573</GrossSalesPriceAmt>
          <GainOrLossAmt>407573</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>407573</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-21</SoldDt>
          <GrossSalesPriceAmt>10861471</GrossSalesPriceAmt>
          <GainOrLossAmt>10861471</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>10861471</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-05</SoldDt>
          <GrossSalesPriceAmt>337833</GrossSalesPriceAmt>
          <GainOrLossAmt>337833</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>337833</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-30</SoldDt>
          <GrossSalesPriceAmt>4222417</GrossSalesPriceAmt>
          <GainOrLossAmt>4222417</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4222417</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-07</SoldDt>
          <GrossSalesPriceAmt>2867922</GrossSalesPriceAmt>
          <GainOrLossAmt>2867922</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2867922</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-09</SoldDt>
          <GrossSalesPriceAmt>3302350</GrossSalesPriceAmt>
          <GainOrLossAmt>3302350</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3302350</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FUND V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-12</SoldDt>
          <GrossSalesPriceAmt>364128</GrossSalesPriceAmt>
          <GainOrLossAmt>364128</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>364128</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ LSV FD I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-12</SoldDt>
          <GrossSalesPriceAmt>3122023</GrossSalesPriceAmt>
          <GainOrLossAmt>3122023</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3122023</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ LSV FD I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-11</SoldDt>
          <GrossSalesPriceAmt>3122023</GrossSalesPriceAmt>
          <GainOrLossAmt>3122023</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3122023</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ LSV FD I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-13</SoldDt>
          <GrossSalesPriceAmt>3314660</GrossSalesPriceAmt>
          <GainOrLossAmt>3314660</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3314660</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ LSV FD I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-14</SoldDt>
          <GrossSalesPriceAmt>2493527</GrossSalesPriceAmt>
          <GainOrLossAmt>2493527</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2493527</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ LSV FD I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-21</SoldDt>
          <GrossSalesPriceAmt>1644627</GrossSalesPriceAmt>
          <GainOrLossAmt>1644627</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1644627</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ LSV FD I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-09</SoldDt>
          <GrossSalesPriceAmt>7951120</GrossSalesPriceAmt>
          <GainOrLossAmt>7951120</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>7951120</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ LSV FD I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-12</SoldDt>
          <CostOrOtherBasisAmt>3122023</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3122023</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3122023</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ARBORETUM IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-22</SoldDt>
          <GrossSalesPriceAmt>2970948</GrossSalesPriceAmt>
          <GainOrLossAmt>2970948</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2970948</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ARBORETUM IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-26</SoldDt>
          <GrossSalesPriceAmt>3604563</GrossSalesPriceAmt>
          <GainOrLossAmt>3604563</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3604563</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ARBORETUM IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-07</SoldDt>
          <GrossSalesPriceAmt>676144</GrossSalesPriceAmt>
          <GainOrLossAmt>676144</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>676144</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ARBORETUM VENTURES IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-26</SoldDt>
          <GrossSalesPriceAmt>2309164</GrossSalesPriceAmt>
          <GainOrLossAmt>2309164</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2309164</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ARBORETUM VENTURES IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-22</SoldDt>
          <GrossSalesPriceAmt>153564</GrossSalesPriceAmt>
          <GainOrLossAmt>153564</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>153564</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BAYVIEW OPPORTUNITY OFFSHORE IVA LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-14</SoldDt>
          <GrossSalesPriceAmt>685417</GrossSalesPriceAmt>
          <GainOrLossAmt>685417</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>685417</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-30</SoldDt>
          <GrossSalesPriceAmt>20000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>21408607</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1408607</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1408607</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-26</SoldDt>
          <GrossSalesPriceAmt>26435</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>27262</CostOrOtherBasisAmt>
          <GainOrLossAmt>-827</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-827</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-25</SoldDt>
          <GrossSalesPriceAmt>30000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>32423251</CostOrOtherBasisAmt>
          <GainOrLossAmt>-2423251</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-2423251</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-28</SoldDt>
          <GrossSalesPriceAmt>24999</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>24901</CostOrOtherBasisAmt>
          <GainOrLossAmt>98</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>98</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-27</SoldDt>
          <GrossSalesPriceAmt>26571</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>26726</CostOrOtherBasisAmt>
          <GainOrLossAmt>-155</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-155</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-10</SoldDt>
          <GrossSalesPriceAmt>21278</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>21637</CostOrOtherBasisAmt>
          <GainOrLossAmt>-359</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-359</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM ASSET HIGH YIELD OFFSHORE FUND LTD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-31</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>2926577</CostOrOtherBasisAmt>
          <GainOrLossAmt>2073423</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2073423</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM ASSET PARTNERS HIGH YIELD FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-31</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>2902961</CostOrOtherBasisAmt>
          <GainOrLossAmt>2097039</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2097039</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM ASSET PARTNERS HIGH YIELD FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-30</SoldDt>
          <GrossSalesPriceAmt>2931</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>1778</CostOrOtherBasisAmt>
          <GainOrLossAmt>1153</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1153</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM CO INVEST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-31</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>3256345</CostOrOtherBasisAmt>
          <GainOrLossAmt>1743655</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1743655</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM CO INVEST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-31</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>3190600</CostOrOtherBasisAmt>
          <GainOrLossAmt>1809400</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1809400</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM CO INVEST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-30</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>3048481</CostOrOtherBasisAmt>
          <GainOrLossAmt>1951519</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1951519</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM CO INVEST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-31</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>3012583</CostOrOtherBasisAmt>
          <GainOrLossAmt>1987417</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1987417</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM CO INVEST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-30</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>2943605</CostOrOtherBasisAmt>
          <GainOrLossAmt>2056395</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2056395</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM CO INVEST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-31</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>2908518</CostOrOtherBasisAmt>
          <GainOrLossAmt>2091482</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2091482</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM CO INVEST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-30</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>3409031</CostOrOtherBasisAmt>
          <GainOrLossAmt>1590969</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1590969</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM CO INVEST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-28</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>2887386</CostOrOtherBasisAmt>
          <GainOrLossAmt>2112614</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2112614</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM CO INVEST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-31</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>2865182</CostOrOtherBasisAmt>
          <GainOrLossAmt>2134818</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2134818</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM CO INVEST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-30</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>3323904</CostOrOtherBasisAmt>
          <GainOrLossAmt>1676096</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1676096</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM CO INVEST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-31</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>3394787</CostOrOtherBasisAmt>
          <GainOrLossAmt>1605213</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1605213</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM CO INVEST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-31</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>2872622</CostOrOtherBasisAmt>
          <GainOrLossAmt>2127378</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2127378</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTERNATIONAL PARTNERS VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-08</SoldDt>
          <GrossSalesPriceAmt>391304</GrossSalesPriceAmt>
          <GainOrLossAmt>391304</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>391304</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTERNATIONAL PARTNERS VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-12</SoldDt>
          <GrossSalesPriceAmt>1190000</GrossSalesPriceAmt>
          <GainOrLossAmt>1190000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1190000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTERNATIONAL PARTNERS VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-27</SoldDt>
          <GrossSalesPriceAmt>1400000</GrossSalesPriceAmt>
          <GainOrLossAmt>1400000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1400000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTERNATIONAL PARTNERS VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-10</SoldDt>
          <GrossSalesPriceAmt>730034</GrossSalesPriceAmt>
          <GainOrLossAmt>730034</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>730034</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTERNATIONAL PARTNERS VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-04</SoldDt>
          <GrossSalesPriceAmt>430500</GrossSalesPriceAmt>
          <GainOrLossAmt>430500</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>430500</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTERNATIONAL PARTNERS VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-13</SoldDt>
          <GrossSalesPriceAmt>930723</GrossSalesPriceAmt>
          <GainOrLossAmt>930723</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>930723</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTERNATIONAL PARTNERS VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-16</SoldDt>
          <GrossSalesPriceAmt>753100</GrossSalesPriceAmt>
          <GainOrLossAmt>753100</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>753100</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTERNATIONAL PARTNERS VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-19</SoldDt>
          <GrossSalesPriceAmt>449037</GrossSalesPriceAmt>
          <GainOrLossAmt>449037</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>449037</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY FD XVII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-23</SoldDt>
          <GrossSalesPriceAmt>8143</GrossSalesPriceAmt>
          <GainOrLossAmt>8143</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>8143</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY FD XVII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-04</SoldDt>
          <GrossSalesPriceAmt>78764</GrossSalesPriceAmt>
          <GainOrLossAmt>78764</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>78764</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY FUND XVI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-28</SoldDt>
          <GrossSalesPriceAmt>209157</GrossSalesPriceAmt>
          <GainOrLossAmt>209157</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>209157</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY FUND XVI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-25</SoldDt>
          <GrossSalesPriceAmt>2576</GrossSalesPriceAmt>
          <GainOrLossAmt>2576</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2576</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY XVII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-23</SoldDt>
          <GrossSalesPriceAmt>2908</GrossSalesPriceAmt>
          <GainOrLossAmt>2908</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2908</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EMERGENCE CAPITAL PARTNERS III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-06</SoldDt>
          <GrossSalesPriceAmt>21425317</GrossSalesPriceAmt>
          <GainOrLossAmt>21425317</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>21425317</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EMERGENCE CAPITAL PARTNERS III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-12</SoldDt>
          <GrossSalesPriceAmt>3595293</GrossSalesPriceAmt>
          <GainOrLossAmt>3595293</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3595293</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EMERGENCE CAPITAL PARTNERS III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-28</SoldDt>
          <GrossSalesPriceAmt>1745588</GrossSalesPriceAmt>
          <GainOrLossAmt>1745588</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1745588</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EMERGENCE CAPITAL PARTNERS IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-02</SoldDt>
          <GrossSalesPriceAmt>3790048</GrossSalesPriceAmt>
          <GainOrLossAmt>3790048</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3790048</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ENERGY FUND XV-A LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-01</SoldDt>
          <GrossSalesPriceAmt>72796</GrossSalesPriceAmt>
          <GainOrLossAmt>72796</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>72796</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS FUND II B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-28</SoldDt>
          <GrossSalesPriceAmt>644037</GrossSalesPriceAmt>
          <GainOrLossAmt>644037</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>644037</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-18</SoldDt>
          <GrossSalesPriceAmt>6893</GrossSalesPriceAmt>
          <GainOrLossAmt>6893</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>6893</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FORTISSIMO IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-08</SoldDt>
          <GrossSalesPriceAmt>2833128</GrossSalesPriceAmt>
          <GainOrLossAmt>2833128</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2833128</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FORTISSIMO IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-26</SoldDt>
          <GrossSalesPriceAmt>1579410</GrossSalesPriceAmt>
          <GainOrLossAmt>1579410</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1579410</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FORTISSIMO IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-29</SoldDt>
          <GrossSalesPriceAmt>87200</GrossSalesPriceAmt>
          <GainOrLossAmt>87200</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>87200</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FORTISSIMO IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-29</SoldDt>
          <GrossSalesPriceAmt>87200</GrossSalesPriceAmt>
          <GainOrLossAmt>87200</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>87200</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCI PUBLIC FD LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-01</SoldDt>
          <GrossSalesPriceAmt>40838</GrossSalesPriceAmt>
          <GainOrLossAmt>40838</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>40838</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCI PUBLIC FD LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-17</SoldDt>
          <GrossSalesPriceAmt>159240</GrossSalesPriceAmt>
          <GainOrLossAmt>159240</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>159240</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES IX LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-25</SoldDt>
          <CostOrOtherBasisAmt>225634</CostOrOtherBasisAmt>
          <GainOrLossAmt>-225634</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-225634</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES IX LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-15</SoldDt>
          <GrossSalesPriceAmt>254331</GrossSalesPriceAmt>
          <GainOrLossAmt>254331</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>254331</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES IX LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-08</SoldDt>
          <GrossSalesPriceAmt>326233</GrossSalesPriceAmt>
          <GainOrLossAmt>326233</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>326233</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES IX LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-31</SoldDt>
          <GrossSalesPriceAmt>2528006</GrossSalesPriceAmt>
          <GainOrLossAmt>2528006</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2528006</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES IX LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-09</SoldDt>
          <GrossSalesPriceAmt>4462880</GrossSalesPriceAmt>
          <GainOrLossAmt>4462880</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4462880</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES IX LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-06</SoldDt>
          <GrossSalesPriceAmt>43664</GrossSalesPriceAmt>
          <GainOrLossAmt>43664</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>43664</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES IX LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-09</SoldDt>
          <GrossSalesPriceAmt>1149177</GrossSalesPriceAmt>
          <GainOrLossAmt>1149177</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1149177</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES X LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-29</SoldDt>
          <GrossSalesPriceAmt>201963</GrossSalesPriceAmt>
          <GainOrLossAmt>201963</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>201963</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES X LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-24</SoldDt>
          <GrossSalesPriceAmt>341938</GrossSalesPriceAmt>
          <GainOrLossAmt>341938</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>341938</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES X LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-15</SoldDt>
          <GrossSalesPriceAmt>312788</GrossSalesPriceAmt>
          <GainOrLossAmt>312788</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>312788</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES X LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-24</SoldDt>
          <GrossSalesPriceAmt>71396</GrossSalesPriceAmt>
          <GainOrLossAmt>71396</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>71396</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES X LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-22</SoldDt>
          <GrossSalesPriceAmt>269979</GrossSalesPriceAmt>
          <GainOrLossAmt>269979</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>269979</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-02</SoldDt>
          <GrossSalesPriceAmt>111027</GrossSalesPriceAmt>
          <GainOrLossAmt>111027</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>111027</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-29</SoldDt>
          <GrossSalesPriceAmt>25580</GrossSalesPriceAmt>
          <GainOrLossAmt>25580</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>25580</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-27</SoldDt>
          <GrossSalesPriceAmt>228439</GrossSalesPriceAmt>
          <GainOrLossAmt>228439</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>228439</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-23</SoldDt>
          <GrossSalesPriceAmt>575546</GrossSalesPriceAmt>
          <GainOrLossAmt>575546</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>575546</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-20</SoldDt>
          <GrossSalesPriceAmt>279264</GrossSalesPriceAmt>
          <GainOrLossAmt>279264</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>279264</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-16</SoldDt>
          <GrossSalesPriceAmt>227636</GrossSalesPriceAmt>
          <GainOrLossAmt>227636</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>227636</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-17</SoldDt>
          <GrossSalesPriceAmt>372092</GrossSalesPriceAmt>
          <GainOrLossAmt>372092</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>372092</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-02</SoldDt>
          <GrossSalesPriceAmt>877858</GrossSalesPriceAmt>
          <GainOrLossAmt>877858</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>877858</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-25</SoldDt>
          <GrossSalesPriceAmt>92332</GrossSalesPriceAmt>
          <GainOrLossAmt>92332</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>92332</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-29</SoldDt>
          <GrossSalesPriceAmt>4551767</GrossSalesPriceAmt>
          <GainOrLossAmt>4551767</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4551767</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-30</SoldDt>
          <GrossSalesPriceAmt>1305759</GrossSalesPriceAmt>
          <GainOrLossAmt>1305759</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1305759</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-23</SoldDt>
          <GrossSalesPriceAmt>465</GrossSalesPriceAmt>
          <GainOrLossAmt>465</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>465</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-17</SoldDt>
          <GrossSalesPriceAmt>160272</GrossSalesPriceAmt>
          <GainOrLossAmt>160272</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>160272</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-23</SoldDt>
          <GrossSalesPriceAmt>319657</GrossSalesPriceAmt>
          <GainOrLossAmt>319657</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>319657</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-30</SoldDt>
          <GrossSalesPriceAmt>49370</GrossSalesPriceAmt>
          <GainOrLossAmt>49370</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>49370</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-12</SoldDt>
          <GrossSalesPriceAmt>764379</GrossSalesPriceAmt>
          <GainOrLossAmt>764379</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>764379</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GAVEA INVESTMENT FUND V B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-21</SoldDt>
          <GrossSalesPriceAmt>334593</GrossSalesPriceAmt>
          <GainOrLossAmt>334593</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>334593</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GAVEA INVESTMENT FUND V B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-06</SoldDt>
          <GrossSalesPriceAmt>740446</GrossSalesPriceAmt>
          <GainOrLossAmt>740446</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>740446</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-23</SoldDt>
          <GrossSalesPriceAmt>10640404</GrossSalesPriceAmt>
          <GainOrLossAmt>10640404</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>10640404</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-13</SoldDt>
          <GrossSalesPriceAmt>1587956</GrossSalesPriceAmt>
          <GainOrLossAmt>1587956</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1587956</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-21</SoldDt>
          <GrossSalesPriceAmt>1855989</GrossSalesPriceAmt>
          <GainOrLossAmt>1855989</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1855989</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-16</SoldDt>
          <GrossSalesPriceAmt>464870</GrossSalesPriceAmt>
          <GainOrLossAmt>464870</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>464870</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-30</SoldDt>
          <GrossSalesPriceAmt>7549283</GrossSalesPriceAmt>
          <GainOrLossAmt>7549283</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>7549283</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-10</SoldDt>
          <GrossSalesPriceAmt>2751418</GrossSalesPriceAmt>
          <GainOrLossAmt>2751418</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2751418</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-09</SoldDt>
          <GrossSalesPriceAmt>3903065</GrossSalesPriceAmt>
          <GainOrLossAmt>3903065</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3903065</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-10</SoldDt>
          <GrossSalesPriceAmt>617418</GrossSalesPriceAmt>
          <GainOrLossAmt>617418</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>617418</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-11</SoldDt>
          <GrossSalesPriceAmt>922213</GrossSalesPriceAmt>
          <GainOrLossAmt>922213</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>922213</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-08</SoldDt>
          <CostOrOtherBasisAmt>287537</CostOrOtherBasisAmt>
          <GainOrLossAmt>-287537</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-287537</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-02</SoldDt>
          <GrossSalesPriceAmt>605568</GrossSalesPriceAmt>
          <GainOrLossAmt>605568</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>605568</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-06</SoldDt>
          <GrossSalesPriceAmt>1832219</GrossSalesPriceAmt>
          <GainOrLossAmt>1832219</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1832219</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-29</SoldDt>
          <GrossSalesPriceAmt>236159</GrossSalesPriceAmt>
          <GainOrLossAmt>236159</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>236159</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-30</SoldDt>
          <GrossSalesPriceAmt>16981</GrossSalesPriceAmt>
          <GainOrLossAmt>16981</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>16981</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-09</SoldDt>
          <GrossSalesPriceAmt>480225</GrossSalesPriceAmt>
          <GainOrLossAmt>480225</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>480225</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2013</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-10</SoldDt>
          <GrossSalesPriceAmt>454688</GrossSalesPriceAmt>
          <GainOrLossAmt>454688</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>454688</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2013</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-30</SoldDt>
          <GrossSalesPriceAmt>328868</GrossSalesPriceAmt>
          <GainOrLossAmt>328868</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>328868</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2018</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-25</SoldDt>
          <GrossSalesPriceAmt>670</GrossSalesPriceAmt>
          <GainOrLossAmt>670</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>670</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2018</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-17</SoldDt>
          <GrossSalesPriceAmt>28185</GrossSalesPriceAmt>
          <GainOrLossAmt>28185</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>28185</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2018</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-17</SoldDt>
          <GrossSalesPriceAmt>85220</GrossSalesPriceAmt>
          <GainOrLossAmt>85220</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>85220</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GOLDEN GATE CAP OPP FUND MGT</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-28</SoldDt>
          <GrossSalesPriceAmt>4036883</GrossSalesPriceAmt>
          <GainOrLossAmt>4036883</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4036883</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GOLDEN GATE CAP OPP FUND MGT</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-14</SoldDt>
          <GrossSalesPriceAmt>9349937</GrossSalesPriceAmt>
          <GainOrLossAmt>9349937</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>9349937</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GOLDEN GATE CAP OPP FUND MGT</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-14</SoldDt>
          <GrossSalesPriceAmt>6593147</GrossSalesPriceAmt>
          <GainOrLossAmt>6593147</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>6593147</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GOLDEN GATE CAP OPP FUND MGT</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-28</SoldDt>
          <GrossSalesPriceAmt>5023730</GrossSalesPriceAmt>
          <GainOrLossAmt>5023730</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>5023730</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GOLDEN GATE CAP OPP FUND MGT</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-31</SoldDt>
          <GrossSalesPriceAmt>51484482</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>80344042</CostOrOtherBasisAmt>
          <GainOrLossAmt>-28859560</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-28859560</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GOLDEN GATE CAP OPP FUND MGT</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-31</SoldDt>
          <GrossSalesPriceAmt>51484482</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>80344042</CostOrOtherBasisAmt>
          <GainOrLossAmt>-28859560</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-28859560</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GOLDENTREE OFFSHORE FUND SIDE POCKET 8</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-30</SoldDt>
          <GrossSalesPriceAmt>53652</GrossSalesPriceAmt>
          <GainOrLossAmt>53652</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>53652</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GOLDENTREE OFFSHORE FUND SIDE POCKET 8</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-28</SoldDt>
          <GrossSalesPriceAmt>130055</GrossSalesPriceAmt>
          <GainOrLossAmt>130055</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>130055</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GOLDENTREE OFFSHORE FUND SIDE POCKET 8</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-28</SoldDt>
          <GrossSalesPriceAmt>1171054</GrossSalesPriceAmt>
          <GainOrLossAmt>1171054</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1171054</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GOLDENTREE OFFSHORE FUND SIDE POCKET 8</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-31</SoldDt>
          <GrossSalesPriceAmt>6253988</GrossSalesPriceAmt>
          <GainOrLossAmt>6253988</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>6253988</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTION</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-22</SoldDt>
          <GrossSalesPriceAmt>150802</GrossSalesPriceAmt>
          <GainOrLossAmt>150802</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>150802</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTIONS FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-29</SoldDt>
          <GrossSalesPriceAmt>54118</GrossSalesPriceAmt>
          <GainOrLossAmt>54118</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>54118</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTIONS FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-24</SoldDt>
          <GrossSalesPriceAmt>12995</GrossSalesPriceAmt>
          <GainOrLossAmt>12995</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>12995</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTIONS FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-27</SoldDt>
          <GrossSalesPriceAmt>72238</GrossSalesPriceAmt>
          <GainOrLossAmt>72238</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>72238</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTIONS FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-30</SoldDt>
          <GrossSalesPriceAmt>12235</GrossSalesPriceAmt>
          <GainOrLossAmt>12235</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>12235</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTIONS FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-20</SoldDt>
          <GrossSalesPriceAmt>31275</GrossSalesPriceAmt>
          <GainOrLossAmt>31275</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>31275</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTIONS FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-18</SoldDt>
          <GrossSalesPriceAmt>17</GrossSalesPriceAmt>
          <GainOrLossAmt>17</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>17</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTIONS FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-02</SoldDt>
          <GrossSalesPriceAmt>2884</GrossSalesPriceAmt>
          <GainOrLossAmt>2884</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2884</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTIONS FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-31</SoldDt>
          <GrossSalesPriceAmt>568666</GrossSalesPriceAmt>
          <GainOrLossAmt>568666</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>568666</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTIONS FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-22</SoldDt>
          <GrossSalesPriceAmt>300933</GrossSalesPriceAmt>
          <GainOrLossAmt>300933</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>300933</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTIONS FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-23</SoldDt>
          <GrossSalesPriceAmt>862970</GrossSalesPriceAmt>
          <GainOrLossAmt>862970</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>862970</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>H.I.G. GROWTH BUYOUTS &amp; EQUITY FUND II L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-09</SoldDt>
          <GrossSalesPriceAmt>4547554</GrossSalesPriceAmt>
          <GainOrLossAmt>4547554</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4547554</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HARBOUR ENERGY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-03-31</SoldDt>
          <GrossSalesPriceAmt>15541938</GrossSalesPriceAmt>
          <GainOrLossAmt>15541938</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15541938</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HARBOUR ENERGY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-03-31</SoldDt>
          <CostOrOtherBasisAmt>17409877</CostOrOtherBasisAmt>
          <GainOrLossAmt>-17409877</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-17409877</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BAYSIDE LOAN OPPORTUNITY FEEDER FUND III (EUROPE-US$) L</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-15</SoldDt>
          <GrossSalesPriceAmt>85392</GrossSalesPriceAmt>
          <GainOrLossAmt>85392</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>85392</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BAYSIDE LOAN OPPORTUNITY FEEDER FUND III (EUROPE-US$) L</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-20</SoldDt>
          <GrossSalesPriceAmt>537186</GrossSalesPriceAmt>
          <GainOrLossAmt>537186</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>537186</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BAYSIDE LOAN OPPORTUNITY FEEDER FUND III (EUROPE-US$) L</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-29</SoldDt>
          <GrossSalesPriceAmt>123915</GrossSalesPriceAmt>
          <GainOrLossAmt>123915</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>123915</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BIOVENTURES II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-03</SoldDt>
          <GrossSalesPriceAmt>1469593</GrossSalesPriceAmt>
          <GainOrLossAmt>1469593</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1469593</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL &amp; LATIN AME PTNRS MASTER B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-01</SoldDt>
          <GrossSalesPriceAmt>192237</GrossSalesPriceAmt>
          <GainOrLossAmt>192237</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>192237</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL &amp; LATIN AME PTNRS MASTER B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-13</SoldDt>
          <GrossSalesPriceAmt>552452</GrossSalesPriceAmt>
          <GainOrLossAmt>552452</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>552452</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL &amp; LATIN AME PTNRS MASTER B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-02</SoldDt>
          <GrossSalesPriceAmt>407271</GrossSalesPriceAmt>
          <GainOrLossAmt>407271</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>407271</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL &amp; LATIN AME PTNRS MASTER C LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-02</SoldDt>
          <GrossSalesPriceAmt>407271</GrossSalesPriceAmt>
          <GainOrLossAmt>407271</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>407271</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL &amp; LATIN AME PTNRS MASTER C LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-13</SoldDt>
          <GrossSalesPriceAmt>552452</GrossSalesPriceAmt>
          <GainOrLossAmt>552452</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>552452</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL &amp; LATIN AME PTNRS MASTER C LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-01</SoldDt>
          <GrossSalesPriceAmt>192237</GrossSalesPriceAmt>
          <GainOrLossAmt>192237</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>192237</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL LATAM B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-01</SoldDt>
          <GrossSalesPriceAmt>187669</GrossSalesPriceAmt>
          <GainOrLossAmt>187669</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>187669</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL LATAM C</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-01</SoldDt>
          <GrossSalesPriceAmt>187669</GrossSalesPriceAmt>
          <GainOrLossAmt>187669</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>187669</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG CAPITAL PARTNERS V L P</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-28</SoldDt>
          <GrossSalesPriceAmt>2457479</GrossSalesPriceAmt>
          <GainOrLossAmt>2457479</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2457479</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG CAPITAL PARTNERS V L P</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-25</SoldDt>
          <GrossSalesPriceAmt>1414386</GrossSalesPriceAmt>
          <GainOrLossAmt>1414386</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1414386</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG CAPITAL PARTNERS V L P</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-26</SoldDt>
          <GrossSalesPriceAmt>8549112</GrossSalesPriceAmt>
          <GainOrLossAmt>8549112</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>8549112</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG CAPITAL PARTNERS V L P</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-29</SoldDt>
          <GrossSalesPriceAmt>1393508</GrossSalesPriceAmt>
          <GainOrLossAmt>1393508</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1393508</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MIDDLE MKT LBO FD II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-24</SoldDt>
          <GrossSalesPriceAmt>1621239</GrossSalesPriceAmt>
          <GainOrLossAmt>1621239</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1621239</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MIDDLE MKT LBO FD II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-22</SoldDt>
          <GrossSalesPriceAmt>3718411</GrossSalesPriceAmt>
          <GainOrLossAmt>3718411</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3718411</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MIDDLE MKT LBO FD II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-25</SoldDt>
          <GrossSalesPriceAmt>1068400</GrossSalesPriceAmt>
          <GainOrLossAmt>1068400</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1068400</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MIDDLE MKT LBO FD II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-14</SoldDt>
          <GrossSalesPriceAmt>4989393</GrossSalesPriceAmt>
          <GainOrLossAmt>4989393</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4989393</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MIDDLE MKT LBO FD II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-03</SoldDt>
          <GrossSalesPriceAmt>5998290</GrossSalesPriceAmt>
          <GainOrLossAmt>5998290</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>5998290</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-07</SoldDt>
          <GrossSalesPriceAmt>10000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>10000212</CostOrOtherBasisAmt>
          <GainOrLossAmt>-212</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-212</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-30</SoldDt>
          <GrossSalesPriceAmt>203549</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>203558</CostOrOtherBasisAmt>
          <GainOrLossAmt>-9</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-9</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-31</SoldDt>
          <GrossSalesPriceAmt>124456</GrossSalesPriceAmt>
          <GainOrLossAmt>124456</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>124456</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-28</SoldDt>
          <GrossSalesPriceAmt>128012</GrossSalesPriceAmt>
          <GainOrLossAmt>128012</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>128012</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-31</SoldDt>
          <GrossSalesPriceAmt>129759</GrossSalesPriceAmt>
          <GainOrLossAmt>129759</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>129759</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-31</SoldDt>
          <GrossSalesPriceAmt>140321</GrossSalesPriceAmt>
          <GainOrLossAmt>140321</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>140321</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-07</SoldDt>
          <GrossSalesPriceAmt>12500000</GrossSalesPriceAmt>
          <GainOrLossAmt>12500000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>12500000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-30</SoldDt>
          <GrossSalesPriceAmt>144929</GrossSalesPriceAmt>
          <GainOrLossAmt>144929</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>144929</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-05</SoldDt>
          <GrossSalesPriceAmt>12500000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>1877387</CostOrOtherBasisAmt>
          <GainOrLossAmt>10622613</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>10622613</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-31</SoldDt>
          <GrossSalesPriceAmt>163006</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>882733</CostOrOtherBasisAmt>
          <GainOrLossAmt>-719727</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-719727</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-30</SoldDt>
          <GrossSalesPriceAmt>109447</GrossSalesPriceAmt>
          <GainOrLossAmt>109447</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>109447</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-31</SoldDt>
          <GrossSalesPriceAmt>99300</GrossSalesPriceAmt>
          <GainOrLossAmt>99300</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>99300</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-07</SoldDt>
          <GrossSalesPriceAmt>18000000</GrossSalesPriceAmt>
          <GainOrLossAmt>18000000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>18000000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-07</SoldDt>
          <GrossSalesPriceAmt>20000000</GrossSalesPriceAmt>
          <GainOrLossAmt>20000000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>20000000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-30</SoldDt>
          <GrossSalesPriceAmt>84495</GrossSalesPriceAmt>
          <GainOrLossAmt>84495</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>84495</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-31</SoldDt>
          <GrossSalesPriceAmt>85060</GrossSalesPriceAmt>
          <GainOrLossAmt>85060</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>85060</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-31</SoldDt>
          <GrossSalesPriceAmt>87509</GrossSalesPriceAmt>
          <GainOrLossAmt>87509</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>87509</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-30</SoldDt>
          <GrossSalesPriceAmt>85692</GrossSalesPriceAmt>
          <GainOrLossAmt>85692</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>85692</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-31</SoldDt>
          <GrossSalesPriceAmt>78622</GrossSalesPriceAmt>
          <GainOrLossAmt>78622</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>78622</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-05</SoldDt>
          <GrossSalesPriceAmt>12500000</GrossSalesPriceAmt>
          <GainOrLossAmt>12500000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>12500000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-30</SoldDt>
          <GrossSalesPriceAmt>68698</GrossSalesPriceAmt>
          <GainOrLossAmt>68698</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>68698</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-07</SoldDt>
          <GrossSalesPriceAmt>12500000</GrossSalesPriceAmt>
          <GainOrLossAmt>12500000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>12500000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-31</SoldDt>
          <GrossSalesPriceAmt>63477</GrossSalesPriceAmt>
          <GainOrLossAmt>63477</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>63477</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-31</SoldDt>
          <GrossSalesPriceAmt>59851</GrossSalesPriceAmt>
          <GainOrLossAmt>59851</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>59851</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-28</SoldDt>
          <GrossSalesPriceAmt>58784</GrossSalesPriceAmt>
          <GainOrLossAmt>58784</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>58784</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-31</SoldDt>
          <GrossSalesPriceAmt>57314</GrossSalesPriceAmt>
          <GainOrLossAmt>57314</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>57314</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG BREYER CAPITAL FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-21</SoldDt>
          <GrossSalesPriceAmt>125348</GrossSalesPriceAmt>
          <GainOrLossAmt>125348</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>125348</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG CHINA CAPITAL FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-28</SoldDt>
          <GrossSalesPriceAmt>263591</GrossSalesPriceAmt>
          <GainOrLossAmt>263591</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>263591</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG CHINA VENTURE CAP FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-31</SoldDt>
          <GrossSalesPriceAmt>2117895</GrossSalesPriceAmt>
          <GainOrLossAmt>2117895</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2117895</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG-ACCEL CHINA CAPITAL FUND II L.P.</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-29</SoldDt>
          <GrossSalesPriceAmt>1674729</GrossSalesPriceAmt>
          <GainOrLossAmt>1674729</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1674729</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG-ACCEL CHINA CAPITAL FUND II L.P.</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-18</SoldDt>
          <GrossSalesPriceAmt>833149</GrossSalesPriceAmt>
          <GainOrLossAmt>833149</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>833149</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG-ACCEL CHINA CAPITAL FUND II L.P.</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-30</SoldDt>
          <GrossSalesPriceAmt>1641417</GrossSalesPriceAmt>
          <GainOrLossAmt>1641417</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1641417</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG-ACCEL CHINA GROWTH FUND III L.P.</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-17</SoldDt>
          <GrossSalesPriceAmt>849833</GrossSalesPriceAmt>
          <GainOrLossAmt>849833</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>849833</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG-ACCEL CHINA GROWTH FUND III L.P.</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-04</SoldDt>
          <GrossSalesPriceAmt>436414</GrossSalesPriceAmt>
          <GainOrLossAmt>436414</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>436414</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IRON POINT IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-31</SoldDt>
          <GrossSalesPriceAmt>321188</GrossSalesPriceAmt>
          <GainOrLossAmt>321188</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>321188</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IRON POINT RE PARTNERS IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-30</SoldDt>
          <GrossSalesPriceAmt>487378</GrossSalesPriceAmt>
          <GainOrLossAmt>487378</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>487378</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IRON POINT RE PARTNERS IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-31</SoldDt>
          <GrossSalesPriceAmt>483261</GrossSalesPriceAmt>
          <GainOrLossAmt>483261</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>483261</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-30</SoldDt>
          <GrossSalesPriceAmt>25589</GrossSalesPriceAmt>
          <GainOrLossAmt>25589</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>25589</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-31</SoldDt>
          <GrossSalesPriceAmt>25988</GrossSalesPriceAmt>
          <GainOrLossAmt>25988</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>25988</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-04</SoldDt>
          <GrossSalesPriceAmt>14000000</GrossSalesPriceAmt>
          <GainOrLossAmt>14000000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>14000000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-30</SoldDt>
          <GrossSalesPriceAmt>23857</GrossSalesPriceAmt>
          <GainOrLossAmt>23857</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>23857</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-31</SoldDt>
          <GrossSalesPriceAmt>22212</GrossSalesPriceAmt>
          <GainOrLossAmt>22212</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>22212</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-30</SoldDt>
          <GrossSalesPriceAmt>21315</GrossSalesPriceAmt>
          <GainOrLossAmt>21315</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>21315</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-31</SoldDt>
          <GrossSalesPriceAmt>22091</GrossSalesPriceAmt>
          <GainOrLossAmt>22091</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>22091</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-04</SoldDt>
          <GrossSalesPriceAmt>18000000</GrossSalesPriceAmt>
          <GainOrLossAmt>18000000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>18000000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-30</SoldDt>
          <GrossSalesPriceAmt>18763</GrossSalesPriceAmt>
          <GainOrLossAmt>18763</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>18763</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-31</SoldDt>
          <GrossSalesPriceAmt>19529</GrossSalesPriceAmt>
          <GainOrLossAmt>19529</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>19529</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-31</SoldDt>
          <GrossSalesPriceAmt>18757</GrossSalesPriceAmt>
          <GainOrLossAmt>18757</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>18757</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-28</SoldDt>
          <GrossSalesPriceAmt>18298</GrossSalesPriceAmt>
          <GainOrLossAmt>18298</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>18298</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-31</SoldDt>
          <GrossSalesPriceAmt>18593</GrossSalesPriceAmt>
          <GainOrLossAmt>18593</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>18593</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-08</SoldDt>
          <GrossSalesPriceAmt>15000000</GrossSalesPriceAmt>
          <GainOrLossAmt>15000000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15000000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-31</SoldDt>
          <GrossSalesPriceAmt>21719</GrossSalesPriceAmt>
          <GainOrLossAmt>21719</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>21719</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-08</SoldDt>
          <GrossSalesPriceAmt>15000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>15930051</CostOrOtherBasisAmt>
          <GainOrLossAmt>-930051</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-930051</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-29</SoldDt>
          <GrossSalesPriceAmt>21586</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>85504</CostOrOtherBasisAmt>
          <GainOrLossAmt>-63918</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-63918</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-04</SoldDt>
          <GrossSalesPriceAmt>12000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>15442890</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3442890</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3442890</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-06</SoldDt>
          <GrossSalesPriceAmt>8000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>24702789</CostOrOtherBasisAmt>
          <GainOrLossAmt>-16702789</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-16702789</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-30</SoldDt>
          <GrossSalesPriceAmt>26953</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>696465</CostOrOtherBasisAmt>
          <GainOrLossAmt>-669512</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-669512</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-31</SoldDt>
          <GrossSalesPriceAmt>18403</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>686793</CostOrOtherBasisAmt>
          <GainOrLossAmt>-668390</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-668390</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-28</SoldDt>
          <GrossSalesPriceAmt>18241</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>680748</CostOrOtherBasisAmt>
          <GainOrLossAmt>-662507</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-662507</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-31</SoldDt>
          <GrossSalesPriceAmt>18030</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>1226912</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1208882</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1208882</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-31</SoldDt>
          <GrossSalesPriceAmt>19413</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>1321045</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1301632</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1301632</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR INST PARTNERS IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-21</SoldDt>
          <GrossSalesPriceAmt>214413</GrossSalesPriceAmt>
          <GainOrLossAmt>214413</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>214413</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR INST PARTNERS IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-25</SoldDt>
          <GrossSalesPriceAmt>313005</GrossSalesPriceAmt>
          <GainOrLossAmt>313005</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>313005</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR INST PARTNERS IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-06</SoldDt>
          <GrossSalesPriceAmt>88098</GrossSalesPriceAmt>
          <GainOrLossAmt>88098</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>88098</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR INST PARTNERS IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-24</SoldDt>
          <GrossSalesPriceAmt>41943</GrossSalesPriceAmt>
          <GainOrLossAmt>41943</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>41943</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR INST PARTNERS IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-08</SoldDt>
          <GrossSalesPriceAmt>217960</GrossSalesPriceAmt>
          <GainOrLossAmt>217960</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>217960</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR INST PARTNERS IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-29</SoldDt>
          <GrossSalesPriceAmt>61302</GrossSalesPriceAmt>
          <GainOrLossAmt>61302</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>61302</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR INST PARTNERS IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-06</SoldDt>
          <GrossSalesPriceAmt>179609</GrossSalesPriceAmt>
          <GainOrLossAmt>179609</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>179609</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR INST PARTNERS IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-30</SoldDt>
          <GrossSalesPriceAmt>941196</GrossSalesPriceAmt>
          <GainOrLossAmt>941196</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>941196</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR LONGEVITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-03-05</SoldDt>
          <GrossSalesPriceAmt>2599659</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>2272606</CostOrOtherBasisAmt>
          <GainOrLossAmt>327053</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>327053</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR LONGEVITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-30</SoldDt>
          <GrossSalesPriceAmt>2024796</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>1688549</CostOrOtherBasisAmt>
          <GainOrLossAmt>336247</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>336247</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR LONGEVITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-30</SoldDt>
          <GrossSalesPriceAmt>624108</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>523402</CostOrOtherBasisAmt>
          <GainOrLossAmt>100706</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>100706</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ASIA PARTNERS III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-29</SoldDt>
          <GrossSalesPriceAmt>1008201</GrossSalesPriceAmt>
          <GainOrLossAmt>1008201</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1008201</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ISRAEL GP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-17</SoldDt>
          <CostOrOtherBasisAmt>2494266</CostOrOtherBasisAmt>
          <GainOrLossAmt>-2494266</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-2494266</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PRIVATE INVEST VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-16</SoldDt>
          <GrossSalesPriceAmt>212319</GrossSalesPriceAmt>
          <GainOrLossAmt>212319</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>212319</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ROYALTY PTNRS II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-16</SoldDt>
          <CostOrOtherBasisAmt>218281</CostOrOtherBasisAmt>
          <GainOrLossAmt>-218281</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-218281</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ROYALTY PTNRS II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-21</SoldDt>
          <GrossSalesPriceAmt>43808</GrossSalesPriceAmt>
          <GainOrLossAmt>43808</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>43808</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ROYALTY PTNRS II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-13</SoldDt>
          <GrossSalesPriceAmt>32499</GrossSalesPriceAmt>
          <GainOrLossAmt>32499</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>32499</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ROYALTY PTNRS II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-20</SoldDt>
          <GrossSalesPriceAmt>76078</GrossSalesPriceAmt>
          <GainOrLossAmt>76078</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>76078</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEG SECONDARY PE II LP AND AIV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-31</SoldDt>
          <GrossSalesPriceAmt>5046213</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>3928356</CostOrOtherBasisAmt>
          <GainOrLossAmt>1117857</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1117857</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEG SECONDARY PE INVESTORS II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-16</SoldDt>
          <GrossSalesPriceAmt>200459</GrossSalesPriceAmt>
          <GainOrLossAmt>200459</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>200459</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEG SECONDARY PE INVESTORS II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-17</SoldDt>
          <GrossSalesPriceAmt>1026685</GrossSalesPriceAmt>
          <GainOrLossAmt>1026685</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1026685</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEG SECONDARY PE INVESTORS II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-22</SoldDt>
          <GrossSalesPriceAmt>336062</GrossSalesPriceAmt>
          <GainOrLossAmt>336062</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>336062</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEG SECONDARY PE INVESTORS II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-18</SoldDt>
          <CostOrOtherBasisAmt>1943541</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1943541</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1943541</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEG SECONDARY PE INVESTORS III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-15</SoldDt>
          <GrossSalesPriceAmt>280309</GrossSalesPriceAmt>
          <GainOrLossAmt>280309</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>280309</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEG SECONDARY PE INVESTORS III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-23</SoldDt>
          <GrossSalesPriceAmt>826089</GrossSalesPriceAmt>
          <GainOrLossAmt>826089</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>826089</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEG SECONDARY PE INVESTORS LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-26</SoldDt>
          <GrossSalesPriceAmt>154917</GrossSalesPriceAmt>
          <GainOrLossAmt>154917</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>154917</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEG SECONDARY PE INVESTORS LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-18</SoldDt>
          <CostOrOtherBasisAmt>1638552</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1638552</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1638552</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEG SECONDARY PE INVESTORS LLC AND AIV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-31</SoldDt>
          <GrossSalesPriceAmt>2913911</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>1570771</CostOrOtherBasisAmt>
          <GainOrLossAmt>1343140</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1343140</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PITANGO GROWTH</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-30</SoldDt>
          <GrossSalesPriceAmt>1142909</GrossSalesPriceAmt>
          <GainOrLossAmt>1142909</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1142909</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PITANGO VTR VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-28</SoldDt>
          <GrossSalesPriceAmt>1539801</GrossSalesPriceAmt>
          <GainOrLossAmt>1539801</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1539801</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GR FD V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-01</SoldDt>
          <GrossSalesPriceAmt>196564</GrossSalesPriceAmt>
          <GainOrLossAmt>196564</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>196564</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GR FD V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-27</SoldDt>
          <GrossSalesPriceAmt>86521</GrossSalesPriceAmt>
          <GainOrLossAmt>86521</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>86521</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GR FD V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-13</SoldDt>
          <GrossSalesPriceAmt>78915</GrossSalesPriceAmt>
          <GainOrLossAmt>78915</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>78915</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GR FD V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-25</SoldDt>
          <GrossSalesPriceAmt>48653</GrossSalesPriceAmt>
          <GainOrLossAmt>48653</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>48653</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GR FD V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-29</SoldDt>
          <GrossSalesPriceAmt>51318</GrossSalesPriceAmt>
          <GainOrLossAmt>51318</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>51318</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-30</SoldDt>
          <GrossSalesPriceAmt>1141750</GrossSalesPriceAmt>
          <GainOrLossAmt>1141750</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1141750</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-17</SoldDt>
          <GrossSalesPriceAmt>1198782</GrossSalesPriceAmt>
          <GainOrLossAmt>1198782</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1198782</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-28</SoldDt>
          <GrossSalesPriceAmt>443625</GrossSalesPriceAmt>
          <GainOrLossAmt>443625</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>443625</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-18</SoldDt>
          <GrossSalesPriceAmt>1266981</GrossSalesPriceAmt>
          <GainOrLossAmt>1266981</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1266981</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-13</SoldDt>
          <GrossSalesPriceAmt>43933</GrossSalesPriceAmt>
          <GainOrLossAmt>43933</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>43933</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-19</SoldDt>
          <GrossSalesPriceAmt>34901</GrossSalesPriceAmt>
          <GainOrLossAmt>34901</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>34901</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-07</SoldDt>
          <GrossSalesPriceAmt>108588</GrossSalesPriceAmt>
          <GainOrLossAmt>108588</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>108588</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-23</SoldDt>
          <GrossSalesPriceAmt>134841</GrossSalesPriceAmt>
          <GainOrLossAmt>134841</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>134841</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-23</SoldDt>
          <GrossSalesPriceAmt>1768012</GrossSalesPriceAmt>
          <GainOrLossAmt>1768012</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1768012</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-31</SoldDt>
          <GrossSalesPriceAmt>1031481</GrossSalesPriceAmt>
          <GainOrLossAmt>1031481</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1031481</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-08</SoldDt>
          <GrossSalesPriceAmt>1422952</GrossSalesPriceAmt>
          <GainOrLossAmt>1422952</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1422952</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-02</SoldDt>
          <GrossSalesPriceAmt>186195</GrossSalesPriceAmt>
          <GainOrLossAmt>186195</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>186195</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-26</SoldDt>
          <GrossSalesPriceAmt>44991</GrossSalesPriceAmt>
          <GainOrLossAmt>44991</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>44991</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-27</SoldDt>
          <GrossSalesPriceAmt>1850771</GrossSalesPriceAmt>
          <GainOrLossAmt>1850771</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1850771</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-20</SoldDt>
          <GrossSalesPriceAmt>115447</GrossSalesPriceAmt>
          <GainOrLossAmt>115447</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>115447</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-20</SoldDt>
          <GrossSalesPriceAmt>109518</GrossSalesPriceAmt>
          <GainOrLossAmt>109518</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>109518</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-01</SoldDt>
          <GrossSalesPriceAmt>4112210</GrossSalesPriceAmt>
          <GainOrLossAmt>4112210</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4112210</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-29</SoldDt>
          <GrossSalesPriceAmt>1031131</GrossSalesPriceAmt>
          <GainOrLossAmt>1031131</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1031131</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GROWTH IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-25</SoldDt>
          <GrossSalesPriceAmt>984655</GrossSalesPriceAmt>
          <GainOrLossAmt>984655</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>984655</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA GRWTH VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-22</SoldDt>
          <GrossSalesPriceAmt>5552</GrossSalesPriceAmt>
          <GainOrLossAmt>5552</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>5552</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA VENTURE FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-29</SoldDt>
          <GrossSalesPriceAmt>1070083</GrossSalesPriceAmt>
          <GainOrLossAmt>1070083</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1070083</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA VENTURE FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-22</SoldDt>
          <GrossSalesPriceAmt>382817</GrossSalesPriceAmt>
          <GainOrLossAmt>382817</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>382817</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA VENTURE V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-30</SoldDt>
          <GrossSalesPriceAmt>181394</GrossSalesPriceAmt>
          <GainOrLossAmt>181394</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>181394</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA VENTURE V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-10</SoldDt>
          <GrossSalesPriceAmt>1594670</GrossSalesPriceAmt>
          <GainOrLossAmt>1594670</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1594670</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA VENTURE VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-23</SoldDt>
          <GrossSalesPriceAmt>40645</GrossSalesPriceAmt>
          <GainOrLossAmt>40645</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>40645</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA VENTURE VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-13</SoldDt>
          <GrossSalesPriceAmt>111223</GrossSalesPriceAmt>
          <GainOrLossAmt>111223</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>111223</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA VENTURE VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-20</SoldDt>
          <GrossSalesPriceAmt>58656</GrossSalesPriceAmt>
          <GainOrLossAmt>58656</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>58656</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA VENTURE VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-02</SoldDt>
          <GrossSalesPriceAmt>51394</GrossSalesPriceAmt>
          <GainOrLossAmt>51394</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>51394</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA VENTURE VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-22</SoldDt>
          <GrossSalesPriceAmt>37621</GrossSalesPriceAmt>
          <GainOrLossAmt>37621</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>37621</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP CHINA VENTURE VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-27</SoldDt>
          <GrossSalesPriceAmt>36913</GrossSalesPriceAmt>
          <GainOrLossAmt>36913</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>36913</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GR III CHINA ANNEX LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-13</SoldDt>
          <CostOrOtherBasisAmt>119477</CostOrOtherBasisAmt>
          <GainOrLossAmt>-119477</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-119477</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-10</SoldDt>
          <GrossSalesPriceAmt>98211</GrossSalesPriceAmt>
          <GainOrLossAmt>98211</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>98211</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-22</SoldDt>
          <GrossSalesPriceAmt>1782585</GrossSalesPriceAmt>
          <GainOrLossAmt>1782585</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1782585</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-24</SoldDt>
          <GrossSalesPriceAmt>168321</GrossSalesPriceAmt>
          <GainOrLossAmt>168321</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>168321</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-25</SoldDt>
          <GrossSalesPriceAmt>314656</GrossSalesPriceAmt>
          <GainOrLossAmt>314656</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>314656</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-28</SoldDt>
          <GrossSalesPriceAmt>904634</GrossSalesPriceAmt>
          <GainOrLossAmt>904634</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>904634</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-20</SoldDt>
          <GrossSalesPriceAmt>426463</GrossSalesPriceAmt>
          <GainOrLossAmt>426463</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>426463</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-26</SoldDt>
          <GrossSalesPriceAmt>357784</GrossSalesPriceAmt>
          <GainOrLossAmt>357784</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>357784</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-25</SoldDt>
          <GrossSalesPriceAmt>683882</GrossSalesPriceAmt>
          <GainOrLossAmt>683882</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>683882</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-29</SoldDt>
          <GrossSalesPriceAmt>718463</GrossSalesPriceAmt>
          <GainOrLossAmt>718463</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>718463</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-26</SoldDt>
          <GrossSalesPriceAmt>175196</GrossSalesPriceAmt>
          <GainOrLossAmt>175196</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>175196</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-31</SoldDt>
          <GrossSalesPriceAmt>105357</GrossSalesPriceAmt>
          <GainOrLossAmt>105357</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>105357</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-01</SoldDt>
          <GrossSalesPriceAmt>2815736</GrossSalesPriceAmt>
          <GainOrLossAmt>2815736</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2815736</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-02</SoldDt>
          <GrossSalesPriceAmt>725024</GrossSalesPriceAmt>
          <GainOrLossAmt>725024</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>725024</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-23</SoldDt>
          <GrossSalesPriceAmt>198318</GrossSalesPriceAmt>
          <GainOrLossAmt>198318</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>198318</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-27</SoldDt>
          <GrossSalesPriceAmt>1255206</GrossSalesPriceAmt>
          <GainOrLossAmt>1255206</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1255206</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-20</SoldDt>
          <GrossSalesPriceAmt>449556</GrossSalesPriceAmt>
          <GainOrLossAmt>449556</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>449556</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-08</SoldDt>
          <GrossSalesPriceAmt>157090</GrossSalesPriceAmt>
          <GainOrLossAmt>157090</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>157090</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-19</SoldDt>
          <GrossSalesPriceAmt>224874</GrossSalesPriceAmt>
          <GainOrLossAmt>224874</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>224874</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-18</SoldDt>
          <GrossSalesPriceAmt>134380</GrossSalesPriceAmt>
          <GainOrLossAmt>134380</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>134380</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GLOBAL EQ FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-26</SoldDt>
          <GrossSalesPriceAmt>18793401</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>3403850</CostOrOtherBasisAmt>
          <GainOrLossAmt>15389551</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15389551</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GLOBAL EQ FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-26</SoldDt>
          <GrossSalesPriceAmt>11137547</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>2017226</CostOrOtherBasisAmt>
          <GainOrLossAmt>9120321</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>9120321</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GLOBAL EQ FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-26</SoldDt>
          <GrossSalesPriceAmt>1341170</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>242912</CostOrOtherBasisAmt>
          <GainOrLossAmt>1098258</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1098258</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GLOBAL EQ FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-26</SoldDt>
          <GrossSalesPriceAmt>4727882</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>856311</CostOrOtherBasisAmt>
          <GainOrLossAmt>3871571</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3871571</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-26</SoldDt>
          <GrossSalesPriceAmt>130388</GrossSalesPriceAmt>
          <GainOrLossAmt>130388</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>130388</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-12</SoldDt>
          <GrossSalesPriceAmt>526670</GrossSalesPriceAmt>
          <GainOrLossAmt>526670</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>526670</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-18</SoldDt>
          <GrossSalesPriceAmt>541871</GrossSalesPriceAmt>
          <GainOrLossAmt>541871</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>541871</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-24</SoldDt>
          <CostOrOtherBasisAmt>44678</CostOrOtherBasisAmt>
          <GainOrLossAmt>-44678</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-44678</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-24</SoldDt>
          <GrossSalesPriceAmt>44678</GrossSalesPriceAmt>
          <GainOrLossAmt>44678</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>44678</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-18</SoldDt>
          <GrossSalesPriceAmt>420919</GrossSalesPriceAmt>
          <GainOrLossAmt>420919</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>420919</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-22</SoldDt>
          <GrossSalesPriceAmt>561892</GrossSalesPriceAmt>
          <GainOrLossAmt>561892</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>561892</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-23</SoldDt>
          <GrossSalesPriceAmt>61574</GrossSalesPriceAmt>
          <GainOrLossAmt>61574</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>61574</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-11</SoldDt>
          <GrossSalesPriceAmt>227016</GrossSalesPriceAmt>
          <GainOrLossAmt>227016</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>227016</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-24</SoldDt>
          <GrossSalesPriceAmt>44678</GrossSalesPriceAmt>
          <GainOrLossAmt>44678</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>44678</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-16</SoldDt>
          <GrossSalesPriceAmt>19607</GrossSalesPriceAmt>
          <GainOrLossAmt>19607</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>19607</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-13</SoldDt>
          <GrossSalesPriceAmt>136168</GrossSalesPriceAmt>
          <GainOrLossAmt>136168</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>136168</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-02</SoldDt>
          <GrossSalesPriceAmt>20032</GrossSalesPriceAmt>
          <GainOrLossAmt>20032</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>20032</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-28</SoldDt>
          <GrossSalesPriceAmt>435040</GrossSalesPriceAmt>
          <GainOrLossAmt>435040</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>435040</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-25</SoldDt>
          <GrossSalesPriceAmt>27236</GrossSalesPriceAmt>
          <GainOrLossAmt>27236</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>27236</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-28</SoldDt>
          <GrossSalesPriceAmt>317214</GrossSalesPriceAmt>
          <GainOrLossAmt>317214</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>317214</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-08</SoldDt>
          <GrossSalesPriceAmt>51599</GrossSalesPriceAmt>
          <GainOrLossAmt>51599</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>51599</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-02</SoldDt>
          <GrossSalesPriceAmt>314920</GrossSalesPriceAmt>
          <GainOrLossAmt>314920</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>314920</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-16</SoldDt>
          <GrossSalesPriceAmt>309121</GrossSalesPriceAmt>
          <GainOrLossAmt>309121</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>309121</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-29</SoldDt>
          <GrossSalesPriceAmt>46403</GrossSalesPriceAmt>
          <GainOrLossAmt>46403</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>46403</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-11</SoldDt>
          <GrossSalesPriceAmt>104776</GrossSalesPriceAmt>
          <GainOrLossAmt>104776</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>104776</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-30</SoldDt>
          <GrossSalesPriceAmt>98015</GrossSalesPriceAmt>
          <GainOrLossAmt>98015</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>98015</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-19</SoldDt>
          <GrossSalesPriceAmt>18967</GrossSalesPriceAmt>
          <GainOrLossAmt>18967</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>18967</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-22</SoldDt>
          <GrossSalesPriceAmt>622861</GrossSalesPriceAmt>
          <GainOrLossAmt>622861</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>622861</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-24</SoldDt>
          <GrossSalesPriceAmt>14197</GrossSalesPriceAmt>
          <GainOrLossAmt>14197</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>14197</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US VENTURE FD XV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-21</SoldDt>
          <GrossSalesPriceAmt>91993</GrossSalesPriceAmt>
          <GainOrLossAmt>91993</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>91993</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US VENTURE FD XV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-06</SoldDt>
          <GrossSalesPriceAmt>126366</GrossSalesPriceAmt>
          <GainOrLossAmt>126366</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>126366</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US VENTURE FD XV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-13</SoldDt>
          <GrossSalesPriceAmt>60792</GrossSalesPriceAmt>
          <GainOrLossAmt>60792</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>60792</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US VENTURE FD XV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-23</SoldDt>
          <GrossSalesPriceAmt>27490</GrossSalesPriceAmt>
          <GainOrLossAmt>27490</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>27490</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-12</SoldDt>
          <GrossSalesPriceAmt>1480355</GrossSalesPriceAmt>
          <GainOrLossAmt>1480355</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1480355</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-18</SoldDt>
          <GrossSalesPriceAmt>1589407</GrossSalesPriceAmt>
          <GainOrLossAmt>1589407</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1589407</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-26</SoldDt>
          <GrossSalesPriceAmt>583983</GrossSalesPriceAmt>
          <GainOrLossAmt>583983</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>583983</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-26</SoldDt>
          <GrossSalesPriceAmt>292977</GrossSalesPriceAmt>
          <GainOrLossAmt>292977</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>292977</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-02</SoldDt>
          <GrossSalesPriceAmt>1203240</GrossSalesPriceAmt>
          <GainOrLossAmt>1203240</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1203240</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-20</SoldDt>
          <GrossSalesPriceAmt>736170</GrossSalesPriceAmt>
          <GainOrLossAmt>736170</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>736170</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-18</SoldDt>
          <GrossSalesPriceAmt>3285313</GrossSalesPriceAmt>
          <GainOrLossAmt>3285313</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3285313</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-25</SoldDt>
          <GrossSalesPriceAmt>209704</GrossSalesPriceAmt>
          <GainOrLossAmt>209704</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>209704</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-25</SoldDt>
          <GrossSalesPriceAmt>1323352</GrossSalesPriceAmt>
          <GainOrLossAmt>1323352</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1323352</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-24</SoldDt>
          <GrossSalesPriceAmt>677244</GrossSalesPriceAmt>
          <GainOrLossAmt>677244</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>677244</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-24</SoldDt>
          <GrossSalesPriceAmt>107914</GrossSalesPriceAmt>
          <GainOrLossAmt>107914</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>107914</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-11</SoldDt>
          <GrossSalesPriceAmt>1770304</GrossSalesPriceAmt>
          <GainOrLossAmt>1770304</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1770304</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-20</SoldDt>
          <GrossSalesPriceAmt>712545</GrossSalesPriceAmt>
          <GainOrLossAmt>712545</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>712545</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-19</SoldDt>
          <GrossSalesPriceAmt>1009425</GrossSalesPriceAmt>
          <GainOrLossAmt>1009425</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1009425</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-29</SoldDt>
          <GrossSalesPriceAmt>150404</GrossSalesPriceAmt>
          <GainOrLossAmt>150404</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>150404</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-16</SoldDt>
          <GrossSalesPriceAmt>950365</GrossSalesPriceAmt>
          <GainOrLossAmt>950365</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>950365</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-01</SoldDt>
          <GrossSalesPriceAmt>576780</GrossSalesPriceAmt>
          <GainOrLossAmt>576780</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>576780</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-23</SoldDt>
          <GrossSalesPriceAmt>178167</GrossSalesPriceAmt>
          <GainOrLossAmt>178167</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>178167</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-27</SoldDt>
          <GrossSalesPriceAmt>253919</GrossSalesPriceAmt>
          <GainOrLossAmt>253919</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>253919</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-08</SoldDt>
          <GrossSalesPriceAmt>84314</GrossSalesPriceAmt>
          <GainOrLossAmt>84314</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>84314</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-18</SoldDt>
          <GrossSalesPriceAmt>2198913</GrossSalesPriceAmt>
          <GainOrLossAmt>2198913</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2198913</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-18</SoldDt>
          <GrossSalesPriceAmt>71074</GrossSalesPriceAmt>
          <GainOrLossAmt>71074</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>71074</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-11</SoldDt>
          <GrossSalesPriceAmt>1154709</GrossSalesPriceAmt>
          <GainOrLossAmt>1154709</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1154709</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-02</SoldDt>
          <GrossSalesPriceAmt>968788</GrossSalesPriceAmt>
          <GainOrLossAmt>968788</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>968788</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-25</SoldDt>
          <GrossSalesPriceAmt>142592</GrossSalesPriceAmt>
          <GainOrLossAmt>142592</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>142592</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. GROWTH FUND V L.P.</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-12</SoldDt>
          <GrossSalesPriceAmt>1462337</GrossSalesPriceAmt>
          <GainOrLossAmt>1462337</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1462337</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. GROWTH FUND V L.P.</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-18</SoldDt>
          <GrossSalesPriceAmt>1468146</GrossSalesPriceAmt>
          <GainOrLossAmt>1468146</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1468146</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. GROWTH FUND V L.P.</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-09</SoldDt>
          <GrossSalesPriceAmt>20227</GrossSalesPriceAmt>
          <GainOrLossAmt>20227</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>20227</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. GROWTH FUND V L.P.</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-19</SoldDt>
          <GrossSalesPriceAmt>413904</GrossSalesPriceAmt>
          <GainOrLossAmt>413904</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>413904</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. GROWTH FUND V L.P.</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-24</SoldDt>
          <GrossSalesPriceAmt>331097</GrossSalesPriceAmt>
          <GainOrLossAmt>331097</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>331097</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. GROWTH FUND V L.P.</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-25</SoldDt>
          <GrossSalesPriceAmt>648586</GrossSalesPriceAmt>
          <GainOrLossAmt>648586</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>648586</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-17</SoldDt>
          <GrossSalesPriceAmt>127609</GrossSalesPriceAmt>
          <GainOrLossAmt>127609</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>127609</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-28</SoldDt>
          <GrossSalesPriceAmt>786061</GrossSalesPriceAmt>
          <GainOrLossAmt>786061</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>786061</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-22</SoldDt>
          <GrossSalesPriceAmt>1513940</GrossSalesPriceAmt>
          <GainOrLossAmt>1513940</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1513940</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-30</SoldDt>
          <GrossSalesPriceAmt>107591</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>87168</CostOrOtherBasisAmt>
          <GainOrLossAmt>20423</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>20423</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-30</SoldDt>
          <GrossSalesPriceAmt>110280</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>86389</CostOrOtherBasisAmt>
          <GainOrLossAmt>23891</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>23891</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-30</SoldDt>
          <GrossSalesPriceAmt>109497</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>86617</CostOrOtherBasisAmt>
          <GainOrLossAmt>22880</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>22880</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-28</SoldDt>
          <GrossSalesPriceAmt>110494</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>86433</CostOrOtherBasisAmt>
          <GainOrLossAmt>24061</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>24061</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-31</SoldDt>
          <GrossSalesPriceAmt>69135</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>55056</CostOrOtherBasisAmt>
          <GainOrLossAmt>14079</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>14079</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-28</SoldDt>
          <GrossSalesPriceAmt>68370</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>55444</CostOrOtherBasisAmt>
          <GainOrLossAmt>12926</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>12926</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-31</SoldDt>
          <GrossSalesPriceAmt>111438</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>86080</CostOrOtherBasisAmt>
          <GainOrLossAmt>25358</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>25358</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-30</SoldDt>
          <GrossSalesPriceAmt>69964</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>54831</CostOrOtherBasisAmt>
          <GainOrLossAmt>15133</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15133</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-31</SoldDt>
          <GrossSalesPriceAmt>72574</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>53721</CostOrOtherBasisAmt>
          <GainOrLossAmt>18853</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>18853</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-29</SoldDt>
          <GrossSalesPriceAmt>113440</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>85551</CostOrOtherBasisAmt>
          <GainOrLossAmt>27889</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>27889</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-29</SoldDt>
          <GrossSalesPriceAmt>100000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>75415391</CostOrOtherBasisAmt>
          <GainOrLossAmt>24584609</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>24584609</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-30</SoldDt>
          <GrossSalesPriceAmt>109896</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>86385</CostOrOtherBasisAmt>
          <GainOrLossAmt>23511</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>23511</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-31</SoldDt>
          <GrossSalesPriceAmt>70061</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>54718</CostOrOtherBasisAmt>
          <GainOrLossAmt>15343</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15343</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-30</SoldDt>
          <GrossSalesPriceAmt>87366</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>79953</CostOrOtherBasisAmt>
          <GainOrLossAmt>7413</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>7413</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-31</SoldDt>
          <GrossSalesPriceAmt>73681</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>66120</CostOrOtherBasisAmt>
          <GainOrLossAmt>7561</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>7561</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-30</SoldDt>
          <GrossSalesPriceAmt>89074</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>79567</CostOrOtherBasisAmt>
          <GainOrLossAmt>9507</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>9507</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-30</SoldDt>
          <GrossSalesPriceAmt>88564</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>79617</CostOrOtherBasisAmt>
          <GainOrLossAmt>8947</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>8947</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-31</SoldDt>
          <GrossSalesPriceAmt>89392</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>79433</CostOrOtherBasisAmt>
          <GainOrLossAmt>9959</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>9959</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-07</SoldDt>
          <GrossSalesPriceAmt>10000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>8885907</CostOrOtherBasisAmt>
          <GainOrLossAmt>1114093</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1114093</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-30</SoldDt>
          <GrossSalesPriceAmt>84177</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>75885</CostOrOtherBasisAmt>
          <GainOrLossAmt>8292</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>8292</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-10-29</SoldDt>
          <GrossSalesPriceAmt>85408</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>75618</CostOrOtherBasisAmt>
          <GainOrLossAmt>9790</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>9790</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-04</SoldDt>
          <GrossSalesPriceAmt>12500000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>11067200</CostOrOtherBasisAmt>
          <GainOrLossAmt>1432800</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1432800</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-30</SoldDt>
          <GrossSalesPriceAmt>76074</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>71835</CostOrOtherBasisAmt>
          <GainOrLossAmt>4239</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4239</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-06</SoldDt>
          <GrossSalesPriceAmt>12500000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>11803332</CostOrOtherBasisAmt>
          <GainOrLossAmt>696668</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>696668</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-31</SoldDt>
          <GrossSalesPriceAmt>73629</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>66235</CostOrOtherBasisAmt>
          <GainOrLossAmt>7394</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>7394</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-31</SoldDt>
          <GrossSalesPriceAmt>74089</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>66099</CostOrOtherBasisAmt>
          <GainOrLossAmt>7990</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>7990</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-28</SoldDt>
          <GrossSalesPriceAmt>74309</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>66017</CostOrOtherBasisAmt>
          <GainOrLossAmt>8292</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>8292</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-05-28</SoldDt>
          <GrossSalesPriceAmt>89747</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>79490</CostOrOtherBasisAmt>
          <GainOrLossAmt>10257</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>10257</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>VENTURE LENDING &amp; LEASING VII LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-08</SoldDt>
          <GrossSalesPriceAmt>260000</GrossSalesPriceAmt>
          <GainOrLossAmt>260000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>260000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>VENTURE LENDING &amp; LEASING VII LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-09</SoldDt>
          <GrossSalesPriceAmt>300000</GrossSalesPriceAmt>
          <GainOrLossAmt>300000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>300000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>VENTURE LENDING &amp; LEASING VII LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-05</SoldDt>
          <GrossSalesPriceAmt>300000</GrossSalesPriceAmt>
          <GainOrLossAmt>300000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>300000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>VENTURE LENDING &amp; LEASING VII LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-03-10</SoldDt>
          <GrossSalesPriceAmt>140000</GrossSalesPriceAmt>
          <GainOrLossAmt>140000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>140000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>VENTURE LENDING &amp; LEASING VII LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-10</SoldDt>
          <GrossSalesPriceAmt>763849</GrossSalesPriceAmt>
          <GainOrLossAmt>763849</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>763849</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>VENTURE LENDING &amp; LEASING VII LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-02</SoldDt>
          <GrossSalesPriceAmt>1151524</GrossSalesPriceAmt>
          <GainOrLossAmt>1151524</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1151524</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>VENTURE LENDING &amp; LEASING VIII LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-07-02</SoldDt>
          <GrossSalesPriceAmt>1059489</GrossSalesPriceAmt>
          <GainOrLossAmt>1059489</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1059489</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>WTI VLL IX</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-11-24</SoldDt>
          <GrossSalesPriceAmt>116357</GrossSalesPriceAmt>
          <GainOrLossAmt>116357</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>116357</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>WTI VLL VIII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-06-25</SoldDt>
          <GrossSalesPriceAmt>98000</GrossSalesPriceAmt>
          <GainOrLossAmt>98000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>98000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>WTI VLL VIII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-10</SoldDt>
          <GrossSalesPriceAmt>346430</GrossSalesPriceAmt>
          <GainOrLossAmt>346430</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>346430</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>WTI VLL VIII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-09-27</SoldDt>
          <GrossSalesPriceAmt>49000</GrossSalesPriceAmt>
          <GainOrLossAmt>49000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>49000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>WTI VLL VIII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-10</SoldDt>
          <GrossSalesPriceAmt>318500</GrossSalesPriceAmt>
          <GainOrLossAmt>318500</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>318500</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>YORK CO INVEST 1</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-12-14</SoldDt>
          <GrossSalesPriceAmt>452173</GrossSalesPriceAmt>
          <GainOrLossAmt>452173</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>452173</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>YORK DISTRESSED ASSET FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-02-11</SoldDt>
          <GrossSalesPriceAmt>2763089</GrossSalesPriceAmt>
          <GainOrLossAmt>2763089</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2763089</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>YORK DISTRESSED ASSET FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-08-12</SoldDt>
          <GrossSalesPriceAmt>4019690</GrossSalesPriceAmt>
          <GainOrLossAmt>4019690</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4019690</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>YORK EUROPEAN DISTRESSED CREDIT FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-01-26</SoldDt>
          <GrossSalesPriceAmt>635222</GrossSalesPriceAmt>
          <GainOrLossAmt>635222</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>635222</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>YORK EUROPEAN DISTRESSED CREDIT FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2021-04-01</SoldDt>
          <GrossSalesPriceAmt>822574</GrossSalesPriceAmt>
          <GainOrLossAmt>822574</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>822574</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>K-1 ADJUSTMENTS, NET OF UBI AND RELATED AMOUNTS ABOVE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GainOrLossAmt>-138034051</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-138034051</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapitalGainNetIncomeAmt>713350607</CapitalGainNetIncomeAmt>
      </CapGainsLossTxInvstIncmDetail>
      <ExciseTaxBasedOnInvstIncmGrp>
        <InvestmentIncomeExciseTaxAmt>14577769</InvestmentIncomeExciseTaxAmt>
        <TaxUnderSection511Amt>0</TaxUnderSection511Amt>
        <SubtotalAmt>14577769</SubtotalAmt>
        <SubtitleATaxAmt>0</SubtitleATaxAmt>
        <TaxBasedOnInvestmentIncomeAmt>14577769</TaxBasedOnInvestmentIncomeAmt>
        <EstimatedPlusOvpmtIncmTxAmt>15460988</EstimatedPlusOvpmtIncmTxAmt>
        <ExemptFrgnOrgTaxWthldAtSrceAmt>0</ExemptFrgnOrgTaxWthldAtSrceAmt>
        <ExtsnRequestIncomeTaxPaidAmt>4100000</ExtsnRequestIncomeTaxPaidAmt>
        <BackupWithholdingWithheldAmt>0</BackupWithholdingWithheldAmt>
        <TotalPaymentsAndCreditsAmt>19560988</TotalPaymentsAndCreditsAmt>
        <Form2220AttachedInd referenceDocumentId="RetDoc1192000001">X</Form2220AttachedInd>
        <EsPenaltyAmt>0</EsPenaltyAmt>
        <OverpaymentAmt>4983219</OverpaymentAmt>
        <AppliedToESTaxAmt>4983219</AppliedToESTaxAmt>
        <RefundAmt>0</RefundAmt>
      </ExciseTaxBasedOnInvstIncmGrp>
      <StatementsRegardingActyGrp>
        <LegislativePoliticalActyInd>0</LegislativePoliticalActyInd>
        <MoreThan100SpentInd>0</MoreThan100SpentInd>
        <Form1120POLFiledInd>0</Form1120POLFiledInd>
        <Section4955OrganizationTaxAmt>0</Section4955OrganizationTaxAmt>
        <Section4955ManagersTaxAmt>0</Section4955ManagersTaxAmt>
        <TaxReimbursedAmt>0</TaxReimbursedAmt>
        <ActivitiesNotPreviouslyRptInd>0</ActivitiesNotPreviouslyRptInd>
        <ChangesToArticlesOrBylawsInd>0</ChangesToArticlesOrBylawsInd>
        <UnrelatedBusIncmOverLimitInd>1</UnrelatedBusIncmOverLimitInd>
        <Form990TFiledInd>1</Form990TFiledInd>
        <OrganizationDissolvedEtcInd>0</OrganizationDissolvedEtcInd>
        <Section508eRqrSatisfiedInd>1</Section508eRqrSatisfiedInd>
        <AtLeast5000InAssetsInd>1</AtLeast5000InAssetsInd>
        <OrgReportOrRegisterStateCd>NY</OrgReportOrRegisterStateCd>
        <Form990PFFiledWithAttyGenInd>1</Form990PFFiledWithAttyGenInd>
        <PrivateOperatingFoundationInd>0</PrivateOperatingFoundationInd>
        <NewSubstantialContributorsInd>0</NewSubstantialContributorsInd>
        <OwnControlledEntityInd referenceDocumentId="RetDoc2204900001 RetDoc2205000001">1</OwnControlledEntityInd>
        <DonorAdvisedFundInd>0</DonorAdvisedFundInd>
        <ComplyWithPublicInspRqrInd>1</ComplyWithPublicInspRqrInd>
        <WebsiteAddressTxt>HELMSLEYTRUST.ORG</WebsiteAddressTxt>
        <PersonsWithBooksName>
          <BusinessNameLine1Txt>NICHOLAS J SCHIAVO CFO</BusinessNameLine1Txt>
        </PersonsWithBooksName>
        <PhoneNum>2126793600</PhoneNum>
        <LocationOfBooksUSAddress>
          <AddressLine1Txt>230 PARK AVENUE SUITE 659</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10169</ZIPCd>
        </LocationOfBooksUSAddress>
        <ForeignAccountsQuestionInd>1</ForeignAccountsQuestionInd>
        <ForeignCountryCd>AS</ForeignCountryCd>
        <ForeignCountryCd>AU</ForeignCountryCd>
        <ForeignCountryCd>BA</ForeignCountryCd>
        <ForeignCountryCd>BG</ForeignCountryCd>
        <ForeignCountryCd>BE</ForeignCountryCd>
        <ForeignCountryCd>BC</ForeignCountryCd>
        <ForeignCountryCd>BR</ForeignCountryCd>
        <ForeignCountryCd>CA</ForeignCountryCd>
        <ForeignCountryCd>CI</ForeignCountryCd>
        <ForeignCountryCd>CO</ForeignCountryCd>
        <ForeignCountryCd>HR</ForeignCountryCd>
        <ForeignCountryCd>CY</ForeignCountryCd>
        <ForeignCountryCd>EZ</ForeignCountryCd>
        <ForeignCountryCd>DA</ForeignCountryCd>
        <ForeignCountryCd>EG</ForeignCountryCd>
        <ForeignCountryCd>FI</ForeignCountryCd>
        <ForeignCountryCd>FR</ForeignCountryCd>
        <ForeignCountryCd>GM</ForeignCountryCd>
        <ForeignCountryCd>GR</ForeignCountryCd>
        <ForeignCountryCd>HK</ForeignCountryCd>
        <ForeignCountryCd>HU</ForeignCountryCd>
        <ForeignCountryCd>IC</ForeignCountryCd>
        <ForeignCountryCd>IN</ForeignCountryCd>
        <ForeignCountryCd>ID</ForeignCountryCd>
        <ForeignCountryCd>IS</ForeignCountryCd>
        <ForeignCountryCd>IT</ForeignCountryCd>
        <ForeignCountryCd>JA</ForeignCountryCd>
        <ForeignCountryCd>JO</ForeignCountryCd>
        <ForeignCountryCd>KZ</ForeignCountryCd>
        <ForeignCountryCd>KE</ForeignCountryCd>
        <ForeignCountryCd>KU</ForeignCountryCd>
        <ForeignCountryCd>LH</ForeignCountryCd>
        <ForeignCountryCd>MY</ForeignCountryCd>
        <ForeignCountryCd>MX</ForeignCountryCd>
        <ForeignCountryCd>MO</ForeignCountryCd>
        <ForeignCountryCd>NL</ForeignCountryCd>
        <ForeignCountryCd>NZ</ForeignCountryCd>
        <ForeignCountryCd>NI</ForeignCountryCd>
        <ForeignCountryCd>NO</ForeignCountryCd>
        <ForeignCountryCd>MU</ForeignCountryCd>
        <ForeignCountryCd>PK</ForeignCountryCd>
        <ForeignCountryCd>PM</ForeignCountryCd>
        <ForeignCountryCd>RP</ForeignCountryCd>
        <ForeignCountryCd>PL</ForeignCountryCd>
        <ForeignCountryCd>PO</ForeignCountryCd>
        <ForeignCountryCd>QA</ForeignCountryCd>
        <ForeignCountryCd>RO</ForeignCountryCd>
        <ForeignCountryCd>RS</ForeignCountryCd>
        <ForeignCountryCd>SN</ForeignCountryCd>
        <ForeignCountryCd>SI</ForeignCountryCd>
        <ForeignCountryCd>SF</ForeignCountryCd>
        <ForeignCountryCd>KS</ForeignCountryCd>
        <ForeignCountryCd>SP</ForeignCountryCd>
        <ForeignCountryCd>CE</ForeignCountryCd>
        <ForeignCountryCd>SW</ForeignCountryCd>
        <ForeignCountryCd>SZ</ForeignCountryCd>
        <ForeignCountryCd>TW</ForeignCountryCd>
        <ForeignCountryCd>TZ</ForeignCountryCd>
        <ForeignCountryCd>TH</ForeignCountryCd>
        <ForeignCountryCd>TS</ForeignCountryCd>
        <ForeignCountryCd>AE</ForeignCountryCd>
        <ForeignCountryCd>UK</ForeignCountryCd>
        <ForeignCountryCd>VM</ForeignCountryCd>
        <ForeignCountryCd>ZA</ForeignCountryCd>
        <ForeignCountryCd>ZI</ForeignCountryCd>
      </StatementsRegardingActyGrp>
      <StatementsRegardingActy4720Grp>
        <SaleOrExchDisqualifiedPrsnInd>1</SaleOrExchDisqualifiedPrsnInd>
        <BrrwOrLendDisqualifiedPrsnInd>0</BrrwOrLendDisqualifiedPrsnInd>
        <FurnGoodsDisqualifiedPrsnInd>1</FurnGoodsDisqualifiedPrsnInd>
        <PayCompDisqualifiedPrsnInd>1</PayCompDisqualifiedPrsnInd>
        <TransferAstDisqualifiedPrsnInd>0</TransferAstDisqualifiedPrsnInd>
        <PaymentToGovernmentOfficialInd>0</PaymentToGovernmentOfficialInd>
        <ActsFailToQlfyAsExceptionsInd>0</ActsFailToQlfyAsExceptionsInd>
        <UncorrectedPriorActsInd>0</UncorrectedPriorActsInd>
        <UndistributedIncomePYInd>0</UndistributedIncomePYInd>
        <BusinessHoldingsInd>1</BusinessHoldingsInd>
        <ExcessBusinessHoldingsInd>0</ExcessBusinessHoldingsInd>
        <JeopardyInvestmentsInd>0</JeopardyInvestmentsInd>
        <UncorrectedPYJeopardyInvstInd>0</UncorrectedPYJeopardyInvstInd>
        <InfluenceLegislationInd>0</InfluenceLegislationInd>
        <InfluenceElectionInd>0</InfluenceElectionInd>
        <GrantsToIndividualsInd>0</GrantsToIndividualsInd>
        <GrantsToOrganizationsInd>1</GrantsToOrganizationsInd>
        <NoncharitablePurposeInd>0</NoncharitablePurposeInd>
        <TransactionsFailToQlfyAsExcInd>0</TransactionsFailToQlfyAsExcInd>
        <MaintainedExpenditureRspnsInd referenceDocumentId="RetDoc2118100001">1</MaintainedExpenditureRspnsInd>
        <RcvFndsToPayPrsnlBnftCntrctInd>0</RcvFndsToPayPrsnlBnftCntrctInd>
        <PayPremiumsPrsnlBnftCntrctInd>0</PayPremiumsPrsnlBnftCntrctInd>
        <ProhibitedTaxShelterTransInd>0</ProhibitedTaxShelterTransInd>
        <SubjToTaxRmnrtnExPrchtPymtInd>1</SubjToTaxRmnrtnExPrchtPymtInd>
      </StatementsRegardingActy4720Grp>
      <OfficerDirTrstKeyEmplInfoGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>SANDOR FRANKEL</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>25.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>125000</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>DAVID PANZIRER</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>35.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>125000</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>WALTER PANZIRER</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>32.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>125000</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>SARAH E PAUL</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>CEO &amp; GENERAL COUNSEL (STMT 22)</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>703476</CompensationAmt>
          <EmployeeBenefitProgramAmt>164438</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>STEPHANIE A CUSKLEY</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>CHIEF EXECUTIVE OFFICER THRU 10/31/21</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>1578355</CompensationAmt>
          <EmployeeBenefitProgramAmt>128388</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>ROSALIND M HEWSENIAN</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>CHIEF INVESTMENT OFFICER</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>1671096</CompensationAmt>
          <EmployeeBenefitProgramAmt>204786</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>NICHOLAS J SCHIAVO</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>CHIEF FINANCIAL OFFICER</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>393338</CompensationAmt>
          <EmployeeBenefitProgramAmt>117317</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>MEENAKSHI C LAKSHMAN</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>DIR. OF STRATEGY &amp; R</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>938579</CompensationAmt>
          <EmployeeBenefitsAmt>173897</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>AL Y KIM</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>DIRECTOR OF INVESTME</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>915458</CompensationAmt>
          <EmployeeBenefitsAmt>171409</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>JOSHUA W FENTON</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>DIRECTOR OF INVESTME</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>914728</CompensationAmt>
          <EmployeeBenefitsAmt>171522</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>CHRISTOPHER J RAPCEWICZ</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>DIR. OF RISK MNGMT.</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>910449</CompensationAmt>
          <EmployeeBenefitsAmt>157200</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>BRIAN B CHUN</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>INVESTMENT OFFICER</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>461296</CompensationAmt>
          <EmployeeBenefitsAmt>88692</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <OtherEmployeePaidOver50kCnt>84</OtherEmployeePaidOver50kCnt>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>HIG MIDDLE MARKET LBO FUND II LP</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>600 5TH AVE 24TH FL</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10020</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>4581511</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>HIG CAPITAL PARTNERS V LP</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>600 5TH AVE 24TH FL</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10020</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>3220352</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>HIGHCLERE INTERNATIONAL INVESTORS</BusinessNameLine1Txt>
          </BusinessName>
          <ForeignAddress>
            <AddressLine1Txt>2 MANCHESTER SQUARE</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </ForeignAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>2901443</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>IFP GLOBAL EQUITY LP</BusinessNameLine1Txt>
          </BusinessName>
          <ForeignAddress>
            <AddressLine1Txt>LEVEL 1 10 PORTMAN SQUARE</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
            <ForeignPostalCd>W1H 6AZ</ForeignPostalCd>
          </ForeignAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>1516005</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>ACADIAN ASSET MANAGEMENT LLC</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>PO BOX 412216</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02241</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>1206736</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <ContractorPaidOver50kCnt>47</ContractorPaidOver50kCnt>
      </OfficerDirTrstKeyEmplInfoGrp>
      <SummaryOfDirectChrtblActyGrp>
        <Description1Txt>FOR THE PRODUCTION OF VIDEO AND OTHER DESIGN SUPPORT TO COMMUNICATE IMPACT IN FURTHERANCE OF THE FOUNDATION'S MISSION.</Description1Txt>
        <Expenses1Amt>1003948</Expenses1Amt>
        <Description2Txt>FOR TECHNICAL SUPPORT TO GRANTEES TO MEET THEIR STRATEGIC AND COMMUNICATIONS NEEDS TO DRIVE FURTHER IMPACT OF THEIR CHARITABLE WORK.</Description2Txt>
        <Expenses2Amt>334053</Expenses2Amt>
        <Description3Txt>FOR CONVENING EXPERTS TO EXPLORE PROGRAM PRIORITIES, SHARE RESEARCH AND IDEAS, AND BRAINSTORM NEW AREAS OF IMPACT IN SUPPORT OF THE FOUNDATION'S MISSION.</Description3Txt>
        <Expenses3Amt>60868</Expenses3Amt>
      </SummaryOfDirectChrtblActyGrp>
      <SumOfProgramRelatedInvstGrp>
        <Description1Txt>THETIS PHARMACEUTICALS, LLC - DEVELOPMENT OF NOVEL RESOLVIN E1 THERAPY FOR CROHN'S TREATMENT</Description1Txt>
        <Expenses1Amt>3285274</Expenses1Amt>
        <Description2Txt>PERCUSENSE, INC. - DEVELOPMENT OF CONTINUOUS GLUCOSE AND KETONE METER FOR TREATMENT IN T1D</Description2Txt>
        <Expenses2Amt>600000</Expenses2Amt>
        <AllOtherProgramRltdInvstTotAmt referenceDocumentId="RetDoc2063500001">410000</AllOtherProgramRltdInvstTotAmt>
        <TotalAmt>4295274</TotalAmt>
      </SumOfProgramRelatedInvstGrp>
      <MinimumInvestmentReturnGrp>
        <AverageMonthlyFMVOfSecAmt>8179026450</AverageMonthlyFMVOfSecAmt>
        <AverageMonthlyCashBalancesAmt>194222475</AverageMonthlyCashBalancesAmt>
        <FMVAllOtherNoncharitableAstAmt>497417</FMVAllOtherNoncharitableAstAmt>
        <TotalFMVOfUnusedAssetsAmt>8373746342</TotalFMVOfUnusedAssetsAmt>
        <ReductionClaimedAmt>0</ReductionClaimedAmt>
        <AcquisitionIndebtednessAmt>0</AcquisitionIndebtednessAmt>
        <AdjustedTotalFMVOfUnusedAstAmt>8373746342</AdjustedTotalFMVOfUnusedAstAmt>
        <CashDeemedCharitableAmt>125606195</CashDeemedCharitableAmt>
        <NetVlNoncharitableAssetsAmt>8248140147</NetVlNoncharitableAssetsAmt>
        <MinimumInvestmentReturnAmt>412407007</MinimumInvestmentReturnAmt>
      </MinimumInvestmentReturnGrp>
      <DistributableAmountGrp>
        <MinimumInvestmentReturnAmt>412407007</MinimumInvestmentReturnAmt>
        <TaxBasedOnInvestmentIncomeAmt>14577769</TaxBasedOnInvestmentIncomeAmt>
        <TotalTaxAmt>14577769</TotalTaxAmt>
        <DistributableBeforeAdjAmt>397829238</DistributableBeforeAdjAmt>
        <RecoveriesQualfiedDistriAmt>451754</RecoveriesQualfiedDistriAmt>
        <DistributableBeforeDedAmt>398280992</DistributableBeforeDedAmt>
        <DeductionFromDistributableAmt>0</DeductionFromDistributableAmt>
        <DistributableAsAdjustedAmt>398280992</DistributableAsAdjustedAmt>
      </DistributableAmountGrp>
      <PFQualifyingDistributionsGrp>
        <ExpensesAndContributionsAmt>409514790</ExpensesAndContributionsAmt>
        <ProgramRelatedInvstTotalAmt>4295274</ProgramRelatedInvstTotalAmt>
        <CharitableAssetsAcquisPaidAmt>4560789</CharitableAssetsAcquisPaidAmt>
        <QualifyingDistributionsAmt>418370853</QualifyingDistributionsAmt>
      </PFQualifyingDistributionsGrp>
      <UndistributedIncomeGrp>
        <DistributableAsAdjustedAmt>398280992</DistributableAsAdjustedAmt>
        <UndistributedIncomePYAmt>120476741</UndistributedIncomePYAmt>
        <TotalForPriorYearsAmt>0</TotalForPriorYearsAmt>
        <TotalExcessDistributionCyovAmt>0</TotalExcessDistributionCyovAmt>
        <QualifyingDistributionsAmt>418370853</QualifyingDistributionsAmt>
        <AppliedToYear1Amt>120476741</AppliedToYear1Amt>
        <AppliedToPriorYearsAmt>0</AppliedToPriorYearsAmt>
        <TreatedAsDistriFromCorpusAmt>0</TreatedAsDistriFromCorpusAmt>
        <AppliedToCurrentYearAmt>297894112</AppliedToCurrentYearAmt>
        <RemainingDistriFromCorpusAmt>0</RemainingDistriFromCorpusAmt>
        <ExcessDistriCyovAppCYCorpusAmt>0</ExcessDistriCyovAppCYCorpusAmt>
        <ExcessDistributionCyovAppCYAmt>0</ExcessDistributionCyovAppCYAmt>
        <TotalCorpusAmt>0</TotalCorpusAmt>
        <PriorYearUndistributedIncmAmt>0</PriorYearUndistributedIncmAmt>
        <PriorYearDeficiencyOrTaxAmt>0</PriorYearDeficiencyOrTaxAmt>
        <Taxable1Amt>0</Taxable1Amt>
        <Taxable2Amt>0</Taxable2Amt>
        <UndistributedIncomeCYAmt>100386880</UndistributedIncomeCYAmt>
        <CorpusDistri170b1EOr4942g3Amt>0</CorpusDistri170b1EOr4942g3Amt>
        <ExcessDistriCyovFromYr5Amt>0</ExcessDistriCyovFromYr5Amt>
        <ExcessDistriCyovToNextYrAmt>0</ExcessDistriCyovToNextYrAmt>
      </UndistributedIncomeGrp>
      <SupplementaryInformationGrp>
        <OnlyContriToPreselectedInd>X</OnlyContriToPreselectedInd>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>4YOUANDME</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2901 THIRD AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WEARABLES TO MEASURE STRESS AND FORECAST CROHNS SYMPTOMS</GrantOrContributionPurposeTxt>
          <Amt>84107</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>A GLIMMER OF HOPE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3103 BEE CAVES ROAD</AddressLine1Txt>
            <CityNm>AUSTIN</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>78746</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PF</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTEGRATED COMMUNITY DEVELOPMENT IN ODA BULTUM, ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>1449415</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AGRICULTURAL RESEARCH ORGANIZATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DERECH HAMACCABIM 68 RISHON</AddressLine1Txt>
            <AddressLine2Txt>LETSIYON</AddressLine2Txt>
            <CityNm>RISHON LETSIYON</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY CENTER FOR AI IN AGRICULTURE AT THE VOLCANI CENTER</GrantOrContributionPurposeTxt>
          <Amt>1591900</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALASKA NATIVE TRIBAL HEALTH CONSORTIUM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4000 AMBASSADOR DRIVE</AddressLine1Txt>
            <CityNm>ANCHORAGE</CityNm>
            <StateAbbreviationCd>AK</StateAbbreviationCd>
            <ZIPCd>99508</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TULUKSAK WATER AND WASTEWATER SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>792660</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALBERT EINSTEIN COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 MORRIS PARK AVE</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>104611975</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECLINICAL WORK TO ADVANCE D-PEPTIDES AS ANTIGEN-SPECIFIC IMMUNOTHERAPY</GrantOrContributionPurposeTxt>
          <Amt>2381358</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALIMENTIV INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD</GrantOrContributionPurposeTxt>
          <Amt>366257</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALIMENTIV INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>116515</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALVIN AILEY DANCE FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE JOAN WEILL CENTER FOR DANCE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10019</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALYN HOSPITAL - REHABILITATION CENTER FOR CHILDREN AND YOUTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>84 SHMARYAHU LEVIN ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ALYN CENTER FOR INNOVATION IN PEDIATRIC REHABILITATION RESEARCH</GrantOrContributionPurposeTxt>
          <Amt>777749</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMC MEDICAL RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION OF BIOMARKERS FOR PERIANAL FISTULIZING DISEASE</GrantOrContributionPurposeTxt>
          <Amt>942690</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMC MEDICAL RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION OF BIOMARKERS FOR PERIANAL FISTULIZING DISEASE</GrantOrContributionPurposeTxt>
          <Amt>50570</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN CAMPING ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5000 STATE ROAD 67 NORTH</AddressLine1Txt>
            <CityNm>MARTINSVILLE</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>46151</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACA PROFESSIONAL DEVELOPMENT 2022 - 2024</GrantOrContributionPurposeTxt>
          <Amt>46860</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADA MENTAL HEALTH EDUCATION PROGRAM 2022 - 2024</GrantOrContributionPurposeTxt>
          <Amt>382893</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2022-2024 TYPE 1 DIABETES CAMP INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>331219</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM SUPPORT FOR ADAS HEALTH EQUITY NOW 4TH NETWORK - COLUMBUS STUDY</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOCUS ON FELLOWS, DIABETES IS PRIMARY, PROFESSIONAL MEMBERSHIP PROJECTS</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PATRON SUPPORT OF THE ASSOCIATION'S 79TH, 80TH, AND 81ST SESSIONS</GrantOrContributionPurposeTxt>
          <Amt>75000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AMERICAN BOARD OF TELEHEALTH PROGRAM EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>1346286</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MISSION: LIFELINE STROKE MT AND POST-ACUTE STROKE CARE QUALITY STANDARDS</GrantOrContributionPurposeTxt>
          <Amt>1144990</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MISSION: LIFELINE STROKE SYSTEM OF CARE IN NEBRASKA</GrantOrContributionPurposeTxt>
          <Amt>1034941</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN PHARMACISTS ASSOCIATION FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2215 CONSTITUTION AVE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ACCESS TO CGM THROUGH COMMUNITY PHARMACY</GrantOrContributionPurposeTxt>
          <Amt>249913</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN TELEMEDICINE ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>901 NGLEBE RD</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>24000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICARES FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>88 HAMILTON AVE</AddressLine1Txt>
            <CityNm>STAMFORD</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06840</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL, NEWBORN, AND CHILD HEALTH INTERVENTIONS</GrantOrContributionPurposeTxt>
          <Amt>930374</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICARES FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>88 HAMILTON AVE</AddressLine1Txt>
            <CityNm>STAMFORD</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06840</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>OXYGEN FOR SUNTRESO HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>183200</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 SOUTH WACKER DRIVE SUITE 600</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60606</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF DANATECH PLATFORM</GrantOrContributionPurposeTxt>
          <Amt>400000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 SOUTH WACKER DRIVE SUITE 600</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60606</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AADE TECHNOLOGY INSTITUTE: DANA - DIABETES ADVANCED NETWORK ACCESS</GrantOrContributionPurposeTxt>
          <Amt>216544</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LEVEL 2</AddressLine1Txt>
            <CityNm>FITZROY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE: THE MIRO STUDY</GrantOrContributionPurposeTxt>
          <Amt>758947</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1325 S CLIFF AVENUE</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AVERA BEHAVIORAL HEALTH CENTER EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>3000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1325 S CLIFF AVENUE</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AVERA BEHAVIORAL HEALTH CENTER EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AVERA MERRILL PIONEER HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 S 10TH AVE</AddressLine1Txt>
            <CityNm>ROCK RAPIDS</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51246</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AND EPHARMACY AT AVERA MERRILL PIONEER HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>19959</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BALLAD RESEARCH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10865 ROAD TO THE CURE</AddressLine1Txt>
            <CityNm>SAN DIEGO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CD127-HIGH T-CELL POPULATIONS AS BIOMARKERS</GrantOrContributionPurposeTxt>
          <Amt>516369</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAPTIST MEDICAL CENTRE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BAPTIST MEDICAL CENTRE ROAD</AddressLine1Txt>
            <CityNm>NALERIGU</CityNm>
            <CountryCd>GH</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY CENTRE AND DOCTOR HOUSING DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>1513500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAYLOR COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH</AddressLine1Txt>
            <CityNm>HOUSTON</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMR-BASED PREDICTIVE ANALYTICS FOR TARGETED &amp; PROACTIVE T1D CARE</GrantOrContributionPurposeTxt>
          <Amt>500994</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAYLOR COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH</AddressLine1Txt>
            <CityNm>HOUSTON</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE</GrantOrContributionPurposeTxt>
          <Amt>501482</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 NINTH AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981012795</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GUIDELINES FOR CLINICAL FOLLOW-UP OF MULTIPLE ISLET AUTOANTIBODIES</GrantOrContributionPurposeTxt>
          <Amt>70000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 NINTH AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981012795</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN IN T1D</GrantOrContributionPurposeTxt>
          <Amt>581045</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 NINTH AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981012795</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GUIDELINES FOR CLINICAL PRACTICE OF AUTOANTIBODY POSITIVE INDIVIDUALS</GrantOrContributionPurposeTxt>
          <Amt>70000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BETH ISRAEL DEACONESS MEDICAL CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>330 BROOKLINE AVENUE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022155491</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD</GrantOrContributionPurposeTxt>
          <Amt>526637</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEYOND TYPE 1</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1001 LAUREL ST STE B</AddressLine1Txt>
            <CityNm>SAN CARLOS</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABETIC KETOACIDOSIS (DKA) CAMPAIGN PHASE 3</GrantOrContributionPurposeTxt>
          <Amt>451667</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BIG HORN HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>17 N MILES AVE</AddressLine1Txt>
            <CityNm>HARDIN</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59034</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AND EPHARMACY AT BIG HORN HOSPITAL ASSOCIATION IN HARDIN, MT</GrantOrContributionPurposeTxt>
          <Amt>24948</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MONTANA PSYCHIATRY RESIDENCY PROGRAM SUSTAINING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BIPARTISAN POLICY CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1225 I ST NW 1000</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING HEALTH CARE DELIVERY AND SERVICES IN RURAL AMERICA</GrantOrContributionPurposeTxt>
          <Amt>622488</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BIPARTISAN POLICY CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1225 I ST NW 1000</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RURAL HEALTH CARE TASK FORCE</GrantOrContributionPurposeTxt>
          <Amt>149200</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>15576000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON MEDICAL CENTER CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE BOSTON MEDICAL PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02118</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STAGING CROHNS DISEASE USING MUCOSAL EXOSOMES</GrantOrContributionPurposeTxt>
          <Amt>94406</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON MEDICAL CENTER CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE BOSTON MEDICAL PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02118</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STAGING CROHNS DISEASE USING MUCOSAL EXOSOMES</GrantOrContributionPurposeTxt>
          <Amt>55704</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON SYMPHONY ORCHESTRA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>301 MASSACHUSETTS AVENUE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOULDER CITY HOSPITAL INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>901 ADAMS BLVD</AddressLine1Txt>
            <CityNm>BOULDER CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BOULDER CITY HOSPITAL ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>100838</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOULDER CITY HOSPITAL INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>901 ADAMS BLVD</AddressLine1Txt>
            <CityNm>BOULDER CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BOULDER CITY HOSPITAL EQUIPMENT REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>663285</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIDGES TO PROSPERITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1031 33RD STREET</AddressLine1Txt>
            <CityNm>DENVER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMATIVE CONNECTIVITY IN RURAL ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>5262850</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS</GrantOrContributionPurposeTxt>
          <Amt>548201</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PEN-PLUS EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>1325594</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INVESTIGATION OF ANTI-GM-CSF AUAB AS A DISEASE DETERMINANT IN CD</GrantOrContributionPurposeTxt>
          <Amt>872027</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>20000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS</GrantOrContributionPurposeTxt>
          <Amt>3031033</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BURGESS HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1600 DIAMOND STREET</AddressLine1Txt>
            <CityNm>ONAWA</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51040</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AND EPHARMACY AT BURGESS HEALTH CENTER</GrantOrContributionPurposeTxt>
          <Amt>33587</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HILLS ROAD</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO CD TREATMENTS</GrantOrContributionPurposeTxt>
          <Amt>312018</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CANDID</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>32 OLD SLIP 24TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>17551</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CARE FOR THE HOMELESS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>30 EAST 33RD STREET 5TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10016</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW YORK CITY COLLABORATIVE FOR HOMELESS HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CARE-FOR-RARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DR VON HAUNERSCHES KINDERSPITAL</AddressLine1Txt>
            <CityNm>MUNICH</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VEOIBD FROM PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES - MUNICH</GrantOrContributionPurposeTxt>
          <Amt>643036</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BOUSSOUMA AND ZIGA, BURKINA FASO IMPROVED WASH INFRASTRUCTURE &amp; SERVICES</GrantOrContributionPurposeTxt>
          <Amt>2045026</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTEGRATED COMMUNITY WATER, SANITATION AND HYGIENE IMPROVEMENT IN GHANA</GrantOrContributionPurposeTxt>
          <Amt>2589304</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MAYI MWANA PROJECT: HELPING ZAMBIAN MOTHERS &amp; NEWBORNS SURVIVE &amp; THRIVE</GrantOrContributionPurposeTxt>
          <Amt>1066649</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RURAL EMERGENCY HEALTH SERVICE AND TRANSPORT FOR SYSTEM DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>1597757</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMMUNITY RECOVERY AND RESILIENCE IN EASTERN ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>2752636</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LONG-TERM RESPONSE TO SARS-COV-2 VACCINATION IN A DIVERSE IBD POPULATION</GrantOrContributionPurposeTxt>
          <Amt>976541</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES CEDARS-SINAI</GrantOrContributionPurposeTxt>
          <Amt>115500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING MICROORGANISMS IN CREEPING FAT</GrantOrContributionPurposeTxt>
          <Amt>375747</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING MICROORGANISMS IN CREEPING FAT</GrantOrContributionPurposeTxt>
          <Amt>393039</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTER FOR EXCELLENCE IN HEALTH CARE JOURNALISM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10 NEFF HALL</AddressLine1Txt>
            <CityNm>COLUMBIA</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>65211</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOII</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRAINING AND DEVELOPMENT OF HEALTH CARE JOURNALISTS AND HEALTH REPORTING</GrantOrContributionPurposeTxt>
          <Amt>180005</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTER FOR URBAN COMMUNITY SERVICES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>198 EAST 121ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10035</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW YORK CITY COLLABORATIVE FOR HOMELESS HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTRAL MONTANA MEDICAL FACILITIES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>408 WENDELL AVE</AddressLine1Txt>
            <CityNm>LEWISTOWN</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59457</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CANCER CENTER AT CENTRAL MONTANA MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>1840000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTRE HOSPITALIER REGIONAL DE NANCY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>29 AVENUE MAL DE LATTRE DE TASSIGNY</AddressLine1Txt>
            <CityNm>NANCY</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE</GrantOrContributionPurposeTxt>
          <Amt>173555</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN OF THE LIGHT INTERNATIONAL MINISTRIES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1171 E 95TH STREET</AddressLine1Txt>
            <CityNm>BROOKLYN</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11236</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>25000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES- BOSTON</GrantOrContributionPurposeTxt>
          <Amt>1155528</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULINS</GrantOrContributionPurposeTxt>
          <Amt>662214</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>1162617</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE-RESPONSIVE APPROACHES TO INSULIN AND GLUCAGON DELIVERY</GrantOrContributionPurposeTxt>
          <Amt>567507</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>SABAN RESEARCH INSTITUTE</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90027</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TEAM CLINIC: EXPANSION OF A CARE MODEL FOR ADOLESCENTS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>360832</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>SABAN RESEARCH INSTITUTE</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90027</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE</GrantOrContributionPurposeTxt>
          <Amt>527168</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP A PROGNOSTIC AI MODEL FOR FORECASTING CD PATIENT OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>1242522</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>833493</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECISION CROHNS DISEASE MANAGEMENT UTILIZING PREDICTIVE PROTEIN PANELS</GrantOrContributionPurposeTxt>
          <Amt>613632</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BIOMARKERS OF INTESTINAL FIBROSIS IN SMALL BOWEL CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>692740</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL OF PHILADELPHIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2716 SOUTH STREET</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191462305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHNS DISEASE EPITHELIAL STEM CELL ATLAS: PEDIATRIC TO ADULT CONTINUUM</GrantOrContributionPurposeTxt>
          <Amt>281734</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL OF PHILADELPHIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2716 SOUTH STREET</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191462305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHNS DISEASE EPITHELIAL STEM CELL ATLAS: PEDIATRIC TO ADULT CONTINUUM</GrantOrContributionPurposeTxt>
          <Amt>424937</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HUNGER FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13931 BALBOA BLVD</AddressLine1Txt>
            <CityNm>SYLMAR</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91342</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MEDICAL AND ORPHAN CARE INITIATIVE IN ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>250409</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S MERCY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2401 GILLHAM ROAD</AddressLine1Txt>
            <CityNm>KANSAS CITY</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>64108</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RAPID LEARNING LAB</GrantOrContributionPurposeTxt>
          <Amt>445112</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S MERCY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2401 GILLHAM ROAD</AddressLine1Txt>
            <CityNm>KANSAS CITY</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>64108</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RAPID LEARNING LAB</GrantOrContributionPurposeTxt>
          <Amt>2012361</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITIZENS HOUSING AND PLANNING COUNCIL OF NEW YORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>42 BROADWAY STE 2010</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10004</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDUCATION FOR NYC POLICYMAKERS ON HOUSING INITIATIVES TO IMPROVE HEALTH</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY PARKS FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>830 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CATALYST: GROWING INTENSIVE PARK ENGAGEMENT IN VULNERABLE COMMUNITIES</GrantOrContributionPurposeTxt>
          <Amt>479444</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY PARKS FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>830 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC GREEN RELIEF &amp; RECOVERY FUND</GrantOrContributionPurposeTxt>
          <Amt>537825</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CIVICA FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2912 WEST EXECUTIVE PARKWAY</AddressLine1Txt>
            <CityNm>LEHI</CityNm>
            <StateAbbreviationCd>UT</StateAbbreviationCd>
            <ZIPCd>84043</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AFFORDABLE INSULIN BIOSIMILARS</GrantOrContributionPurposeTxt>
          <Amt>5000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>KIRYAT SHMONA MEDICAL CLINIC</GrantOrContributionPurposeTxt>
          <Amt>1118393</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BIO-MDT APPROACH TO PERSONALIZED TREATMENT OF POUCHITIS</GrantOrContributionPurposeTxt>
          <Amt>748810</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>589062</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE IBDMED NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL &amp; PREVENTION</GrantOrContributionPurposeTxt>
          <Amt>451795</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PET/CT SCANNER FOR EMEK MEDICAL CENTER IN AFULA, ISRAEL</GrantOrContributionPurposeTxt>
          <Amt>2075000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MEDICAL EQUIPMENT FOR CARMEL MEDICAL CENTER IN HAIFA, ISRAEL</GrantOrContributionPurposeTxt>
          <Amt>3896000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COVID-19 VACCINE RESPONSES IN PATIENTS WITH IBD</GrantOrContributionPurposeTxt>
          <Amt>165855</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>589062</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EARLY CROHNS DISEASE: UNDERSTANDING PATHOGENESIS, BEHAVIOR, RESPONSE</GrantOrContributionPurposeTxt>
          <Amt>112000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAELI IBD RESEARCH NUCLEUS (IIRN): CONSORTIUM MANAGEMENT</GrantOrContributionPurposeTxt>
          <Amt>32000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BIO-MDT APPROACH TO PERSONALIZED TREATMENT OF POUCHITIS</GrantOrContributionPurposeTxt>
          <Amt>582660</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>KIRYAT SHMONA MEDICAL CLINIC</GrantOrContributionPurposeTxt>
          <Amt>1405714</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLARINDA REGIONAL HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>220 ESSIE DAVISON DRIVE</AddressLine1Txt>
            <CityNm>CLARINDA</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51632</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT CLARINDA REGIONAL HEALTH CENTER</GrantOrContributionPurposeTxt>
          <Amt>16247</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 WEST 15TH STREET SUITE 800</AddressLine1Txt>
            <CityNm>AUSTIN</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>78701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CDISC STANDARDS DEVELOPMENT PROJECT FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>14355</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLINTON HEALTH ACCESS INITIATIVE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>383 DORCHESTER AVENUE SUITE 400</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02127</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE</GrantOrContributionPurposeTxt>
          <Amt>845202</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POVERTY TRACKER SURVEY: HEALTHCARE NEEDS &amp; USE OF LOW-INCOME NEW YORKERS</GrantOrContributionPurposeTxt>
          <Amt>81367</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL SPATIALLY RESOLVED GENOMIC PROFILING OF CROHNS DISEASE TISSUE</GrantOrContributionPurposeTxt>
          <Amt>210228</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POVERTY TRACKER SURVEY: HEALTHCARE NEEDS &amp; USE OF LOW-INCOME NEW YORKERS</GrantOrContributionPurposeTxt>
          <Amt>110040</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL SPATIALLY RESOLVED GENOMIC PROFILING OF CROHNS DISEASE TISSUE</GrantOrContributionPurposeTxt>
          <Amt>146811</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>232672</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COMMUNITY CENTERS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2 ST ROCH AVENUE</AddressLine1Txt>
            <CityNm>GREENWICH</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06830</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>35000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COMMUNITY MEMORIAL HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2731 HEALTHCARE DRIVE</AddressLine1Txt>
            <CityNm>SYRACUSE</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68446</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE EMERGENCY AT SYRACUSE AREA HEALTH</GrantOrContributionPurposeTxt>
          <Amt>33296</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CONSORCI INSTITUT D'INVESTIGACIONES BIOMEDICAS AUGUST</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>ROSSELL 149</AddressLine1Txt>
            <CityNm>BARCELONA</CityNm>
            <CountryCd>SP</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EARLY DETECTION OF PERIANAL FISTULIZING DISEASE</GrantOrContributionPurposeTxt>
          <Amt>270828</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CONSORCI INSTITUT D'INVESTIGACIONES BIOMEDICAS AUGUST</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>ROSSELL 149</AddressLine1Txt>
            <CityNm>BARCELONA</CityNm>
            <CountryCd>SP</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EARLY DETECTION OF PERIANAL FISTULIZING DISEASE</GrantOrContributionPurposeTxt>
          <Amt>262204</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COUNCIL ON FOUNDATIONS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1255 23RD ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>34000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COUNCIL ON THE ENVIRONMENT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>100 GOLD ST SUITE 3300</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTER-GENERATIONAL, VIABLE GREENSPACE IN NYCHA COMMUNITIES</GrantOrContributionPurposeTxt>
          <Amt>116600</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT FOR CCF'S CROHNS AND COLITIS CONGRESS- JANUARY, 2022</GrantOrContributionPurposeTxt>
          <Amt>205000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD</GrantOrContributionPurposeTxt>
          <Amt>544115</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT JUNIOR SCIENTISTS TO ESTABLISH CAREERS IN IBD RESEARCH.</GrantOrContributionPurposeTxt>
          <Amt>1067400</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD</GrantOrContributionPurposeTxt>
          <Amt>494615</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>323983</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE</GrantOrContributionPurposeTxt>
          <Amt>261030</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT FOR CROHNS &amp; COLITIS CANADA 2020- 21 PATIENT PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>65990</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE</GrantOrContributionPurposeTxt>
          <Amt>315009</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>165648</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS UK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 BISHOPS SQUARE</AddressLine1Txt>
            <CityNm>HATFIELD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2021 2022 OPERATING SUPPORT FOR CROHNS AND COLITIS UK</GrantOrContributionPurposeTxt>
          <Amt>75900</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S COLITIS CURE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 OCONNELL STREET</AddressLine1Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF CCCARE-P, A PEDIATRIC CD EMR TO DRIVE CONSISTENCY IN CARE</GrantOrContributionPurposeTxt>
          <Amt>175233</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DARTMOUTH- HITCHCOCK CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE MEDICAL CENTER DRIVE</AddressLine1Txt>
            <CityNm>LEBANON</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03756</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING FOR VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>195140</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DE LA SALLE SOLIDARIETAINTERNAZIONALE ONLUS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>VIA AUREALIA 476</AddressLine1Txt>
            <CityNm>ROME</CityNm>
            <CountryCd>IT</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ESTABLISHING A ROBUST MEDICAL EDUCATION CENTER - ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>294372</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DE LA SALLE SOLIDARIETAINTERNAZIONALE ONLUS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>VIA AUREALIA 476</AddressLine1Txt>
            <CityNm>ROME</CityNm>
            <CountryCd>IT</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ETHIOPIAN CATHOLIC UNIVERSITY DIAGNOSTIC LABORATORY</GrantOrContributionPurposeTxt>
          <Amt>1043204</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DELAWARE COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>709 W MAIN ST</AddressLine1Txt>
            <CityNm>MANCHESTER</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52057</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AND EPHARMACY AT REGIONAL MEDICAL CENTER IN MANCHESTER, IA</GrantOrContributionPurposeTxt>
          <Amt>29195</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DUKE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O OFFICE OF RESEARCH SUPPORT</AddressLine1Txt>
            <CityNm>DURHAM</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>277054677</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS &amp; GIP IN PANCREATIC CELLS</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ELLSWORTH MUNICIPAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>920 SOUTH OAK STREET</AddressLine1Txt>
            <CityNm>IOWA FALLS</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50126</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPHARMACY AT HANSEN FAMILY HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>8493</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ENGINEERING MINISTRIES INTERNATIONAL USA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7025 CAMPUS DRIVE</AddressLine1Txt>
            <CityNm>COLORADO SPRINGS</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80920</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ALASKA WASH PROJECT</GrantOrContributionPurposeTxt>
          <Amt>6680429</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FALL RIVER HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 HIGHWAY 71 S</AddressLine1Txt>
            <CityNm>HOT SPRINGS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57747</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT FALL RIVER HEALTH SERVICES</GrantOrContributionPurposeTxt>
          <Amt>17325</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FEEDING SOUTH DAKOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4701 N WESTPORT AVE</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>571070123</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>25000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FIRST AFFILIATED HOSPITAL OF SUN YAT-SEN UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>58 ZHONGSHAN II ROAD</AddressLine1Txt>
            <CityNm>GUANGZHOU</CityNm>
            <CountryCd>CH</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INDUSTRIALIZATION RELATED ENVIRONMENTAL CHANGES &amp; MICROBIOME ALTERATIONS</GrantOrContributionPurposeTxt>
          <Amt>120000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FLORESTA USA INCORPORATED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4747 MORENA BLVD STE 100</AddressLine1Txt>
            <CityNm>SAN DIEGO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92117</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING AT THE WATERSHED LEVEL TO EQUIP RURAL FAMILIES</GrantOrContributionPurposeTxt>
          <Amt>1048129</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FLOYD VALLEY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>714 LINCOLN STREET NE</AddressLine1Txt>
            <CityNm>LE MARS</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51031</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT FLOYD VALLEY HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>14837</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FOR INSPIRATION AND RECOGNITION OF SCIENCE TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 BEDFORD STREET</AddressLine1Txt>
            <CityNm>MANCHESTER</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INSPIRE YOUNG PEOPLE TO BE SCIENCE AND TECHNOLOGY LEADERS</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FORSCHERGRUPPE DIABETES EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FR1DA-PLUS COHORT STUDY</GrantOrContributionPurposeTxt>
          <Amt>467844</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FRANCISCAN CARE SERVICES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>430 N MONITOR ST</AddressLine1Txt>
            <CityNm>WEST POINT</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68788</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT FRANCISCAN HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>114632</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FRIENDS OF THE ISRAEL DEFENSE FORCES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>60 EAST 42 STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10165</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE UNIFORM TO UNIVERSITY SCHOLARSHIP PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>334400</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FUND FOR PUBLIC HEALTH IN NEW YORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>22 CORTLANDT STREET SUITE 802</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10007</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC VACCINE EQUITY PARTNER ENGAGEMENT PROJECT</GrantOrContributionPurposeTxt>
          <Amt>2249533</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FUND FOR PUBLIC HOUSING INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>90 CHURCH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10007</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRATEGIC PLANNING AND DEMONSTRATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GALILEE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>GALILEE MEDICAL CENTER</AddressLine1Txt>
            <CityNm>NAHARIYA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PURCHASE OF TWO ECMO MACHINES FOR GALILEE MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>157000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEORGIA TECH RESEARCH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>505 10TH STREET NW</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>303320420</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRACKING &amp; INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>951960</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GIRLS WITH GUTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>6024 RIDGE AVENUE</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>19128</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2021 &amp; 2022 OPERATING SUPPORT TO GIRLS WITH GUTS.</GrantOrContributionPurposeTxt>
          <Amt>9862</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GIRLS WITH GUTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>6024 RIDGE AVENUE</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>19128</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2021 2022 OPERATING SUPPORT TO GIRLS WITH GUTS.</GrantOrContributionPurposeTxt>
          <Amt>9862</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GLOBAL SOLIDARITY FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>425 LEXINGTON AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JOB CREATION IN ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>1508200</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GORDON MEMORIAL HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 E 8TH ST</AddressLine1Txt>
            <CityNm>GORDON</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69343</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT GORDON MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>14384</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GRAND CANYON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3300 WEST CAMELBACK ROAD</AddressLine1Txt>
            <CityNm>PHOENIX</CityNm>
            <StateAbbreviationCd>AZ</StateAbbreviationCd>
            <ZIPCd>85017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR</GrantOrContributionPurposeTxt>
          <Amt>766986</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GRANTMAKERS FOR EFFECTIVE ORGANIZATIONS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1310 L STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>18920</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GRANTMAKERS IN HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 CT AVENUE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>23760</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GRANTMAKERS IN HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 CT AVENUE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GRANTMAKERS IN HEALTH EFFECTIVE PHILANTHROPY FUND</GrantOrContributionPurposeTxt>
          <Amt>30197</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GUARDIAN ORG FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>900 17TH STREET NW SUITE 250</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN INDEPENDENT JOURNALISM SERIES ON NON-COMMUNICABLE DISEASES</GrantOrContributionPurposeTxt>
          <Amt>875000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GUTTENBERG MUNICIPAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 MAIN ST</AddressLine1Txt>
            <CityNm>GUTTENBERG</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52052</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AND EPHARMACY AT GUTTENBERG MUNICIPAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>26922</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HANNOVERSCHE KINDERHEILANSTALT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>JANUSZ-KORCZAK-ALLEE 12</AddressLine1Txt>
            <CityNm>HANNOVER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FR1DA IN NORTH GERMANY: PRE-SYMPTOMATIC TYPE 1 DIABETES TESTING IN KIDS</GrantOrContributionPurposeTxt>
          <Amt>286700</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HARLAN COUNTY HEALTH SYSTEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>717 NORTH BROWN</AddressLine1Txt>
            <CityNm>ALMA</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>689200836</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPHARMACY AT HARLAN COUNTY HEALTH SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>9737</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEALTH ADVOCACY SUMMIT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1962 DOCKSIDE DRIVE</AddressLine1Txt>
            <CityNm>GREENWOOD</CityNm>
            <StateAbbreviationCd>ID</StateAbbreviationCd>
            <ZIPCd>46143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2021 OPERATING SUPPORT FOR HEALTH ADVOCACY SUMMIT AND THE CCYAN</GrantOrContributionPurposeTxt>
          <Amt>25000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEALTH ADVOCACY SUMMIT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1962 DOCKSIDE DRIVE</AddressLine1Txt>
            <CityNm>GREENWOOD</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>46143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2021 OPERATING SUPPORT FOR HEALTH ADVOCACY SUMMIT AND THE CCYAN</GrantOrContributionPurposeTxt>
          <Amt>25000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEALTH FINANCE INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1690 NORTH QUINN STREET</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22209</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CATALYZE FINANCE &amp; PARTNERS TO ADDRESS GLOBAL BURDEN OF CHRONIC DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1633848</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEALTHPARTNERS INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 1309</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55440</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIRECT INTEGRATION OF CGM DATA INTO THE EMR</GrantOrContributionPurposeTxt>
          <Amt>284446</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEALTHPARTNERS INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 1309</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55440</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIRECT INTEGRATION OF CGM DATA INTO THE EMR</GrantOrContributionPurposeTxt>
          <Amt>258500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEBREW UNIVERSITY OF JERUSALEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OFFICE OF THE PRESIDENT</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>775164</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEBREW UNIVERSITY OF JERUSALEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OFFICE OF THE PRESIDENT</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>18350</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEBREW UNIVERSITY OF JERUSALEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OFFICE OF THE PRESIDENT</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>249301</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELEN KELLER INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE DAG HAMMARSKJOLD PLAZA</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT</GrantOrContributionPurposeTxt>
          <Amt>1902757</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD DRIED BLOOD SPOT OMICS TO PREDICT HEALTH OUTCOMES IN CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>604654</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>1800000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION OF THE GPPAD-02-STUDY</GrantOrContributionPurposeTxt>
          <Amt>2428367</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>668907</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT</GrantOrContributionPurposeTxt>
          <Amt>263397</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION OF INFANTS WITH HIGH RISK OF T1D - PRIMARY PREVENTION</GrantOrContributionPurposeTxt>
          <Amt>3653834</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>2705330</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HENRY J KAISER FAMILY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>185 BERRY STREET NO 2000</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94107</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>KHN RURAL HEALTH DESK</GrantOrContributionPurposeTxt>
          <Amt>1451938</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HERLEV OG GENTOFTE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERLEV AND GENTOFTE HOSPITAL</AddressLine1Txt>
            <CityNm>HERLEV</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS &amp; GIP IN PANCREATIC CELLS</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HERLEV OG GENTOFTE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERLEV AND GENTOFTE HOSPITAL</AddressLine1Txt>
            <CityNm>HERLEV</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D</GrantOrContributionPurposeTxt>
          <Amt>249897</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HILLEL YAFFE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HA-SHALOM ST</AddressLine1Txt>
            <CityNm>HADERA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PURCHASE TWO ECMO MACHINES FOR HILLEL YAFFE MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>155418</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HUMBOLDT COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>118 E HASKELL STREET</AddressLine1Txt>
            <CityNm>WINNEMUCCA</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89445</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRASOUND EQUIPMENT</GrantOrContributionPurposeTxt>
          <Amt>209393</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VEOIBD: PRECISION DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES</GrantOrContributionPurposeTxt>
          <Amt>220000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MODULATING EARLY LIFE MICROBIOME THROUGH DIETARY INTERVENTION IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>479190</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SAFETY AND TOLERABILITY OF ORAL BFAHF-2 IN PEDIATRIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>267814</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATING AID TECHNOLOGY IN PREGNANT WOMEN WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>482282</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>664751</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MODULATING EARLY LIFE MICROBIOME THROUGH DIETARY INTERVENTION IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>492812</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SAFETY AND TOLERABILITY OF ORAL BFAHF-2 IN PEDIATRIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>375235</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICHUD HATZALAH ISRAEL 1221 (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>78 YIRMIYAHU ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNITED HATZALAH HUMANITARIAN MISSION FOR UKRAINE</GrantOrContributionPurposeTxt>
          <Amt>385000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICHUD HATZALAH ISRAEL 1221 (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>78 YIRMIYAHU ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>URGENT NEED FOR PROTECTIVE VESTS AND HELMETS</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IDA COUNTY IOWA COMMUNITY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>701 EAST SECOND STREET</AddressLine1Txt>
            <CityNm>IDA GROVE</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51445</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE PHARMACY AT HORN MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>24192</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IDEOORG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>444 SPEAR STREET</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN-CENTERED DESIGN STUDY OF T1D IN MEDICALLY UNDERSERVED COMMUNITIES.</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IDEOORG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>444 SPEAR STREET</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN-CENTERED DESIGN STUDY OF T1D IN MEDICALLY UNDERSERVED COMMUNITIES.</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INCLINE VILLAGE COMMUNITY HOSPITAL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>880 ALDER AVE</AddressLine1Txt>
            <CityNm>INCLINE VILLAGE</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89451</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIAGNOSTIC IMAGING EQUIPMENT RELATED FUNDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1796260</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INDIANA UNIVERSITY (AMPATH PROJECT)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>702 ROTARY CIRCLE</AddressLine1Txt>
            <CityNm>INDIANAPOLIS</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>46202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AMPATH MODEL REPLICATION IN GHANA</GrantOrContributionPurposeTxt>
          <Amt>2131500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INDIANA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>702 ROTARY CIRCLE</AddressLine1Txt>
            <CityNm>INDIANAPOLIS</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>46202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AMPATH MODEL REPLICATION IN GHANA</GrantOrContributionPurposeTxt>
          <Amt>3474440</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>41401</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT NATIONALE DE LA SANTE DE LA RECHERCHE MEDICALE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>86 RUE REGNAULT</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BENIGN ISLET AUTOIMMUNITY TO T1D: CD8+ T-CELL BIOMARKERS OF PROGRESSION</GrantOrContributionPurposeTxt>
          <Amt>373431</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT NATIONALE DE LA SANTE ET DE LA RECHERCHE MEDICALE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>86 RUE REGNAULT</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BENIGN ISLET AUTOIMMUNITY TO T1D: CD8+ T-CELL BIOMARKERS OF PROGRESSION</GrantOrContributionPurposeTxt>
          <Amt>178286</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSULIN FOR LIFE USA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2555 SW 76TH STREET</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>32608</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INSULIN FOR LIFE USA STRENGTHENING ORGANIZATIONAL CAPACITY</GrantOrContributionPurposeTxt>
          <Amt>296175</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE DEVELOPMENT OF A DISEASE ACTIVITY INDEX FOR INTESTINAL ULTRASOUND</GrantOrContributionPurposeTxt>
          <Amt>693935</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL WATER MANAGEMENT INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>127 SUNIL MAWATHA</AddressLine1Txt>
            <CityNm>BATTARAMULLA</CityNm>
            <CountryCd>CE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WATER SECURE AFRICA INITIATIVE: OPEN DATA CUBE EXTENSION</GrantOrContributionPurposeTxt>
          <Amt>942226</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IOWA DEPARTMENT OF PUBLIC HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>321 EAST 12TH</AddressLine1Txt>
            <CityNm>DES MOINES</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50319</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IOWA FIRST RESPONDER AED INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>5283804</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ISRAEL ANTIQUITIES AUTHORITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>27 SULTAN SULEIMAN STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JAY &amp; JEANIE SCHOTTENSTEIN NATIONAL CAMPUS FOR THE ARCHAEOLOGY OF ISRAEL</GrantOrContributionPurposeTxt>
          <Amt>2600000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ISRAEL CROHN'S DISEASE AND ULCERATIVE COLITIS FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>YOKNEAM 5</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2020 OPERATING SUPPORT FOR CCFI'S EMERGENCY TRANSPORTATION PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>57428</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ISRAEL CROHN'S DISEASE AND ULCERATIVE COLITIS FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>YOKNEAM 5</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2020 OPERATING SUPPORT FOR CCFI'S EMERGENCY TRANSPORTATION PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>59407</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>56265</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY</GrantOrContributionPurposeTxt>
          <Amt>600000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM MONITORING OF MATERNAL DYSGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>453159</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>80-84 CHANDOS STREET</AddressLine1Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDIA FOLLOW UP 2020-2022</GrantOrContributionPurposeTxt>
          <Amt>1133601</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>80-84 CHANDOS STREET</AddressLine1Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDIA EARLY TO MID-CAREER SCIENCE ACCELERATOR AWARDS 2021</GrantOrContributionPurposeTxt>
          <Amt>239784</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF NOVEL INSULIN INFUSION SET</GrantOrContributionPurposeTxt>
          <Amt>432631</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JDRF GLOBAL DIABETES ACCESS INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>999800</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JDRF TRAINING PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>1250000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HCP T1D EDUCATION PROGRAM (STATE OF AFFAIRS AND PEAK)</GrantOrContributionPurposeTxt>
          <Amt>99699</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AUTOIMMUNITY SCREENING IN KIDS (ASK) RENEWAL</GrantOrContributionPurposeTxt>
          <Amt>400000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF T1D FUND LLC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>99 HIGH STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JDRF T1D FUND PHASE III</GrantOrContributionPurposeTxt>
          <Amt>3000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JENNIE M MELHAM MEMORIAL MEDICAL CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>145 MEMORIAL DRIVE</AddressLine1Txt>
            <CityNm>BROKEN BOW</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68822</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPHARMACY AT JENNIE M MELHAM MEMORIAL MEDICAL CENTER, INC.</GrantOrContributionPurposeTxt>
          <Amt>11360</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JERUSALEM COLLEGE OF TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>21 HAVAAD HALEUMI ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY FACULTY OF LIFE AND HEALTH SCIENCES BUILDING</GrantOrContributionPurposeTxt>
          <Amt>2859000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOHNS HOPKINS UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 NORTH BROADWAY MRB 117</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A MULTIDISCIPLINARY BIOENGINEERING APPROACH TO FISTULA-IN-ANO IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>360255</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOHNS HOPKINS UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 NORTH BROADWAY MRB 117</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A MULTIDISCIPLINARY BIOENGINEERING APPROACH TO FISTULA-IN-ANO IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>239373</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOSLIN DIABETES CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE JOSLIN PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02215</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1177265</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JUVENILE DIABETES RESEARCH FOUNDATION CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>235 YORKLAND BLVD SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JDRF CANADA PSYCHOSOCIAL HEALTH INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>54000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INNODIA HARVEST</GrantOrContributionPurposeTxt>
          <Amt>481994</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT</GrantOrContributionPurposeTxt>
          <Amt>530355</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT FOR INNODIA HARVEST ACTIVITIES AT ACADEMIC CONSORTIUM MEMBERS.</GrantOrContributionPurposeTxt>
          <Amt>792845</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT</GrantOrContributionPurposeTxt>
          <Amt>497699</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1509981</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>740062</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATE THE BIOLOGICAL, SOCIAL AND ECONOMIC IMPACT OF HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>46929</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KITTSON MEMORIAL HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1010 SOUTH BIRCH AVENUE</AddressLine1Txt>
            <CityNm>HALLOCK</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>56728</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT KITTSON HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>29321</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITT MUNCHEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>FEODOR-LYNEN-STRAE 17</AddressLine1Txt>
            <CityNm>MUNCHEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>639055</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KMR ADVANCEMENT OF MEDICAL CENTERS LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>8 HAALIYAH ST</AddressLine1Txt>
            <CityNm>HAIFA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ESTABLISHMENT OF THE HEALTH DISCOVERY TOWER</GrantOrContributionPurposeTxt>
          <Amt>2950750</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LAKES REGIONAL HEALTHCARE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>HIGHWAY 71 SOUTH</AddressLine1Txt>
            <CityNm>SPIRIT LAKE</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51360</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE PHARMACY AT LAKES REGIONAL HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>27140</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LANDER COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>535 SOUTH HUMBOLDT STREET</AddressLine1Txt>
            <CityNm>BATTLE MOUNTAIN</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>898201988</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RADIOLOGY EQUIPMENT FOR BATTLE MOUNTAIN GENERAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>142265</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LINCOLN COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>700 NORTH SPRING STREET</AddressLine1Txt>
            <CityNm>CALIENTE</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89008</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GROVER C. DILS MEDICAL CENTER EQUIPMENT REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>666782</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LIVING WATER INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4001 GREENBRIAR DRIVE</AddressLine1Txt>
            <CityNm>STAFFORD</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77477</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTEGRATED WASH PROGRAM IN CHIPATA DISTRICT, ZAMBIA</GrantOrContributionPurposeTxt>
          <Amt>1251684</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LUCAS COUNTY HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1200 NORTH 7TH STREET</AddressLine1Txt>
            <CityNm>CHARITON</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50049</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AVERA ECARE EMERGENCY VIRTUAL HEALTH AT LUCAS COUNTY HEALTH CENTER</GrantOrContributionPurposeTxt>
          <Amt>118418</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MACCABI HEALTHCARE SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>27 HAMERED ST</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOBILE MAMMOGRAPHY UNIT</GrantOrContributionPurposeTxt>
          <Amt>877000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MACCABI HEALTHCARE SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>27 HAMERED ST</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DA VINCI 4XI SYSTEM DUAL CONSOLE SURGICAL ROBOT AND STERILIZATION EQUIP.</GrantOrContributionPurposeTxt>
          <Amt>3505000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MADISON COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 W HUTCHINGS STREET</AddressLine1Txt>
            <CityNm>WINTERSET</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50273</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF EEMERGENCY AT MADISON COUNTY HEALTH CARE SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>111961</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAINEHEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>22 BRAMHALL STREET</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>ME</StateAbbreviationCd>
            <ZIPCd>04102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMING RURAL DIABETES CARE IN MAINE</GrantOrContributionPurposeTxt>
          <Amt>729688</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MARY C WHEELER SCHOOL INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>216 HOPE STREET</AddressLine1Txt>
            <CityNm>PROVIDENCE</CityNm>
            <StateAbbreviationCd>RI</StateAbbreviationCd>
            <ZIPCd>02906</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TETHERED CAPSULE ENDOMICROSCOPY VISUALIZATION OF THE CROHNS BOWEL WALL</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHNS DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION</GrantOrContributionPurposeTxt>
          <Amt>350279</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAT-SU TRAILS &amp; PARKS FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 652</AddressLine1Txt>
            <CityNm>PALMER</CityNm>
            <StateAbbreviationCd>AK</StateAbbreviationCd>
            <ZIPCd>99645</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INDEPENDENCE MINE REHABILITATION</GrantOrContributionPurposeTxt>
          <Amt>1339417</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 FIRST STREET SW</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55905</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD</GrantOrContributionPurposeTxt>
          <Amt>495833</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 FIRST STREET SW</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55905</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2019-2021 MILITARY SCIENCES MEDICAL TRAINING/SUPPORT PROJECT (ARIZONA)</GrantOrContributionPurposeTxt>
          <Amt>124891</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEDICAL COLLEGE OF CORNELL UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 YORK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100654805</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING THE MYCOBIOME IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>283903</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEEKER MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>612 S SIBLEY AVE</AddressLine1Txt>
            <CityNm>LITCHFIELD</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55355</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT MEEKER MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>18524</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEEKER MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>612 S SIBLEY AVE</AddressLine1Txt>
            <CityNm>LITCHFIELD</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55355</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPHARMACY AT MEEKER MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>30671</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MERCY HEALTH SERVICES IOWA CORP</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>308 NORTH MAPLE AVENUE</AddressLine1Txt>
            <CityNm>NEW HAMPTON</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50659</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT MERCYONE NEW HAMPTON MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>15178</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MI STATE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>HANNAH ADMINISTRATION BUILDING</AddressLine1Txt>
            <CityNm>EAST LANSING</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>488242601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A C-PEPTIDE COMPLEX FOR IMPROVED GLUCOSE METABOLISM IN PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>430158</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MIDDLE EAST MEDIA AND RESEARCH INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 27837</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IRAN STUDIES PROJECT</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MONROE COUNTY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>6580 165TH STREET</AddressLine1Txt>
            <CityNm>ALBIA</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52531</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPHARMACY AT MONROE COUNTY HOSPITAL &amp; CLINICS</GrantOrContributionPurposeTxt>
          <Amt>156759</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MONTANA DEPARTMENT OF HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 202951</AddressLine1Txt>
            <CityNm>HELENA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59620</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MONTANA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>191663</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MONTANA DEPARTMENT PUBLIC HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 202951</AddressLine1Txt>
            <CityNm>HELENA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59620</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MONTANA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>219190</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MONUMENT HEALTH NETWORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2140 JUNCTION AVE</AddressLine1Txt>
            <CityNm>STURGIS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57785</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT MONUMENT HEALTH STURGIS HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>129650</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL COMMITTEE FOR QUALITY ASSURANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 13TH ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORM HEALTHCARE THROUGH MEASUREMENT, TRANSPARENCY, &amp; ACCOUNTABILITY</GrantOrContributionPurposeTxt>
          <Amt>1336294</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL PARK FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 K ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BERING LAND BRIDGE VISITOR CENTER</GrantOrContributionPurposeTxt>
          <Amt>848202</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATURAL AREAS CONSERVANCY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1234 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FORMALIZING A NEW YORK CITY TRAIL SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATURE CONSERVANCY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4245 NORTH FAIRFAX DRIVE SUITE 100</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FUTURE FOREST NEW YORK CITY PHASE II</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NCD ALLIANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>31-33 AVENUE GIUSEPPE MOTTA</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PUTTING PEOPLE WITH NCDS FIRST: DRIVING ADVOCACY, CHANGE, IMPROVING CARE</GrantOrContributionPurposeTxt>
          <Amt>1015450</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NCD ALLIANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>31-33 AVENUE GIUSEPPE MOTTA</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>42500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NCD ALLIANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>31-33 AVENUE GIUSEPPE MOTTA</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PUTTING PEOPLE WITH NCDS FIRST: DRIVING ADVOCACY, CHANGE, IMPROVING CARE</GrantOrContributionPurposeTxt>
          <Amt>1055700</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEBRASKA DEPARTMENT OF HEALTH &amp; HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>301 CENTENNIAL MALL SOUTH</AddressLine1Txt>
            <CityNm>LINCOLN</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68508</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEBRASKA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>5608814</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA COMMUNITY FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1980 FESTIVAL PLAZA DRIVE</AddressLine1Txt>
            <CityNm>LAS VEGAS</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89135</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DESERT VIEW AND MESA VIEW HOSPITAL EQUIPMENT REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>2216426</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW DESTINY HOUSING CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>12 W 37TH STREET 7TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AFTERCARE INTERVENTION TO IMPROVE HOUSING &amp; HEALTH STABILITY</GrantOrContributionPurposeTxt>
          <Amt>376970</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW VENTURE FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 CT AVE NW SUITE 300</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024)</GrantOrContributionPurposeTxt>
          <Amt>3302000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW VENTURE FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 CT AVE NW SUITE 300</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR THE OPEN RESEARCH FUNDERS GROUP</GrantOrContributionPurposeTxt>
          <Amt>45000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW VENTURE FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 CT AVE NW SUITE 300</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024)</GrantOrContributionPurposeTxt>
          <Amt>102000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK CITY BALLET INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>DAVID H KOCH THEATER</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10023</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR NEW COMBINATIONS FUND</GrantOrContributionPurposeTxt>
          <Amt>15000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK CITY HEALTH AND HOSPITALS CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 WORTH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10013</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPRESSCARE TELE-BEHAVIORAL SERV. &amp; STRATEGIES (NYC HIGH NEEDS PATIENTS)</GrantOrContributionPurposeTxt>
          <Amt>1657500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK CITY HEALTH AND HOSPITALS CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 WORTH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10013</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPRESSCARE PLATFORM UPDATE AND SERVICE DELIVERY TO HOMELESS PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>665 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANALYSIS OF MEDICAID DATA TO IMPROVE CARE FOR HOMELESS PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>98834</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>665 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF INTERVENTIONS FOR COLLABORATIVE FOR HOMELESS HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>194404</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>665 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFYING ENVIRONMENTAL CONTRIBUTORS TO CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>695626</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK-PRESBYTERIAN FUND INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>850 THIRD AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10022</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING CARE FOR UNDERSERVED CHILDREN WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEWCASTLE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NEWCASTLE UPON TYNE</AddressLine1Txt>
            <CityNm>NEWCASTLE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD UK EXPANSION: NEWCASTLE</GrantOrContributionPurposeTxt>
          <Amt>15776</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NORTH DAKOTA DEPARTMENT OF HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>600 E BOULEVARD AVENUE</AddressLine1Txt>
            <CityNm>BISMARCK</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>585050200</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORTH DAKOTA LAW ENFORCEMENT AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>153789</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NORTHERN WESTCHESTER HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>400 EAST MAIN STREET</AddressLine1Txt>
            <CityNm>MOUNT KISCO</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10549</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL CHILD HEALTH UNIT FACILITIES RENOVATION</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NURU INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2020 PENNSYLVANIA AVE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NURU ETHIOPIA: SUSTAINING IMPACT THROUGH 2021 AND BEYOND</GrantOrContributionPurposeTxt>
          <Amt>550893</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OREGON HEALTH &amp; SCIENCE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3181 SW SAM JACKSON PARK RD</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>972393098</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DESIGN AND EVALUATION OF A MDI DECISION SUPPORT SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>515974</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OREGON HEALTH &amp; SCIENCE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3181 SW SAM JACKSON PARK RD</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>972393098</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TO EXPAND THE NICH PROGRAM IN THE CALIFORNIA BAY AREA</GrantOrContributionPurposeTxt>
          <Amt>1316877</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PALO ALTO VETERANS INSTITUTE FOR RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3801 MIRANDA AVENUE</AddressLine1Txt>
            <CityNm>PALO ALTO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>943040038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CELL ATLAS OF INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>499175</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PALO ALTO VETERANS INSTITUTE FOR RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3801 MIRANDA AVENUE</AddressLine1Txt>
            <CityNm>PALO ALTO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>943040038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CELL ATLAS OF INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>500825</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PANORAMA GLOBAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2101 FOURTH AVENUE SUITE 2100</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND</GrantOrContributionPurposeTxt>
          <Amt>833440</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 LETTERMAN DRIVE</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94129</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDYING AUTOIMMUNE DIABETES FOLLOWING CERTAIN CANCER IMMUNOTHERAPIES.</GrantOrContributionPurposeTxt>
          <Amt>750000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PATH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2201 WESTLAKE AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>17750</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PATH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2201 WESTLAKE AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE</GrantOrContributionPurposeTxt>
          <Amt>1404393</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PAWNEE COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>600 I STREET</AddressLine1Txt>
            <CityNm>PAWNEE CITY</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68420</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT PAWNEE COUNTY MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>11936</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PAWNEE COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>600 I STREET</AddressLine1Txt>
            <CityNm>PAWNEE CITY</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68420</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE PHARMACY AT PAWNEE COUNTY MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>150545</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PERSHING COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>855 SIXTH STREET</AddressLine1Txt>
            <CityNm>LOVELOCK</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89419</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PERSHING GENERAL HOSPITAL EQUIPMENT REVITALIZATION PROJECT.</GrantOrContributionPurposeTxt>
          <Amt>401978</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PHILANTHROPY NEW YORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>320 EAST 43RD STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>39250</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PHILIP HEALTH SERVICES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>503 W PINE STREET</AddressLine1Txt>
            <CityNm>PHILIP</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57567</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF AVERA EEMERGENCY AT PHILIP HEALTH SERVICES</GrantOrContributionPurposeTxt>
          <Amt>29491</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PLATTE VALLEY HEALTHCARE PROJECT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>203 S 1ST ST</AddressLine1Txt>
            <CityNm>SARATOGA</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82331</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CT SCANNER AT NORTH PLATTE VALLEY MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PRESIDENT AND FELLOWS OF HARVARD COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>25 SHATTUCK STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATING MICRONEEDLE-BASED SENSOR TO ENHANCE AUTOMATED INSULIN DELIVERY</GrantOrContributionPurposeTxt>
          <Amt>924309</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PROJECT HOSPITALITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>100 PARK AVENUE</AddressLine1Txt>
            <CityNm>STATEN ISLAND</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10302</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>25000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PROJECT NYAME NSA LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>33 WILLETS LANE</AddressLine1Txt>
            <CityNm>MANHASSET</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROJECT NYAME NSA ZAMBIA EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>277650</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PROJECT RENEWAL INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VARICK STREET SUITE 900</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10014</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW YORK CITY COLLABORATIVE FOR HOMELESS HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PROVIDENCE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1200 PROVIDENCE ROAD</AddressLine1Txt>
            <CityNm>WAYNE</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68787</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT PROVIDENCE MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>16407</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PROVIDENCE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1200 PROVIDENCE ROAD</AddressLine1Txt>
            <CityNm>WAYNE</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68787</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPHARMACY AT PROVIDENCE MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>21140</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PUBLIC HEALTH SOLUTIONS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>40 WORTH STREET 5TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10013</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW YORK CITY COLLABORATIVE FOR HOMELESS HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PUBLIC HEALTH SOLUTIONS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>40 WORTH STREET 5TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10013</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW YORK CITY FUND FOR YOUTH AND FAMILY HOMELESSNESS</GrantOrContributionPurposeTxt>
          <Amt>550000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PULITZER CENTER ON CRISIS REPORTING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1779 MASSACHUSETTS AVE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING RESILIENCE THROUGH JOURNALISM AND EDUCATION</GrantOrContributionPurposeTxt>
          <Amt>223410</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RAMBAM HEALTH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HAALIA HASNIA 8</AddressLine1Txt>
            <CityNm>HAIFA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POINT OF CARE ASSAY FOR SERUM NEUTRALIZING ANTI-IFX ANTIBODIES</GrantOrContributionPurposeTxt>
          <Amt>142800</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RAMBAM HEALTH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HAALIA HASNIA 8</AddressLine1Txt>
            <CityNm>HAIFA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POINT OF CARE ASSAY FOR SERUM NEUTRALIZING ANTI-IFX ANTIBODIES</GrantOrContributionPurposeTxt>
          <Amt>120355</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RAMBAM HEALTH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HAALIA HASNIA 8</AddressLine1Txt>
            <CityNm>HAIFA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREDICTING AND OPTIMIZING DRUG THERAPY IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>350000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS</GrantOrContributionPurposeTxt>
          <Amt>412982</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING PERSISTENT SYMPTOMS IN QUIESCENT CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>270158</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USE NLP FOR EXTRACTION OF CD RELEVANT DATA FROM CLINICAL RECORDS.</GrantOrContributionPurposeTxt>
          <Amt>381754</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING PERSISTENT SYMPTOMS IN QUIESCENT CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>30894</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55455</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MINNESOTA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>12644876</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55455</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PHASE 2: ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR T1D</GrantOrContributionPurposeTxt>
          <Amt>350000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55455</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REDEFINING THE FUTURE OF EMERGENCY MEDICINE</GrantOrContributionPurposeTxt>
          <Amt>1752819</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55455</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECLINICAL DEVELOPMENT OF A MONOCLONAL ANTIBODY TO SERPINB13</GrantOrContributionPurposeTxt>
          <Amt>875045</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGION HOVEDSTADEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>KONGENS VAENGE 2</AddressLine1Txt>
            <CityNm>HILLERD</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION/SCREENING OF NOVEL GLUCAGONOTROPIC ALPHA-CELL RECEPTORS</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ROCKEFELLER PHILANTHROPY ADVISORS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>6 WEST 48TH STREET 10TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FUNDING TO SUPPORT COVID COLLABORATIVE - BEREAVED CHILDREN PROJECT</GrantOrContributionPurposeTxt>
          <Amt>175000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ROCKEFELLER PHILANTHROPY ADVISORS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>6 WEST 48TH STREET 10TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COVID COLLABORATIVE - INCREASING VACCINE UPTAKE IN RURAL AMERICA</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ROSEBUD COMMUNITY HOSPITAL INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>383 NORTH 17TH AVENUE</AddressLine1Txt>
            <CityNm>FORSYTH</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPHARMACY AND ADM AT ROSEBUD HEALTH CARE CENTER IN FORSYTH, MONTANA</GrantOrContributionPurposeTxt>
          <Amt>11262</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ROUNDABOUT THEATRE COMPANY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>231 W 39TH STREET 1200</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAFE WATER NETWORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>122 EAST 42ND STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10168</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING AFFORDABLE SAFELY MANAGED WATER SUPPLY</GrantOrContributionPurposeTxt>
          <Amt>2367100</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAGE BIONETWORKS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2901 THIRD AVE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981213014</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXTENSION OF VEOIBD DATA COORDINATION</GrantOrContributionPurposeTxt>
          <Amt>71204</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAINT LOUIS UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>221 NORTH GRAND BOULEVARD</AddressLine1Txt>
            <CityNm>SAINT LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>631032006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL TARGET TO FIGHT ALPHA CELL DYSFUNCTION &amp; STOP HYPOGLYCEMIA IN T1D</GrantOrContributionPurposeTxt>
          <Amt>260774</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SALVATION ARMY WORLD SERVICE OFFICE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 SLATERS LANE</AddressLine1Txt>
            <CityNm>ALEXANDRIA</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22314</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WATER SYSTEM IMPROVEMENTS AT CHIKANKATA MISSION</GrantOrContributionPurposeTxt>
          <Amt>1200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SANFORD RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2301 E 60TH STREET N</AddressLine1Txt>
            <CityNm>SIOUX FALL</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>571040569</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SANFORD PLEDGE: PHASES 1 AND 2</GrantOrContributionPurposeTxt>
          <Amt>603695</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SCHWARTZREISMAN SCIENCE EDUCATION CENTER REHOVOT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERZL ST 234</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY CAMPUS FOR SCIENCE EDUCATION IN NETIVOT</GrantOrContributionPurposeTxt>
          <Amt>2540089</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POPULATION-BASED ANALYSES OF IBD USING ADMINISTRATIVE DATABASE</GrantOrContributionPurposeTxt>
          <Amt>143000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>"TASTY &amp; HEALTHY" DIET: A RANDOMIZED CONTROLLED TRIAL FOR INDUCING AND MAINTAINING REMISSION IN CROHN'S DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>666492</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREVENTION OF INFLAMMATORY BOWEL DISEASES IN PERSONS AT RISK</GrantOrContributionPurposeTxt>
          <Amt>379439</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POPULATION-BASED ANALYSES OF IBD USING ADMINISTRATIVE DATABASE</GrantOrContributionPurposeTxt>
          <Amt>137000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>"TASTY &amp; HEALTHY" DIET: A RANDOMIZED CONTROLLED TRIAL FOR INDUCING AND MAINTAINING REMISSION IN CROHN'S DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>415669</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREVENTION OF INFLAMMATORY BOWEL DISEASES IN PERSONS AT RISK</GrantOrContributionPurposeTxt>
          <Amt>413468</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY CANCER CENTER AT SHAARE ZEDEK MEDICAL CENTER JERUSALEM</GrantOrContributionPurposeTxt>
          <Amt>9908264</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EQUIPMENT PURCHASES FOR THE NEW RADIOTHERAPY CENTER</GrantOrContributionPurposeTxt>
          <Amt>791105</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHATTERPROOF A NONPROFIT CORP</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 MERRITT 7 CORPORATE PARK</AddressLine1Txt>
            <CityNm>NORWALK</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06851</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHATTERPROOF A NONPROFIT CORP</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 MERRITT 7 CORPORATE PARK</AddressLine1Txt>
            <CityNm>NORWALK</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06851</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHENANDOAH MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 PERSHING AVE</AddressLine1Txt>
            <CityNm>SHENANDOAH</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SHENANDOAH MEDICAL CENTER / AVERA EEMERGENCY IMPLEMENTATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>38299</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIMULATION IN MOTION MONTANA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O MONTANA MEDICAL ASSOCIATION</AddressLine1Txt>
            <CityNm>HELENA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING FOR A SUSTAINABLE SIMULATION IN MOTION MONTANA PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIMULATION IN MOTION MONTANA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O MONTANA MEDICAL ASSOCIATION</AddressLine1Txt>
            <CityNm>HELENA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING TOWARD A SUSTAINABLE SIMULATION IN MOTION MONTANA</GrantOrContributionPurposeTxt>
          <Amt>96066</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIOUX COUNCIL BOY SCOUTS OF AMERICA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>800 N WEST AVENUE</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57104</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WETLAND\NATURE STUDY AREA DEVELOPMENT: LEWIS AND CLARK SCOUT CAMP</GrantOrContributionPurposeTxt>
          <Amt>75000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIOUX VALLEY MEMORIAL HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 SIOUX VALLEY DRIVE</AddressLine1Txt>
            <CityNm>CHEROKEE</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE EMERGENCY AT CHEROKEE REGIONAL MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>34691</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SNV NETHERLANDS DEVELOPMENT ORGANISATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PARKSTRAAT 83</AddressLine1Txt>
            <CityNm>DEN HAAG</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTHY FUTURE FOR ALL IMPROVING WATER, SANITATION, HYGIENE &amp; NUTRITION</GrantOrContributionPurposeTxt>
          <Amt>1191913</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOCIETY FOR THE PRESERVATION OF NEW ENGLAND ANTIQUITIES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>141 CAMBRIDGE STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02114</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>35000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOS CHILDREN'S VILLAGES-USA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1620 I STREET NW SUITE 220</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDUCARE 4.0: DEBRE TABOR AND GONDAR CITY, ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>2401776</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTH DAKOTA HALL OF FAME</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1480 S MAIN ST</AddressLine1Txt>
            <CityNm>CHAMBERLAIN</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57325</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>20000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTH DAKOTA PARKS &amp; WILDLIFE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>523 E CAPITOL</AddressLine1Txt>
            <CityNm>PIERRE</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57501</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CUSTER STATE PARK BISON CENTER</GrantOrContributionPurposeTxt>
          <Amt>3000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTH LYON HEALTH CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>213 S WHITACRE ST</AddressLine1Txt>
            <CityNm>YERINGTON</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>894472561</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SOUTH LYON MEDICAL CENTER EQUIPMENT REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>518553</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTHCENTRAL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4501 DIPLOMACY DR</AddressLine1Txt>
            <CityNm>ANCHORAGE</CityNm>
            <StateAbbreviationCd>AK</StateAbbreviationCd>
            <ZIPCd>99508</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>1425805</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST LUKE HEALTH CARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>28W609 HICKORY LN</AddressLine1Txt>
            <CityNm>WEST CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60185</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TEACHING HOSPITAL INFRASTRUCTURE IMPROVEMENTS</GrantOrContributionPurposeTxt>
          <Amt>210306</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST ROSE DOMINICAN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>102 E LAKE MEAD PARKWAY</AddressLine1Txt>
            <CityNm>HENDERSON</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89015</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MEDICAL SIMULATION EQUIPMENT</GrantOrContributionPurposeTxt>
          <Amt>462090</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EFFECTS OF AN INTERMITTENT REDUCED CALORIE DIET ON CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>331803</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A CONTINUOUS MULTIANALYTE SENSOR FOR T1D</GrantOrContributionPurposeTxt>
          <Amt>1366476</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INVESTIGATING THE ROLE OF THE HUMAN EXPOSOME IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>758929</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>990845</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION &amp; EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON IIT</GrantOrContributionPurposeTxt>
          <Amt>1296812</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LONGITUDINAL STUDY OF MYOELECTRIC GUTPRINT OF CROHNS PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>243550</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EFFECTS OF AN INTERMITTENT REDUCED CALORIE DIET ON CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>334722</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE EDUCATION AT NEW ONSET OF T1D</GrantOrContributionPurposeTxt>
          <Amt>249169</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE EDUCATION AT NEW ONSET OF T1D</GrantOrContributionPurposeTxt>
          <Amt>183151</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STATE OF SOUTH DAKOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>600 E CAPITOL AVENUE</AddressLine1Txt>
            <CityNm>PIERRE</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57501</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SOUTH DAKOTA FIRST RESPONDER AUTOMATED EXTERNAL DEFIBRILLATOR PROJECT</GrantOrContributionPurposeTxt>
          <Amt>178000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING ACCESS TO MEDICINE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NARITAWEG 227</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ACCESS TO T1D CARE</GrantOrContributionPurposeTxt>
          <Amt>625000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING HEALTH ACTION INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OVERTOOM 60/II</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLLY</GrantOrContributionPurposeTxt>
          <Amt>1246224</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING PHARMACCESS INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AHTC TOWER C4 PAASHEUVELWEG 25</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INVESTING IN QUALITY HEALTHCARE THROUGH SAFECARE</GrantOrContributionPurposeTxt>
          <Amt>254457</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SYNERGOS INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3 EAST 54TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10022</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING LIVES AND LIVELIHOODS OF SMALLHOLDER FARMERS</GrantOrContributionPurposeTxt>
          <Amt>998553</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SYNERGOS INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3 EAST 54TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10022</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING LIVES AND LIVELIHOODS OF SMALLHOLDER FARMERS</GrantOrContributionPurposeTxt>
          <Amt>1485316</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>11 AVENUE DE LAFAYETTE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02111</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>513697</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>11 AVENUE DE LAFAYETTE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02111</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>354000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>11 AVENUE DE LAFAYETTE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02111</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>354000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>11 AVENUE DE LAFAYETTE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02111</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>3686424</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>11 AVENUE DE LAFAYETTE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02111</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>513696</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>11 AVENUE DE LAFAYETTE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02111</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>354000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TAMPERE UNIVERSITY FOUNDATION SR</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>KALEVANTIE 4 33100</AddressLine1Txt>
            <CityNm>TAMPERE</CityNm>
            <CountryCd>FI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VIRUSES AND ANTIVIRAL IMMUNE MARKERS IN TWO ENDOTYPES OF TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>305030</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TAMPERE UNIVERSITY FOUNDATION SR</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>KALEVANTIE 4 33100</AddressLine1Txt>
            <CityNm>TAMPERE</CityNm>
            <CountryCd>FI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF MULTIPLEX MICROBIAL ANTIBODY SCREENING ARRAY FOR STUDIES</GrantOrContributionPurposeTxt>
          <Amt>481830</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TECHNISCHE UNIVERSITT DRESDEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZSTR 10</AddressLine1Txt>
            <CityNm>DRESDEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENOMIC INFLUENCE OF MATERNAL T1D - UNDERSTANDING PROTECTION AGAINST T1D</GrantOrContributionPurposeTxt>
          <Amt>271691</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TECHNISCHE UNIVERSITT DRESDEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZSTR 10</AddressLine1Txt>
            <CityNm>DRESDEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT SCREENING FOR ISLET AUTOANTIBODIES IN CHILDREN.</GrantOrContributionPurposeTxt>
          <Amt>212157</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ACADEMIC COLLEGE AT TEL-HAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL-HAI COLLEGE</AddressLine1Txt>
            <CityNm>UPPER GALILEE</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY SCIENCE BUILDING FOR HEALTH, ENVIRONMENT, AND BIOTECH STUDIES</GrantOrContributionPurposeTxt>
          <Amt>634900</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ASPEN INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2300 N STREET</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE ASPEN INSTITUTE IS AN EDUCATIONAL AND POLICY STUDIES ORGANIZATION</GrantOrContributionPurposeTxt>
          <Amt>995988</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BARUCH PADEH MEDICAL CENTER PORIYA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE BARUCH PADEH MEDICAL CENTERPORI</AddressLine1Txt>
            <AddressLine2Txt>A</AddressLine2Txt>
            <CityNm>TIBERIAS</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY REHABILITATION CENTER OF THE NORTH</GrantOrContributionPurposeTxt>
          <Amt>5115157</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BARUCH PADEH MEDICAL CENTER PORIYA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE BARUCH PADEH MEDICAL CENTERPORI</AddressLine1Txt>
            <AddressLine2Txt>A</AddressLine2Txt>
            <CityNm>TIBERIAS</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONSTRUCTION OF THE 12-BED INTENSIVE CARE AND RESPIRATION UNIT</GrantOrContributionPurposeTxt>
          <Amt>2321666</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN COLON AND SMALL INTESTINE CELL ATLAS IN HEALTH AND CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>476319</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN COLON AND SMALL INTESTINE CELL ATLAS IN HEALTH AND CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>719309</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>3000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CENTER FOR EFFECTIVE PHILANTHROPY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>675 MASSACHUSETTS AVENUE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02139</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>41500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHINESE UNIVERSITY OF HONG KONG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PI CHIU BUILDING</AddressLine1Txt>
            <CityNm>SHATIN</CityNm>
            <CountryCd>HK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL TRANSFER OF SPECIALIZED CELLS FOR TREATMENT OF BOWEL DISEASE</GrantOrContributionPurposeTxt>
          <Amt>506838</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHINESE UNIVERSITY OF HONG KONG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PI CHIU BUILDING</AddressLine1Txt>
            <CityNm>SHATIN</CityNm>
            <CountryCd>HK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN</GrantOrContributionPurposeTxt>
          <Amt>423667</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHINESE UNIVERSITY OF HONG KONG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PI CHIU BUILDING</AddressLine1Txt>
            <CityNm>SHATIN</CityNm>
            <CountryCd>HK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL TRANSFER OF SPECIALIZED CELLS FOR TREATMENT OF BOWEL DISEASE</GrantOrContributionPurposeTxt>
          <Amt>481225</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHINESE UNIVERSITY OF HONG KONG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PI CHIU BUILDING</AddressLine1Txt>
            <CityNm>SHATIN</CityNm>
            <CountryCd>HK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN</GrantOrContributionPurposeTxt>
          <Amt>239672</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 E DUARTE RD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING GENETIC PROTECTION FROM T1D.</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD</GrantOrContributionPurposeTxt>
          <Amt>808555</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP IUS AND HISTOPATHOLOGY INDICES FOR MONITORING STRICTURING CD</GrantOrContributionPurposeTxt>
          <Amt>403400</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS</GrantOrContributionPurposeTxt>
          <Amt>573271</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE DIATRIBE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>804 HAIGHT ST</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94117</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIATRIBE LEARN</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE END FUND INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2 PARK AVENUE 18TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10016</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ELIMINATION OF PARASITIC WORMS IN ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>1300001</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VISUALIZATION OF COVID-19 VACCINE SEROLOGY IN CD</GrantOrContributionPurposeTxt>
          <Amt>84762</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP PROTEIN PANEL TO IDENTIFY FIBROSTENOTIC CD PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>631739</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE CHANGING EPIDEMIOLOGY OF CROHNS IN THE WESTERN WORLD</GrantOrContributionPurposeTxt>
          <Amt>188736</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HARDING FORD VISION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>157-22 TUSKEGEE AIRMEN WAY</AddressLine1Txt>
            <CityNm>JAMAICA</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11433</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>25000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HEALTH &amp; HOUSING CONSORTIUM INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>STADIUM STATION</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10452</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRATEGY BUILDING FOR HEALTH AND HOUSING CONSORTIUM EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>290000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HOLE IN THE WALL GANG FUND INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>555 LONG WHARF DRIVE</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06511</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>15000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE JEWISH AGENCY FOR ISRAEL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>48 KING GEORGE STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JEWISH REFUGEES/ALIYAH CANDIDATES FROM UKRAINE</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE LEGATUM INSTITUTE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>11 CHARLES STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PHASE TWO OF THE UNITED STATES PROSPERITY INDEX</GrantOrContributionPurposeTxt>
          <Amt>50000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>YEZREEL VALLEY</AddressLine1Txt>
            <CityNm>YEZREEL VALLEY</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>OPP. FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS SEEKING NURSING DEG</GrantOrContributionPurposeTxt>
          <Amt>220000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE MILKEN INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1250 FOURTH STREET</AddressLine1Txt>
            <CityNm>SANTA MONICA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90401</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORTS TO CREATE A STRATEGIC ROADMAP FOR T1D TO INCLUDE SCREENING</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE MILKEN INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1250 FOURTH STREET</AddressLine1Txt>
            <CityNm>SANTA MONICA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90401</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CURES FOR LIFE: PATIENT ACCESS TO CELL AND GENE THERAPY</GrantOrContributionPurposeTxt>
          <Amt>174998</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ONE LOVE FOUNDATION IN HONOR OF YEARDLEY LOVE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>44 PONDFIELD ROAD SUITE 12</AddressLine1Txt>
            <CityNm>BRONXVILLE</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING FOR THE FUTURE: SUPPORT FOR DIGITAL PROGRAMS AND OPERATIONS</GrantOrContributionPurposeTxt>
          <Amt>2000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>CHARLOTTESVILLE</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>229044195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS</GrantOrContributionPurposeTxt>
          <Amt>241490</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 GILMAN DRIVE - MAIL CODE 0934</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92093</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PERSONALIZING CROHNS DISEASE THERAPEUTICS THROUGH PHASE 0 HUMAN TRIALS</GrantOrContributionPurposeTxt>
          <Amt>593024</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ASK - REMOTE SCREENING AND MONITORING</GrantOrContributionPurposeTxt>
          <Amt>64636</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CULTURALLY SENSITIVE GROUP CLINIC MODEL FOR LATINO PATIENTS W/ DIABETES</GrantOrContributionPurposeTxt>
          <Amt>512661</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEEDS PATHWAY: EMPOWERMENT FOR DIABETES TECHNOLOGY EARLY DEVICE SUCCESS</GrantOrContributionPurposeTxt>
          <Amt>1113823</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR</GrantOrContributionPurposeTxt>
          <Amt>313924</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SINGLE PERSISTENT ISLET AUTOANTIBODY PHENOTYPE: CUSTOMIZED RISK ANALYSIS</GrantOrContributionPurposeTxt>
          <Amt>264224</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D</GrantOrContributionPurposeTxt>
          <Amt>228012</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPLEMENT SYSTEM IN INITIATION AND PROGRESSION OF ISLET AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>224138</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION</GrantOrContributionPurposeTxt>
          <Amt>580677</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FAILED GENETIC PROTECTION: T1D IN THE PRESENCE OF DQB1*06:02</GrantOrContributionPurposeTxt>
          <Amt>268700</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ASK THE EXPERTS</GrantOrContributionPurposeTxt>
          <Amt>507558</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR</GrantOrContributionPurposeTxt>
          <Amt>119036</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF NEW MEXICO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>SPONSORED PROJECTS - PREAWARD</AddressLine1Txt>
            <CityNm>ALBUQUERQUE</CityNm>
            <StateAbbreviationCd>NM</StateAbbreviationCd>
            <ZIPCd>871310001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE ECHO INSTITUTE: REPLICATION OF THE ECHO MODEL</GrantOrContributionPurposeTxt>
          <Amt>1413438</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SDEROT DEVELOPMENT FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>6 BAR LEV STREET</AddressLine1Txt>
            <CityNm>SDEROT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ESTABLISHING A WARM HOME COMPLEX FOR CHILDREN AT RISK IN SDEROT</GrantOrContributionPurposeTxt>
          <Amt>1422851</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL-HASHOMER</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPREHENSIVE INDIVIDUALIZED PROACTIVE THERAPY OF CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>452624</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SONIA NABETA FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 2222</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100082222</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROJECT BODA</GrantOrContributionPurposeTxt>
          <Amt>314814</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TEL AVIV JAFFA ACADEMIC COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RABENU YERUHAM ST 2 POB 8401</AddressLine1Txt>
            <CityNm>TEL AVIV YAFFO</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCHOLARSHIP SUPPORT FOR ULTRA-ORTHODOX MEN PURSUING NURSING DEGREES</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNITED NATIONS INSTITUTE FOR TRAINING AND RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNITED NATIONS INSTITUTE FOR</AddressLine1Txt>
            <AddressLine2Txt>TRAINING AND RESEARCH</AddressLine2Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING ACCESS: TREATMENT FOR NCDS IN LOW /MIDDLE-INCOME COUNTRIES.</GrantOrContributionPurposeTxt>
          <Amt>2000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF ADELAIDE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE UNIVERSITY OF ADELAIDE</AddressLine1Txt>
            <CityNm>ADELAIDE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDIA EXPANDED SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>620581</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF ADELAIDE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE UNIVERSITY OF ADELAIDE</AddressLine1Txt>
            <CityNm>ADELAIDE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENVIRONMENTAL DETERMINANTS OF ISLET AUTOIMMUNITY (ENDIA) STUDY</GrantOrContributionPurposeTxt>
          <Amt>710992</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5801 SOUTH ELLIS AVENUE</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60637</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNO PHARMACOGENOMICS TO PREDICT RESPONSE TO BIOLOGICS IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>305349</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5801 SOUTH ELLIS AVENUE</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60637</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A CELL ATLAS OF THE ILEAL COLONIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>487806</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5801 SOUTH ELLIS AVENUE</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60637</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNO PHARMACOGENOMICS TO PREDICT RESPONSE TO BIOLOGICS IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>411939</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5801 SOUTH ELLIS AVENUE</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60637</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A CELL ATLAS OF THE ILEAL COLONIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>487806</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DISCERN ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN T1D</GrantOrContributionPurposeTxt>
          <Amt>65459</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GCA - HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION</GrantOrContributionPurposeTxt>
          <Amt>469844</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>CENTRE FOR CARDIOVASCULAR SCIENCES</AddressLine1Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GCA - HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>400400</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY OFFICES WELLINGTON</AddressLine1Txt>
            <AddressLine2Txt>SQUARE</AddressLine2Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE</GrantOrContributionPurposeTxt>
          <Amt>244860</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY OFFICES WELLINGTON</AddressLine1Txt>
            <AddressLine2Txt>SQUARE</AddressLine2Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDY OF COVID-19 ANTIBODY RESPONSE UNDER SUSTAINED IMMUNE SUPPRESSION</GrantOrContributionPurposeTxt>
          <Amt>152072</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY OFFICES WELLINGTON</AddressLine1Txt>
            <AddressLine2Txt>SQUARE</AddressLine2Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PHARMACOLOGICAL MODULATION TO ADDRESS GLUCAGON SECRETION IN T1D</GrantOrContributionPurposeTxt>
          <Amt>131216</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY OFFICES WELLINGTON</AddressLine1Txt>
            <AddressLine2Txt>SQUARE</AddressLine2Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDY OF COVID-19 ANTIBODY RESPONSE UNDER SUSTAINED IMMUNE SUPPRESSION</GrantOrContributionPurposeTxt>
          <Amt>627089</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF QUEENSLAND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>CUMBRAE STEWART BUILDING 72</AddressLine1Txt>
            <CityNm>BRISBANE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET T1D</GrantOrContributionPurposeTxt>
          <Amt>1231993</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF WESTERN AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>35 STIRLING HIGHWAY</AddressLine1Txt>
            <CityNm>CRAWLEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM ASSESSMENTS OF ENDIA CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>102133</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PERSONALIZED NUTRITIONAL, MICROBIOME AND HOST PATTERNS IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>100904</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE QUANTUM MATERIALS DEVICES FABRICATION LAB</GrantOrContributionPurposeTxt>
          <Amt>165000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TOWNSEND HEALTH SYSTEMS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>110 NORTH OAK</AddressLine1Txt>
            <CityNm>TOWNSEND</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59644</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-PHARMACY AT BILLINGS CLINIC BROADWATER</GrantOrContributionPurposeTxt>
          <Amt>329602</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TOWNSEND HEALTH SYSTEMS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>110 NORTH OAK</AddressLine1Txt>
            <CityNm>TOWNSEND</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59644</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT BROADWATER HEALTH CENTER</GrantOrContributionPurposeTxt>
          <Amt>12933</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRICKLE UP PROGRAM INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 WEST 27TH STREET 12TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>25000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF INDIANA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>509 E 3RD ST</AddressLine1Txt>
            <CityNm>BLOOMINGTON</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>474013654</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE EFFORT TO VALIDATE MICRORNAS AS BIOMARKERS OF T1D</GrantOrContributionPurposeTxt>
          <Amt>569823</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF INDIANA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>509 E 3RD ST</AddressLine1Txt>
            <CityNm>BLOOMINGTON</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>474013654</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF REGULATORY ROADMAP FOR COLONOSCOPY BOWEL PREP FOR CD PTS</GrantOrContributionPurposeTxt>
          <Amt>290356</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF INDIANA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>509 E 3RD ST</AddressLine1Txt>
            <CityNm>BLOOMINGTON</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>474013654</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOLECULAR DESIGN AND TESTING OF GLUCOSE-RESPONSIVE THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>793072</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH SERVICES</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191046205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD</GrantOrContributionPurposeTxt>
          <Amt>256967</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH SERVICES</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191046205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD</GrantOrContributionPurposeTxt>
          <Amt>256967</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED HOSPITAL FUND OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1411 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW YORK STATE MEDICAL RESPITE PILOT PROGRAM DESIGN</GrantOrContributionPurposeTxt>
          <Amt>375000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED HOSPITAL FUND OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1411 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW YORK STATE MEDICAL RESPITE PILOT PROGRAM DESIGN</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED NATIONS DEVELOPMENT PROGRAMME</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 UNITED NATIONS PLAZA</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNITED NATIONS MULTILATERAL AGENCY</GrantOrContributionPurposeTxt>
          <Amt>257967</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED OSTOMY ASSOCIATIONS OF AMERICA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 525</AddressLine1Txt>
            <CityNm>KENNEBUNK</CityNm>
            <StateAbbreviationCd>ME</StateAbbreviationCd>
            <ZIPCd>040430525</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF CROHNS DISEASE CONTENT AND AWARENESS FOR THE UOAA</GrantOrContributionPurposeTxt>
          <Amt>19104</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED OSTOMY ASSOCIATIONS OF AMERICA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 525</AddressLine1Txt>
            <CityNm>KENNEBUNK</CityNm>
            <StateAbbreviationCd>ME</StateAbbreviationCd>
            <ZIPCd>040430525</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF CROHNS DISEASE CONTENT AND AWARENESS FOR THE UOAA</GrantOrContributionPurposeTxt>
          <Amt>40350</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED STATES FUND FOR UNICEF</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 MAIDEN LANE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>775779</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITAIR MEDISCH CENTRUM UTRECHT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HEIDELBERGLAAN 100</AddressLine1Txt>
            <CityNm>UTRECHT</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPITHELIAL BASED DIAGNOSTICS FOR TARGETED THERAPIES OF VEOIBD</GrantOrContributionPurposeTxt>
          <Amt>173250</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE CATHOLIQUE DE LOUVAIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLACE DE LUNIVERSITE 1</AddressLine1Txt>
            <CityNm>LOUVAINLANEUVE</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDY OF THE GLUCAGON RESPONSE TO HYPOGLYCEMIA IN CHILDREN WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>144419</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE CATHOLIQUE DE LOUVAIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLACE DE LUNIVERSITE 1</AddressLine1Txt>
            <CityNm>LOUVAINLANEUVE</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIRECT AND INDIRECT CAUSES FOR THE IMPAIRED GLUCAGON SECRETION IN T1D</GrantOrContributionPurposeTxt>
          <Amt>246186</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P C</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1001 MAIN STREET</AddressLine1Txt>
            <CityNm>BUFFALO</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>14203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELEHEALTH REIMBURSEMENT STUDY FOR UNDERSERVED T1D PEDIATRIC POPULATIONS</GrantOrContributionPurposeTxt>
          <Amt>627429</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>GOWER STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SPIT-C: USING SALIVA TO PREDICT CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>380649</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF BIRMINGHAM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INSTITUTE OF IMMUNOLOGY</AddressLine1Txt>
            <CityNm>BIRMINGHAM</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR T1D.</GrantOrContributionPurposeTxt>
          <Amt>413518</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF BIRMINGHAM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INSTITUTE OF IMMUNOLOGY</AddressLine1Txt>
            <CityNm>BIRMINGHAM</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANTIGEN SPECIFIC IMMUNOTHERAPY IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>102647</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CALIFORNIA LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCLA OFFICE OF CONTRACTS AND GRANTS</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>900951406</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE RESPONSIVE GLUCAGON TO REDUCE HYPOGLYCEMIA IN PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>601142</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 CALIFORNIA STREET SUITE 315</AddressLine1Txt>
            <AddressLine2Txt>BOX 0962</AddressLine2Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALIDATING A CLASS OF DRUGS THAT MAY PROTECT BETA CELLS IN T1D</GrantOrContributionPurposeTxt>
          <Amt>108185</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISLET AUTOIMMUNITY IN PATIENTS WITH STAT GAIN-OF-FUNCTION MUTATIONS</GrantOrContributionPurposeTxt>
          <Amt>128169</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ID ANALYSIS OF EXTREME FORMS OF T1D, ESTABLISHMENT OF PATIENT REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>433333</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERING ISLET ANTIGEN-SPECIFIC TREGS FOR T1D</GrantOrContributionPurposeTxt>
          <Amt>500120</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE OLD SCHOOLS</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH T1D PART 2</GrantOrContributionPurposeTxt>
          <Amt>247545</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CINCINNATI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 210641</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45221</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING THE EFFECT OF C-PEPTIDE CO-INFUSION WITH INSULIN</GrantOrContributionPurposeTxt>
          <Amt>363107</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF DUNDEE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NETHERGATE</AddressLine1Txt>
            <CityNm>DUNDEE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HYPO-RESOLVE - UNDERSTANDING ORGAN SPECIFIC CONSEQUENCES OF HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>145758</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING EXTREMELY EARLY-ONSET TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>615166</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T CELL RECEPTOR SEQUENCING IN T1D - BIOMARKER &amp; TECHNOLOGY DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>248597</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE T1D RESEARCH: NETWORK FOR PANCREATIC ORGAN DONORS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>1199692</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN ATLAS NEONATAL DEVELOPMENTAL EARLY LIFE PANCREAS/IMMUNITY CON'T</GrantOrContributionPurposeTxt>
          <Amt>1034449</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF GLASGOW COURT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY AVENUE</AddressLine1Txt>
            <CityNm>GLASGOW</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE CLINICAL EFFECTIVENESS OF CD-TREAT IN PATIENTS WITH ACTIVE CROHNS</GrantOrContributionPurposeTxt>
          <Amt>391290</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF IOWA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>DIVISION OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52442</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION IOWA (SIM-IA)</GrantOrContributionPurposeTxt>
          <Amt>2470869</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF IOWA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>DIVISION OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52442</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RUPRI HEALTH PANEL SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>174321</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 LAKE AVENUE NORTH</AddressLine1Txt>
            <CityNm>WORCESTER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01655</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS</GrantOrContributionPurposeTxt>
          <Amt>541529</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MELBOURNE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LEVEL 4 ALAN GILBERT BUILDING</AddressLine1Txt>
            <CityNm>CARLTON</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANIMAL AND CLINICAL EVALUATION OF A NOVEL CONTINUOUS KETONE SENSOR</GrantOrContributionPurposeTxt>
          <Amt>552076</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MIAMI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1320 SOUTH DIXIE HIGHWAY SUITE 650</AddressLine1Txt>
            <CityNm>CORAL GABLES</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33146</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICE</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MIAMI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1320 SOUTH DIXIE HIGHWAY SUITE 650</AddressLine1Txt>
            <CityNm>CORAL GABLES</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33146</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A HOLISTIC DIET INTERVENTION FOR PEOPLE WITH CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>637761</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MIAMI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1320 SOUTH DIXIE HIGHWAY SUITE 650</AddressLine1Txt>
            <CityNm>CORAL GABLES</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33146</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE</GrantOrContributionPurposeTxt>
          <Amt>323935</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NEBRASKA FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1010 LINCOLN MALL</AddressLine1Txt>
            <CityNm>LINCOLN</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68501</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOBILE RURAL HEALTHCARE PROVIDER TRAINING</GrantOrContributionPurposeTxt>
          <Amt>592963</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MONITORING COVID-19 VACCINE EFFECTIVENESS IN IBD PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>236320</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFYING MOLECULAR PROFILES PREDICTIVE OF POST-OPERATIVE CD OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>585750</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MONITORING COVID-19 VACCINE EFFECTIVENESS IN IBD PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>93422</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANTI-TNF COMBINATION CLINICAL TRIAL IN PEDIATRIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>42022</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NOTRE DAME DU LAC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>940 GRACE HALL</AddressLine1Txt>
            <CityNm>NOTRE DAME</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>465565708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES</GrantOrContributionPurposeTxt>
          <Amt>736645</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NOTRE DAME DU LAC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>940 GRACE HALL</AddressLine1Txt>
            <CityNm>NOTRE DAME</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>465565708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>581100</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF OULU</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PO BOX 8000</AddressLine1Txt>
            <CityNm>OULU</CityNm>
            <CountryCd>FI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL AND PATERNAL T1D - MECHANISMS FOR RECURRENCE RISK IN OFFSPRING</GrantOrContributionPurposeTxt>
          <Amt>452607</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF PITTSBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3420 FORBES AVENUE</AddressLine1Txt>
            <CityNm>PITTSBURGH</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>152603203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RANDOMIZED CONTROLLED TRIAL: ANALOGUE VS HUMAN INSULIN</GrantOrContributionPurposeTxt>
          <Amt>1184954</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF TOLEDO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3000 ARLINGTON AVENUE</AddressLine1Txt>
            <CityNm>TOLEDO</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>436142595</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES CAR TREG THERAPEUTIC APPROACH</GrantOrContributionPurposeTxt>
          <Amt>110480</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF UTAH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>201 S PRESIDENTS CIRCLE</AddressLine1Txt>
            <CityNm>SALT LAKE CITY</CityNm>
            <StateAbbreviationCd>UT</StateAbbreviationCd>
            <ZIPCd>84112</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANTI-PHAGE ANTIBODIES: CROHNS DISEASE DIAGNOSIS AND TREATMENT RESPONSE</GrantOrContributionPurposeTxt>
          <Amt>291996</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF UTAH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>201 S PRESIDENTS CIRCLE</AddressLine1Txt>
            <CityNm>SALT LAKE CITY</CityNm>
            <StateAbbreviationCd>UT</StateAbbreviationCd>
            <ZIPCd>84112</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANTI-PHAGE ANTIBODIES: CROHNS DISEASE DIAGNOSIS AND TREATMENT RESPONSE</GrantOrContributionPurposeTxt>
          <Amt>246267</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF VIRGINIA LAW SCHOOL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>580 MASSIE ROAD</AddressLine1Txt>
            <CityNm>CHARLOTTESVILLE</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22903</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>50000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF ZURICH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEPARTMENT OF IMMUNOLOGY</AddressLine1Txt>
            <CityNm>ZURICH</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERATE BISPECIFIC INTERLEUKIN-2 IMMUNOTHERAPY TO TREAT T1D MELLITUS</GrantOrContributionPurposeTxt>
          <Amt>118250</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UPPSALA UNIVERSITET</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BOX 256</AddressLine1Txt>
            <CityNm>UPPSALA</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ALPHA-CELL SIGNALING FOR GLUCAGON SECRETION</GrantOrContributionPurposeTxt>
          <Amt>121182</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UPPSALA UNIVERSITY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>SJUKHUSVGEN 20</AddressLine1Txt>
            <CityNm>UPPSALA</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISOLATING ISLETS TO UNDERSTAND ALPHA CELL DYSFUNCTION AND HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>400000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAN BUREN COUNTY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>304 FRANKLIN STREET</AddressLine1Txt>
            <CityNm>KEOSAUQUA</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52565</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT VAN BUREN COUNTY HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>17766</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPING AN ISLET MODEL THAT MIMICS T1D</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USE OF MRI OF THE PANCREAS IN T1D</GrantOrContributionPurposeTxt>
          <Amt>504261</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PANCREATLAS DATABASE EXPANSION.</GrantOrContributionPurposeTxt>
          <Amt>825315</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS</GrantOrContributionPurposeTxt>
          <Amt>676092</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFY SMALL MOLECULES ENHANCING GLUCAGON SECRETION UNDER HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>330000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA</GrantOrContributionPurposeTxt>
          <Amt>522458</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS</GrantOrContributionPurposeTxt>
          <Amt>166933</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS</GrantOrContributionPurposeTxt>
          <Amt>509159</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2201 WEST END AVE</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37235</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING CALCIUM SIGNALING IN ALPHA CELLS AND HOW THEY WORK IN T1D</GrantOrContributionPurposeTxt>
          <Amt>231831</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU FEASIBILITY PILOT</GrantOrContributionPurposeTxt>
          <Amt>591068</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VETERANS MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>40 1ST STREET SE</AddressLine1Txt>
            <CityNm>WAUKON</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52172</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE PHARMACY AND EMERGENCY SERVICES AT VETERANS MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>299175</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VILLAGES OF HOPE AFRICA SOCIETY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2450 MILLTOWER COURT</AddressLine1Txt>
            <CityNm>MISSISSAUGA</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ZAMBIA DEVELOPMENT: FOOD PRODUCTION, WATER SUPPLY, EDUCATION FACILITIES</GrantOrContributionPurposeTxt>
          <Amt>622818</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VIVLI INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>14 STORY STREET SUITE 406</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02138</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PUBLICLY SHARING THE DATA FROM EXERCISE AND T1D STUDIES</GrantOrContributionPurposeTxt>
          <Amt>147174</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VIVLI INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>14 STORY STREET SUITE 406</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02138</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VIVLI TECHNICAL DEBT AMELIORATION</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>660 S EUCLID AVE</AddressLine1Txt>
            <CityNm>ST LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>63110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VACCINE SAFETY AND EFFICACY</GrantOrContributionPurposeTxt>
          <Amt>800222</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>660 S EUCLID AVE</AddressLine1Txt>
            <CityNm>ST LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>63110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MANIPULATING ALPHA CELL SIGNALING TO RESTORE NORMAL GLUCAGON SECRETORY</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>660 S EUCLID AVE</AddressLine1Txt>
            <CityNm>ST LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>63110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT DRUG DISCOVERY/UNDERSTANDING AND PREVENTING HYPOGLYCEMIA IN T1D</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHOE BARTON MEDICAL CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1107 US HIGHWAY 395 N</AddressLine1Txt>
            <CityNm>GARDNERVILLE</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89410</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRASOUND EQUIPMENT FOR CARSON VALLEY MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>437369</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHOE BARTON MEDICAL CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1107 US HIGHWAY 395 N</AddressLine1Txt>
            <CityNm>GARDNERVILLE</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89410</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RADIOLOGY AND INTERVENTIONAL EQUIPMENT WITH CONSTRUCTION RELATED COSTS.</GrantOrContributionPurposeTxt>
          <Amt>2160914</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WATER4 INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2405 NW 10TH STREET</AddressLine1Txt>
            <CityNm>OKLAHOMA CITY</CityNm>
            <StateAbbreviationCd>OK</StateAbbreviationCd>
            <ZIPCd>73107</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING THE NUMA MODEL TO DELIVER SAFE, SUSTAINABLE WATER</GrantOrContributionPurposeTxt>
          <Amt>1180873</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WATERAID AMERICA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>233 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10279</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SYSTEM STRENGTHENING FOR SUSTAINABLE WASH SERVICES</GrantOrContributionPurposeTxt>
          <Amt>900001</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WATERAID AMERICA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>233 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10279</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATING A NEW REALITY FOR WASH IN HEALTHCARE FACILITIES IN ZAMBIA</GrantOrContributionPurposeTxt>
          <Amt>2839148</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WHITE PINE COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 AVENUE H</AddressLine1Txt>
            <CityNm>ELY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89301</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INCREASED ULTRASOUND AVAILABILITY AND ABILITY FOR RURAL NORTHEAST NEVADA</GrantOrContributionPurposeTxt>
          <Amt>265831</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WHITE PINE COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 AVENUE H</AddressLine1Txt>
            <CityNm>ELY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89301</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RADIOLOGY EQUIPMENT FOR HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>958500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WILDLIFE CONSERVATION SOCIETY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2300 SOUTHERN BOULEVARD</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10460</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR THE ELEPHANT CONSERVATION PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WNET FOR THE WLIW-21 PUBLIC BROADCASTING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>825 EIGHTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100197435</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WYOMING DEPARTMENT OF HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>6101 YELLOWSTONE RD SUITE 400</AddressLine1Txt>
            <CityNm>CHEYENNE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82009</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>269693</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WYOMING STATE PARKS AND CULTURAL RESOURCES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2301 CENTRAL AVENUE</AddressLine1Txt>
            <CityNm>CHEYENNE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82002</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERPRETIVE CENTER AT FORT PHIL KEARNY STATE HISTORIC SITE</GrantOrContributionPurposeTxt>
          <Amt>885000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YAD SARAH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>124 HERZL BLVD</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOME HOSPITAL PROGRAM FOR SOUTHERN ISRAEL</GrantOrContributionPurposeTxt>
          <Amt>1376648</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROJECTS</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR CLASS OF 1982 40TH REUNION</GrantOrContributionPurposeTxt>
          <Amt>20000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROJECTS</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THERAPEUTIC TARGETS AT THE HOST MICROBIOTA INTERFACE FOR FIBROSIS</GrantOrContributionPurposeTxt>
          <Amt>336846</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROJECTS</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>405488</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROJECTS</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THERAPEUTIC TARGETS AT THE HOST MICROBIOTA INTERFACE FOR FIBROSIS</GrantOrContributionPurposeTxt>
          <Amt>156907</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YEHUDA ABARBANEL GOVERNMENT HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>15 KEREN KAYEMET ST</AddressLine1Txt>
            <CityNm>BAT YAM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MODERNIZATION OF ABARBANELS INFORMATION TECHNOLOGY AND SECURITY SYSTEMS</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YITZHAK SHAMIR MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEER YAAKOV</AddressLine1Txt>
            <CityNm>TZRIFIN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION AND RENOVATION OF SHAMIR MEDICAL CENTER'S CANCER INSTITUTE</GrantOrContributionPurposeTxt>
          <Amt>729642</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YOUNG MEN'S CHRISTIAN ASSOCIATION RETIREMENT FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>120 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10271</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YOUTH DEVELOPMENT ORGANIZATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15 UNION STREET 563</AddressLine1Txt>
            <CityNm>LAWRENCE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01840</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDUCATION AND CHARACTER DEVELOPMENT FOR LOCAL YOUTH</GrantOrContributionPurposeTxt>
          <Amt>14516</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ZEFAT ACADEMIC COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>11 JERUSALEM STREET POB 160</AddressLine1Txt>
            <CityNm>ZEFAT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EQUIPPING ZEFAT ACADEMIC COLLEGE'S INST. FOR ADV. HEALTH TRAINING &amp; ED.</GrantOrContributionPurposeTxt>
          <Amt>4114152</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ZIV MEDICAL CENTER ZEFAT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RAMBAM ST</AddressLine1Txt>
            <CityNm>ZEFAT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PURCHASE OF TWO ECMO MACHINES FOR ZIV MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>151611</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ZIV MEDICAL CENTER ZEFAT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RAMBAM ST</AddressLine1Txt>
            <CityNm>ZEFAT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REINFORCE CRUCIAL SITES DURING EMERGENCIES: ORS, BLOOD BANK &amp; PHARMACY</GrantOrContributionPurposeTxt>
          <Amt>1503124</Amt>
        </GrantOrContributionPdDurYrGrp>
        <TotalGrantOrContriPdDurYrAmt>385014429</TotalGrantOrContriPdDurYrAmt>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>4YOUANDME</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2901 THIRD AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WEARABLES TO MEASURE STRESS AND FORECAST CROHNS SYMPTOMS</GrantOrContributionPurposeTxt>
          <Amt>110128</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>A GLIMMER OF HOPE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3103 BEE CAVES ROAD</AddressLine1Txt>
            <CityNm>AUSTIN</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>78746</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PF</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTEGRATED COMMUNITY DEVELOPMENT IN ODA BULTUM, ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>1854222</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALBERT EINSTEIN COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 MORRIS PARK AVE</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>104611975</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPLEMENTAL SUPPORT FOR T1DTECHCHW</GrantOrContributionPurposeTxt>
          <Amt>163648</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALBERT EINSTEIN COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 MORRIS PARK AVE</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>104611975</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECLINICAL WORK TO ADVANCE D-PEPTIDES AS ANTIGEN-SPECIFIC IMMUNOTHERAPY</GrantOrContributionPurposeTxt>
          <Amt>556499</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALBERT EINSTEIN COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 MORRIS PARK AVE</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>104611975</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPLEMENTAL SUPPORT FOR T1DTECHCHW</GrantOrContributionPurposeTxt>
          <Amt>168556</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALBERT EINSTEIN COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 MORRIS PARK AVE</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>104611975</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPLEMENTAL SUPPORT FOR T1DTECHCHW</GrantOrContributionPurposeTxt>
          <Amt>173613</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALIMENTIV INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>948511</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALIMENTIV INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD</GrantOrContributionPurposeTxt>
          <Amt>267835</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALIMENTIV INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD</GrantOrContributionPurposeTxt>
          <Amt>259951</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALYN HOSPITAL - REHABILITATION CENTER FOR CHILDREN AND YOUTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>84 SHMARYAHU LEVIN ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ALYN CENTER FOR INNOVATION IN PEDIATRIC REHABILITATION RESEARCH</GrantOrContributionPurposeTxt>
          <Amt>717219</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALYN HOSPITAL - REHABILITATION CENTER FOR CHILDREN AND YOUTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>84 SHMARYAHU LEVIN ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ALYN CENTER FOR INNOVATION IN PEDIATRIC REHABILITATION RESEARCH</GrantOrContributionPurposeTxt>
          <Amt>694034</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMC MEDICAL RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION OF BIOMARKERS FOR PERIANAL FISTULIZING DISEASE</GrantOrContributionPurposeTxt>
          <Amt>50570</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMC MEDICAL RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION OF BIOMARKERS FOR PERIANAL FISTULIZING DISEASE</GrantOrContributionPurposeTxt>
          <Amt>610817</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN CAMPING ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5000 STATE ROAD 67 NORTH</AddressLine1Txt>
            <CityNm>MARTINSVILLE</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>46151</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACA PROFESSIONAL DEVELOPMENT 2022 - 2024</GrantOrContributionPurposeTxt>
          <Amt>48955</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN CAMPING ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5000 STATE ROAD 67 NORTH</AddressLine1Txt>
            <CityNm>MARTINSVILLE</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>46151</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACA PROFESSIONAL DEVELOPMENT 2022 - 2024</GrantOrContributionPurposeTxt>
          <Amt>51040</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOCUS ON FELLOWS, DIABETES IS PRIMARY, PROFESSIONAL MEMBERSHIP PROJECTS</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADA MENTAL HEALTH EDUCATION PROGRAM 2022 - 2024</GrantOrContributionPurposeTxt>
          <Amt>337310</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2022-2024 TYPE 1 DIABETES CAMP INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>399368</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADA MENTAL HEALTH EDUCATION PROGRAM 2022 - 2024</GrantOrContributionPurposeTxt>
          <Amt>278350</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2022-2024 TYPE 1 DIABETES CAMP INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>399368</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN GASTROENTEROLOGICAL ASSOCIATION INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4930 DEL RAY AVE</AddressLine1Txt>
            <CityNm>BETHESDA</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>20814</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SPECIALIZED IBD TRAINING FOR ADVANCE PRACTICE PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>155930</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MISSION: LIFELINE STROKE MT AND POST-ACUTE STROKE CARE QUALITY STANDARDS</GrantOrContributionPurposeTxt>
          <Amt>1654728</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MISSION: LIFELINE STROKE MT AND POST-ACUTE STROKE CARE QUALITY STANDARDS</GrantOrContributionPurposeTxt>
          <Amt>690948</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICARES FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>88 HAMILTON AVE</AddressLine1Txt>
            <CityNm>STAMFORD</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06840</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL, NEWBORN, AND CHILD HEALTH INTERVENTIONS</GrantOrContributionPurposeTxt>
          <Amt>752688</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICARES FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>88 HAMILTON AVE</AddressLine1Txt>
            <CityNm>STAMFORD</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06840</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL, NEWBORN, AND CHILD HEALTH INTERVENTIONS</GrantOrContributionPurposeTxt>
          <Amt>749599</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>APHP ST ANTOINE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>184 RUE DU FAUBOURG SAINT-ANTOINE</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>474464</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>APHP ST ANTOINE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>184 RUE DU FAUBOURG SAINT-ANTOINE</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>474464</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>APHP ST ANTOINE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>184 RUE DU FAUBOURG SAINT-ANTOINE</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>367129</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>APHP ST ANTOINE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>184 RUE DU FAUBOURG SAINT-ANTOINE</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>421681</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASIAN HEALTH CARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>6-3-661 SOMAJIGUDA</AddressLine1Txt>
            <CityNm>HYDERABAD</CityNm>
            <CountryCd>IN</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCESS TO CROHNS DIAGNOSTICS IN INDIA FOR PATIENTS LIVING IN POVERTY</GrantOrContributionPurposeTxt>
          <Amt>210551</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 SOUTH WACKER DRIVE SUITE 600</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60606</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF DANATECH PLATFORM</GrantOrContributionPurposeTxt>
          <Amt>413127</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 SOUTH WACKER DRIVE SUITE 600</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60606</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF DANATECH PLATFORM</GrantOrContributionPurposeTxt>
          <Amt>831327</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 SOUTH WACKER DRIVE SUITE 600</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60606</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF DANATECH PLATFORM</GrantOrContributionPurposeTxt>
          <Amt>855546</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION SANTE DIABETE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>17 AVENUE MALHERBE</AddressLine1Txt>
            <CityNm>GRENOBLE</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABETES SUPPORT TO PEOPLE IN BURKINA FASO, MALI AND UNION OF COMOROS</GrantOrContributionPurposeTxt>
          <Amt>272362</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION SANTE DIABETE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>17 AVENUE MALHERBE</AddressLine1Txt>
            <CityNm>GRENOBLE</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABETES SUPPORT TO PEOPLE IN BURKINA FASO, MALI AND UNION OF COMOROS</GrantOrContributionPurposeTxt>
          <Amt>205984</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LEVEL 2</AddressLine1Txt>
            <CityNm>FITZROY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE: THE MIRO STUDY</GrantOrContributionPurposeTxt>
          <Amt>587840</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LEVEL 2</AddressLine1Txt>
            <CityNm>FITZROY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE: THE MIRO STUDY</GrantOrContributionPurposeTxt>
          <Amt>587840</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1325 S CLIFF AVENUE</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AVERA BEHAVIORAL HEALTH CENTER EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1325 S CLIFF AVENUE</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AVERA BEHAVIORAL HEALTH CENTER EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1325 S CLIFF AVENUE</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AVERA BEHAVIORAL HEALTH CENTER EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1325 S CLIFF AVENUE</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AVERA BEHAVIORAL HEALTH CENTER EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BALLAD RESEARCH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10865 ROAD TO THE CURE</AddressLine1Txt>
            <CityNm>SAN DIEGO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CD127-HIGH T-CELL POPULATIONS AS BIOMARKERS</GrantOrContributionPurposeTxt>
          <Amt>325801</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BANNER HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>801 EAST WILLIAMS AVE</AddressLine1Txt>
            <CityNm>FALLON</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89406</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BANNER CHURCHILL COMMUNITY HOSPITAL ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>139574</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAYLOR COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH</AddressLine1Txt>
            <CityNm>HOUSTON</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE</GrantOrContributionPurposeTxt>
          <Amt>500180</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAYLOR COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH</AddressLine1Txt>
            <CityNm>HOUSTON</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMR-BASED PREDICTIVE ANALYTICS FOR TARGETED PROACTIVE T1D CARE</GrantOrContributionPurposeTxt>
          <Amt>532841</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAYLOR COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH</AddressLine1Txt>
            <CityNm>HOUSTON</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE</GrantOrContributionPurposeTxt>
          <Amt>524854</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAYLOR COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH</AddressLine1Txt>
            <CityNm>HOUSTON</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMR-BASED PREDICTIVE ANALYTICS FOR TARGETED &amp; PROACTIVE T1D CARE</GrantOrContributionPurposeTxt>
          <Amt>547540</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 NINTH AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981012795</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN IN T1D</GrantOrContributionPurposeTxt>
          <Amt>661927</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 NINTH AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981012795</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN IN T1D</GrantOrContributionPurposeTxt>
          <Amt>567763</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BETH ISRAEL DEACONESS MEDICAL CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>330 BROOKLINE AVENUE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022155491</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD</GrantOrContributionPurposeTxt>
          <Amt>519550</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BETH ISRAEL DEACONESS MEDICAL CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>330 BROOKLINE AVENUE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022155491</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD</GrantOrContributionPurposeTxt>
          <Amt>519548</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BETH ISRAEL DEACONESS MEDICAL CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>330 BROOKLINE AVENUE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022155491</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD</GrantOrContributionPurposeTxt>
          <Amt>538077</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BETH ISRAEL DEACONESS MEDICAL CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>330 BROOKLINE AVENUE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022155491</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD</GrantOrContributionPurposeTxt>
          <Amt>538077</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEYOND TYPE 1</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1001 LAUREL ST STE B</AddressLine1Txt>
            <CityNm>SAN CARLOS</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABETIC KETOACIDOSIS (DKA) CAMPAIGN PHASE 3</GrantOrContributionPurposeTxt>
          <Amt>149167</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEYOND TYPE 1</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1001 LAUREL ST STE B</AddressLine1Txt>
            <CityNm>SAN CARLOS</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABETIC KETOACIDOSIS (DKA) CAMPAIGN PHASE 3</GrantOrContributionPurposeTxt>
          <Amt>149166</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MONTANA PSYCHIATRY RESIDENCY PROGRAM SUSTAINING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BIPARTISAN POLICY CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1225 I ST NW 1000</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING HEALTH CARE DELIVERY AND SERVICES IN RURAL AMERICA</GrantOrContributionPurposeTxt>
          <Amt>625293</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1209 ORANGE STREET</AddressLine1Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>1740266</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1209 ORANGE STREET</AddressLine1Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>1740267</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>2500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>3500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>3480533</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>3480533</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>4470844</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>4470844</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>4470843</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOULDER CITY HOSPITAL INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>901 ADAMS BLVD</AddressLine1Txt>
            <CityNm>BOULDER CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BOULDER CITY HOSPITAL EQUIPMENT REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>37497</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOULDER CITY HOSPITAL INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>901 ADAMS BLVD</AddressLine1Txt>
            <CityNm>BOULDER CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BOULDER CITY HOSPITAL EQUIPMENT REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>34997</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIDGES TO PROSPERITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1031 33RD STREET</AddressLine1Txt>
            <CityNm>DENVER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ETHIOPIA ASSESSMENT OF BRIDGE INFRASTRUCTURE</GrantOrContributionPurposeTxt>
          <Amt>142110</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIDGES TO PROSPERITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1031 33RD STREET</AddressLine1Txt>
            <CityNm>DENVER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMATIVE CONNECTIVITY IN RURAL ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>2812542</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIDGES TO PROSPERITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1031 33RD STREET</AddressLine1Txt>
            <CityNm>DENVER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMATIVE CONNECTIVITY IN RURAL ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>2648126</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIDGES TO PROSPERITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1031 33RD STREET</AddressLine1Txt>
            <CityNm>DENVER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ZAMBIA ASSESSMENT OF BRIDGE INFRASTRUCTURE</GrantOrContributionPurposeTxt>
          <Amt>142110</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS</GrantOrContributionPurposeTxt>
          <Amt>1829719</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PEN-PLUS EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>1988392</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INVESTIGATION OF ANTI-GM-CSF AUAB AS A DISEASE DETERMINANT IN CD</GrantOrContributionPurposeTxt>
          <Amt>1326053</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS</GrantOrContributionPurposeTxt>
          <Amt>1308107</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PEN-PLUS EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>1914468</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INVESTIGATION OF ANTI-GM-CSF AUAB AS A DISEASE DETERMINANT IN CD</GrantOrContributionPurposeTxt>
          <Amt>562221</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS</GrantOrContributionPurposeTxt>
          <Amt>1785375</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PEN-PLUS EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>1914468</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INVESTIGATION OF ANTI-GM-CSF AUAB AS A DISEASE DETERMINANT IN CD</GrantOrContributionPurposeTxt>
          <Amt>499459</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PEN-PLUS EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>3802596</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PEN-PLUS EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>6054477</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PASSIVE WIRELESS MONITORING TO PREDICT AND TRACK CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>360771</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HILLS ROAD</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO CD TREATMENTS</GrantOrContributionPurposeTxt>
          <Amt>561004</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HILLS ROAD</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO CD TREATMENTS</GrantOrContributionPurposeTxt>
          <Amt>313576</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HILLS ROAD</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO CD TREATMENTS</GrantOrContributionPurposeTxt>
          <Amt>313576</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CARE-FOR-RARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DR VON HAUNERSCHES KINDERSPITAL</AddressLine1Txt>
            <AddressLine2Txt>KLINIKUM DER UNIVERSITT MUNCHEN</AddressLine2Txt>
            <CityNm>MUNICH</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VEOIBD FROM PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES - MUNICH</GrantOrContributionPurposeTxt>
          <Amt>655603</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CARE-FOR-RARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>KINDERSPITAL KLINIKUM DER</AddressLine1Txt>
            <CityNm>MUNICH</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VEOIBD FROM PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES - MUNICH</GrantOrContributionPurposeTxt>
          <Amt>721252</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RURAL EMERGENCY HEALTH SERVICE AND TRANSPORT FOR SYSTEM DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>1344542</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MAYI MWANA PROJECT: HELPING ZAMBIAN MOTHERS &amp; NEWBORNS SURVIVE &amp; THRIVE</GrantOrContributionPurposeTxt>
          <Amt>1100098</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTEGRATED COMMUNITY WATER, SANITATION AND HYGIENE IMPROVEMENT IN GHANA</GrantOrContributionPurposeTxt>
          <Amt>1556214</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BOUSSOUMA AND ZIGA, BURKINA FASO IMPROVED WASH INFRASTRUCTURE &amp; SERVICES</GrantOrContributionPurposeTxt>
          <Amt>749145</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTEGRATING GENOMIC AND IMAGING DATA WITH SCRNASEQ TO UNDERSTAND CD</GrantOrContributionPurposeTxt>
          <Amt>268151</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY</GrantOrContributionPurposeTxt>
          <Amt>204837</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTEGRATING GENOMIC AND IMAGING DATA WITH SCRNASEQ TO UNDERSTAND CD</GrantOrContributionPurposeTxt>
          <Amt>231849</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY</GrantOrContributionPurposeTxt>
          <Amt>216002</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LONG-TERM RESPONSE TO SARS-COV-2 VACCINATION IN A DIVERSE IBD POPULATION</GrantOrContributionPurposeTxt>
          <Amt>522999</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES CEDARS-SINAI</GrantOrContributionPurposeTxt>
          <Amt>115500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY</GrantOrContributionPurposeTxt>
          <Amt>200041</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LONG-TERM RESPONSE TO SARS-COV-2 VACCINATION IN A DIVERSE IBD POPULATION</GrantOrContributionPurposeTxt>
          <Amt>364763</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY</GrantOrContributionPurposeTxt>
          <Amt>202791</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES CEDARS-SINAI</GrantOrContributionPurposeTxt>
          <Amt>115500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY</GrantOrContributionPurposeTxt>
          <Amt>219514</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY</GrantOrContributionPurposeTxt>
          <Amt>211815</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTER FOR EXCELLENCE IN HEALTH CARE JOURNALISM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10 NEFF HALL</AddressLine1Txt>
            <CityNm>COLUMBIA</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>65211</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOII</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRAINING AND DEVELOPMENT OF HEALTH CARE JOURNALISTS AND HEALTH REPORTING</GrantOrContributionPurposeTxt>
          <Amt>219995</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTRAL MONTANA MEDICAL FACILITIES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>408 WENDELL AVE</AddressLine1Txt>
            <CityNm>LEWISTOWN</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59457</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CANCER CENTER AT CENTRAL MONTANA MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>3469965</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTRAL MONTANA MEDICAL FACILITIES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>408 WENDELL AVE</AddressLine1Txt>
            <CityNm>LEWISTOWN</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59457</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CANCER CENTER AT CENTRAL MONTANA MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>690035</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTRE HOSPITALIER REGIONAL DE NANCY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>29 AVENUE MAL DE LATTRE DE TASSIGNY</AddressLine1Txt>
            <CityNm>NANCY</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE</GrantOrContributionPurposeTxt>
          <Amt>98364</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTRE HOSPITALIER REGIONAL DE NANCY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>29 AVENUE MAL DE LATTRE DE TASSIGNY</AddressLine1Txt>
            <CityNm>NANCY</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE</GrantOrContributionPurposeTxt>
          <Amt>89352</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTRE HOSPITALIER REGIONAL DE NANCY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>29 AVENUE MAL DE LATTRE DE TASSIGNY</AddressLine1Txt>
            <CityNm>NANCY</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE</GrantOrContributionPurposeTxt>
          <Amt>95277</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTRE HOSPITALIER REGIONAL DE NANCY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>29 AVENUE MAL DE LATTRE DE TASSIGNY</AddressLine1Txt>
            <CityNm>NANCY</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE</GrantOrContributionPurposeTxt>
          <Amt>103796</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTRE HOSPITALIER REGIONAL DE NANCY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>29 AVENUE MAL DE LATTRE DE TASSIGNY</AddressLine1Txt>
            <CityNm>NANCY</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE</GrantOrContributionPurposeTxt>
          <Amt>153102</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHASE COUNTY COMMUNITY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>600 WEST 12TH STREET</AddressLine1Txt>
            <CityNm>IMPERIAL</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69033</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT CHASE COUNTY COMMUNITY HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>29056</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHASE COUNTY COMMUNITY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>600 WEST 12TH STREET</AddressLine1Txt>
            <CityNm>IMPERIAL</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69033</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT CHASE COUNTY COMMUNITY HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>12656</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOLECULAR + SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>374591</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOLECULAR + SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>374591</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>1153809</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOLECULAR + SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>374591</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULINS</GrantOrContributionPurposeTxt>
          <Amt>666216</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES- BOSTON</GrantOrContributionPurposeTxt>
          <Amt>1249403</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOLECULAR SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>374591</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>1173337</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES- BOSTON</GrantOrContributionPurposeTxt>
          <Amt>1226580</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULINS</GrantOrContributionPurposeTxt>
          <Amt>665654</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>SABAN RESEARCH INSTITUTE</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90027</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE</GrantOrContributionPurposeTxt>
          <Amt>679025</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>SABAN RESEARCH INSTITUTE</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90027</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE</GrantOrContributionPurposeTxt>
          <Amt>684686</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECISION CROHNS DISEASE MANAGEMENT UTILIZING PREDICTIVE PROTEIN PANELS</GrantOrContributionPurposeTxt>
          <Amt>235507</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BIOMARKERS OF INTESTINAL FIBROSIS IN SMALL BOWEL CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>282554</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>1009535</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP A PROGNOSTIC AI MODEL FOR FORECASTING CD PATIENT OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>1421241</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP A PROGNOSTIC AI MODEL FOR FORECASTING CD PATIENT OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>1093319</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>725157</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL OF PHILADELPHIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2716 SOUTH STREET</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191462305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHNS DISEASE EPITHELIAL STEM CELL ATLAS: PEDIATRIC TO ADULT CONTINUUM</GrantOrContributionPurposeTxt>
          <Amt>272676</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HUNGER FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13931 BALBOA BLVD</AddressLine1Txt>
            <CityNm>SYLMAR</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91342</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOOD SUPPORT IN ETHIOPIA AND ZAMBIA</GrantOrContributionPurposeTxt>
          <Amt>151800</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S MERCY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2401 GILLHAM ROAD</AddressLine1Txt>
            <CityNm>KANSAS CITY</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>64108</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RAPID LEARNING LAB</GrantOrContributionPurposeTxt>
          <Amt>2966873</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S MERCY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2401 GILLHAM ROAD</AddressLine1Txt>
            <CityNm>KANSAS CITY</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>64108</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RAPID LEARNING LAB</GrantOrContributionPurposeTxt>
          <Amt>1399624</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITIZENS HOUSING AND PLANNING COUNCIL OF NEW YORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>42 BROADWAY STE 2010</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10004</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDUCATION FOR NYC POLICYMAKERS ON HOUSING INITIATIVES TO IMPROVE HEALTH</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY PARKS FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>830 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC GREEN RELIEF &amp; RECOVERY FUND</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY PARKS FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>830 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CATALYST: GROWING INTENSIVE PARK ENGAGEMENT IN VULNERABLE COMMUNITIES</GrantOrContributionPurposeTxt>
          <Amt>491131</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>YOSEFTAL HOSPITAL ADDITION</GrantOrContributionPurposeTxt>
          <Amt>2058214</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>YOSEFTAL HOSPITAL ADDITION</GrantOrContributionPurposeTxt>
          <Amt>3847500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COVID-19 VACCINE RESPONSES IN PATIENTS WITH IBD</GrantOrContributionPurposeTxt>
          <Amt>177281</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE IBDMED NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL &amp; PREVENTION</GrantOrContributionPurposeTxt>
          <Amt>242153</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>926084</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>926084</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE IBDMED NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL &amp; PREVENTION</GrantOrContributionPurposeTxt>
          <Amt>243216</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE IBDMED NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL PREVENTION</GrantOrContributionPurposeTxt>
          <Amt>243216</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLINTON HEALTH ACCESS INITIATIVE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>383 DORCHESTER AVENUE SUITE 400</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02127</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE</GrantOrContributionPurposeTxt>
          <Amt>1132215</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLINTON HEALTH ACCESS INITIATIVE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>383 DORCHESTER AVENUE SUITE 400</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02127</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE</GrantOrContributionPurposeTxt>
          <Amt>1372583</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL SPATIALLY RESOLVED GENOMIC PROFILING OF CROHNS DISEASE TISSUE</GrantOrContributionPurposeTxt>
          <Amt>210228</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>210638</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>351258</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>334798</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>429646</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>413263</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COMMUNITY MEMORIAL HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2731 HEALTHCARE DRIVE</AddressLine1Txt>
            <CityNm>SYRACUSE</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68446</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE EMERGENCY AT SYRACUSE AREA HEALTH</GrantOrContributionPurposeTxt>
          <Amt>13320</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CONSORCI INSTITUT D'INVESTIGACIONES BIOMEDICAS AUGUST</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>ROSSELL 149</AddressLine1Txt>
            <CityNm>BARCELONA</CityNm>
            <CountryCd>SP</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EARLY DETECTION OF PERIANAL FISTULIZING DISEASE</GrantOrContributionPurposeTxt>
          <Amt>261948</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CONSORCI INSTITUT D'INVESTIGACIONES BIOMEDICAS AUGUST</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>ROSSELL 149</AddressLine1Txt>
            <CityNm>BARCELONA</CityNm>
            <CountryCd>SP</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EARLY DETECTION OF PERIANAL FISTULIZING DISEASE</GrantOrContributionPurposeTxt>
          <Amt>177122</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COUNCIL ON FOUNDATIONS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1255 23RD ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>34000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD</GrantOrContributionPurposeTxt>
          <Amt>570831</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT JUNIOR SCIENTISTS TO ESTABLISH CAREERS IN IBD RESEARCH.</GrantOrContributionPurposeTxt>
          <Amt>1067400</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD</GrantOrContributionPurposeTxt>
          <Amt>570830</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD</GrantOrContributionPurposeTxt>
          <Amt>588266</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT JUNIOR SCIENTISTS TO ESTABLISH CAREERS IN IBD RESEARCH.</GrantOrContributionPurposeTxt>
          <Amt>1067400</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD</GrantOrContributionPurposeTxt>
          <Amt>588266</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE</GrantOrContributionPurposeTxt>
          <Amt>255521</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>275688</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE</GrantOrContributionPurposeTxt>
          <Amt>253783</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>275588</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE</GrantOrContributionPurposeTxt>
          <Amt>284646</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>286838</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE</GrantOrContributionPurposeTxt>
          <Amt>297612</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>374912</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS UK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 BISHOPS SQUARE</AddressLine1Txt>
            <CityNm>HATFIELD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2021 2022 OPERATING SUPPORT FOR CROHNS AND COLITIS UK</GrantOrContributionPurposeTxt>
          <Amt>75900</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS UK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 BISHOPS SQUARE</AddressLine1Txt>
            <CityNm>HATFIELD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2021 2022 OPERATING SUPPORT FOR CROHNS AND COLITIS UK</GrantOrContributionPurposeTxt>
          <Amt>75900</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS UK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 BISHOPS SQUARE</AddressLine1Txt>
            <CityNm>HATFIELD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2021 2022 OPERATING SUPPORT FOR CROHNS AND COLITIS UK</GrantOrContributionPurposeTxt>
          <Amt>75900</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S COLITIS CURE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 OCONNELL STREET</AddressLine1Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF CCCARE-P, A PEDIATRIC CD EMR TO DRIVE CONSISTENCY IN CARE</GrantOrContributionPurposeTxt>
          <Amt>68358</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S COLITIS CURE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 OCONNELL STREET</AddressLine1Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF CCCARE-P, A PEDIATRIC CD EMR TO DRIVE CONSISTENCY IN CARE</GrantOrContributionPurposeTxt>
          <Amt>99842</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S COLITIS CURE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 OCONNELL STREET</AddressLine1Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF CCCARE-P, A PEDIATRIC CD EMR TO DRIVE CONSISTENCY IN CARE</GrantOrContributionPurposeTxt>
          <Amt>90467</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S COLITIS CURE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 OCONNELL STREET</AddressLine1Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF CCCARE-P, A PEDIATRIC CD EMR TO DRIVE CONSISTENCY IN CARE</GrantOrContributionPurposeTxt>
          <Amt>66267</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DARTMOUTH- HITCHCOCK CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE MEDICAL CENTER DRIVE</AddressLine1Txt>
            <CityNm>LEBANON</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03756</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING FOR VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>197461</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DE LA SALLE SOLIDARIETAINTERNAZIONALE ONLUS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>VIA AUREALIA 476</AddressLine1Txt>
            <CityNm>ROME</CityNm>
            <CountryCd>IT</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ETHIOPIAN CATHOLIC UNIVERSITY DIAGNOSTIC LABORATORY</GrantOrContributionPurposeTxt>
          <Amt>191462</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DE LA SALLE SOLIDARIETAINTERNAZIONALE ONLUS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>VIA AUREALIA 476</AddressLine1Txt>
            <CityNm>ROME</CityNm>
            <CountryCd>IT</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ETHIOPIAN CATHOLIC UNIVERSITY DIAGNOSTIC LABORATORY</GrantOrContributionPurposeTxt>
          <Amt>94780</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DUKE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O OFFICE OF RESEARCH SUPPORT</AddressLine1Txt>
            <CityNm>DURHAM</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>277054677</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS GIP IN PANCREATIC CELLS</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DUNDY COUNTY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1313 N CHEYENNE ST</AddressLine1Txt>
            <CityNm>BENKELMAN</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69021</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>29310</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DUNDY COUNTY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1313 N CHEYENNE ST</AddressLine1Txt>
            <CityNm>BENKELMAN</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69021</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>11725</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DUNDY COUNTY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1313 N CHEYENNE ST</AddressLine1Txt>
            <CityNm>BENKELMAN</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69021</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>121593</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ENGINEERING MINISTRIES INTERNATIONAL USA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7025 CAMPUS DRIVE</AddressLine1Txt>
            <CityNm>COLORADO SPRINGS</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80920</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ALASKA WASH PROJECT</GrantOrContributionPurposeTxt>
          <Amt>7020410</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FLORESTA USA INCORPORATED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4747 MORENA BLVD STE 100</AddressLine1Txt>
            <CityNm>SAN DIEGO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92117</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING AT THE WATERSHED LEVEL TO EQUIP RURAL FAMILIES</GrantOrContributionPurposeTxt>
          <Amt>516231</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FOR INSPIRATION AND RECOGNITION OF SCIENCE TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>200 BEDFORD STREET</AddressLine1Txt>
            <CityNm>MANCHESTER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INSPIRE YOUNG PEOPLE TO BE SCIENCE AND TECHNOLOGY LEADERS</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FRANCISCAN CARE SERVICES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>430 N MONITOR ST</AddressLine1Txt>
            <CityNm>WEST POINT</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68788</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT FRANCISCAN HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>42729</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FRANCISCAN CARE SERVICES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>430 N MONITOR ST</AddressLine1Txt>
            <CityNm>WEST POINT</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68788</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT FRANCISCAN HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>17093</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FRIENDS OF THE ISRAEL DEFENSE FORCES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>60 EAST 42 STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10165</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE UNIFORM TO UNIVERSITY SCHOLARSHIP PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>334400</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FRIENDS OF THE ISRAEL DEFENSE FORCES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>60 EAST 42 STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10165</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE UNIFORM TO UNIVERSITY SCHOLARSHIP PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>334400</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FUND FOR PUBLIC HEALTH IN NEW YORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>22 CORTLANDT STREET SUITE 802</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10007</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC VACCINE EQUITY PARTNER ENGAGEMENT PROJECT</GrantOrContributionPurposeTxt>
          <Amt>150467</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GALILEE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>GALILEE MEDICAL CENTER</AddressLine1Txt>
            <CityNm>NAHARIYA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING</GrantOrContributionPurposeTxt>
          <Amt>2200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GALILEE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>GALILEE MEDICAL CENTER</AddressLine1Txt>
            <CityNm>NAHARIYA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING</GrantOrContributionPurposeTxt>
          <Amt>2200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEORGIA TECH RESEARCH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>505 10TH STREET NW</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>303320420</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRACKING AND INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>480848</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEORGIA TECH RESEARCH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>505 10TH STREET NW</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>303320420</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRACKING INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>480848</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEORGIA TECH RESEARCH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>505 10TH STREET NW</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>303320420</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRACKING INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>485617</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEORGIA TECH RESEARCH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>505 10TH STREET NW</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>303320420</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRACKING &amp; INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>485616</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GIRLS WITH GUTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>6024 RIDGE AVENUE</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>19128</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2021 2022 OPERATING SUPPORT TO GIRLS WITH GUTS.</GrantOrContributionPurposeTxt>
          <Amt>11100</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GIRLS WITH GUTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>6024 RIDGE AVENUE</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>19128</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2021 2022 OPERATING SUPPORT TO GIRLS WITH GUTS.</GrantOrContributionPurposeTxt>
          <Amt>11100</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GLOBAL SOLIDARITY FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>425 LEXINGTON AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JOB CREATION IN ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>1508200</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GLOBAL SOLIDARITY FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>425 LEXINGTON AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JOB CREATION IN ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>1508200</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>27 KINGS COLLEGE CIRCLE</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE RESPONSIVE GLUCAGON MICRONEEDLE PATCH - HYPOGLYCEMIA PREVENTION</GrantOrContributionPurposeTxt>
          <Amt>185460</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GRANTMAKERS IN HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 CT AVENUE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GRANTMAKERS IN HEALTH EFFECTIVE PHILANTHROPY FUND</GrantOrContributionPurposeTxt>
          <Amt>119803</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GUARDIAN ORG FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>900 17TH STREET NW SUITE 250</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN INDEPENDENT JOURNALISM SERIES ON NON-COMMUNICABLE DISEASES</GrantOrContributionPurposeTxt>
          <Amt>625000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HANNOVERSCHE KINDERHEILANSTALT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>JANUSZ-KORCZAK-ALLEE 12</AddressLine1Txt>
            <CityNm>HANNOVER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FR1DA IN NORTH GERMANY: PRE-SYMPTOMATIC TYPE 1 DIABETES TESTING IN KIDS</GrantOrContributionPurposeTxt>
          <Amt>267694</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEBREW UNIVERSITY OF JERUSALEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OFFICE OF THE PRESIDENT</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>671024</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEBREW UNIVERSITY OF JERUSALEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OFFICE OF THE PRESIDENT</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>362703</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELEN KELLER INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE DAG HAMMARSKJOLD PLAZA</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT</GrantOrContributionPurposeTxt>
          <Amt>1652490</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELEN KELLER INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE DAG HAMMARSKJOLD PLAZA</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT</GrantOrContributionPurposeTxt>
          <Amt>1941293</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION OF INFANTS WITH HIGH RISK OF T1D - PRIMARY PREVENTION</GrantOrContributionPurposeTxt>
          <Amt>1431241</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>668906</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>1277602</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>2350161</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION OF THE GPPAD-02-STUDY</GrantOrContributionPurposeTxt>
          <Amt>2428367</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT</GrantOrContributionPurposeTxt>
          <Amt>460108</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>1277602</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION OF THE GPPAD-02-STUDY</GrantOrContributionPurposeTxt>
          <Amt>2451335</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>2622774</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>847748</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD DRIED BLOOD SPOT OMICS TO PREDICT HEALTH OUTCOMES IN CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>80432</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>847748</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>1454620</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION OF THE GPPAD-02-STUDY</GrantOrContributionPurposeTxt>
          <Amt>2451335</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>2622773</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>1454619</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION OF THE GPPAD-02-STUDY</GrantOrContributionPurposeTxt>
          <Amt>2440023</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>3074101</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>870315</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD DRIED BLOOD SPOT OMICS TO PREDICT HEALTH OUTCOMES IN CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>82445</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>870314</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>1339873</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>3074100</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>1339873</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>830769</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>1482901</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>830769</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>1482900</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>1410856</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>1410856</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>1301918</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>1301917</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN GMBH</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>522291</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HENRY J KAISER FAMILY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>185 BERRY STREET NO 2000</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94107</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>KHN RURAL HEALTH DESK</GrantOrContributionPurposeTxt>
          <Amt>1239878</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HENRY J KAISER FAMILY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>185 BERRY STREET NO 2000</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94107</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>KHN RURAL HEALTH DESK</GrantOrContributionPurposeTxt>
          <Amt>1275901</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HERLEV OG GENTOFTE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERLEV AND GENTOFTE HOSPITAL</AddressLine1Txt>
            <CityNm>HERLEV</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D</GrantOrContributionPurposeTxt>
          <Amt>394362</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HERLEV OG GENTOFTE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERLEV AND GENTOFTE HOSPITAL</AddressLine1Txt>
            <CityNm>HERLEV</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS GIP IN PANCREATIC CELLS</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MODULATING EARLY LIFE MICROBIOME THROUGH DIETARY INTERVENTION IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>409388</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>415688</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>415688</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VEOIBD: PRECISION DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES</GrantOrContributionPurposeTxt>
          <Amt>220000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>404688</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>305349</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VEOIBD: PRECISION DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES</GrantOrContributionPurposeTxt>
          <Amt>220000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICHUD HATZALAH ISRAEL 1221 (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>78 YIRMIYAHU ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNITED HATZALAH HUMANITARIAN MISSION FOR UKRAINE</GrantOrContributionPurposeTxt>
          <Amt>739000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IDA COUNTY IOWA COMMUNITY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>701 EAST SECOND STREET</AddressLine1Txt>
            <CityNm>IDA GROVE</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51445</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE PHARMACY AT HORN MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>9677</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IDEOORG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>444 SPEAR STREET</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN-CENTERED DESIGN STUDY OF T1D IN MEDICALLY UNDERSERVED COMMUNITIES.</GrantOrContributionPurposeTxt>
          <Amt>227950</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IDEOORG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>444 SPEAR STREET</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN-CENTERED DESIGN STUDY OF T1D IN MEDICALLY UNDERSERVED COMMUNITIES.</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>81892</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>82380</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>87446</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>90190</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>148458</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>92999</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>98553</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>94105</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>99659</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>97317</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT NATIONALE DE LA SANTE ET DE LA RECHERCHE MEDICALE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>86 RUE REGNAULT</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BENIGN ISLET AUTOIMMUNITY TO T1D: CD8+ T-CELL BIOMARKERS OF PROGRESSION</GrantOrContributionPurposeTxt>
          <Amt>164338</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSULIN FOR LIFE USA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2555 SW 76TH STREET</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>32608</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INSULIN FOR LIFE USA STRENGTHENING ORGANIZATIONAL CAPACITY</GrantOrContributionPurposeTxt>
          <Amt>320933</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSULIN FOR LIFE USA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2555 SW 76TH STREET</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>32608</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INSULIN FOR LIFE USA STRENGTHENING ORGANIZATIONAL CAPACITY</GrantOrContributionPurposeTxt>
          <Amt>341606</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POINT-OF-CARE INTESTINAL ULTRASOUND TRAINING IN THE UNITED STATES</GrantOrContributionPurposeTxt>
          <Amt>172967</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE DEVELOPMENT OF A DISEASE ACTIVITY INDEX FOR INTESTINAL ULTRASOUND</GrantOrContributionPurposeTxt>
          <Amt>779377</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE DEVELOPMENT OF A DISEASE ACTIVITY INDEX FOR INTESTINAL ULTRASOUND</GrantOrContributionPurposeTxt>
          <Amt>718578</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE DEVELOPMENT OF A DISEASE ACTIVITY INDEX FOR INTESTINAL ULTRASOUND</GrantOrContributionPurposeTxt>
          <Amt>375221</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IOWA DEPARTMENT OF PUBLIC HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>321 EAST 12TH</AddressLine1Txt>
            <CityNm>DES MOINES</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50319</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IOWA FIRST RESPONDER AED INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>186944</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IOWA DEPARTMENT OF PUBLIC HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>321 EAST 12TH</AddressLine1Txt>
            <CityNm>DES MOINES</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50319</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IOWA FIRST RESPONDER AED INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>58968</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ISRAEL ANTIQUITIES AUTHORITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>27 SULTAN SULEIMAN STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JAY &amp; JEANIE SCHOTTENSTEIN NATIONAL CAMPUS FOR THE ARCHAEOLOGY OF ISRAEL</GrantOrContributionPurposeTxt>
          <Amt>400000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE IN DIABETES INITIATIVE: LARGE ADULT STUDY</GrantOrContributionPurposeTxt>
          <Amt>159838</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VIRTUAL DIABETES SPECIALTY CLINIC STUDY EVALUATING REMOTE INITIATION CGM</GrantOrContributionPurposeTxt>
          <Amt>724198</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY</GrantOrContributionPurposeTxt>
          <Amt>400000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM MONITORING OF MATERNAL DYSGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>425771</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY</GrantOrContributionPurposeTxt>
          <Amt>625000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY</GrantOrContributionPurposeTxt>
          <Amt>283542</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>286747</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>384845</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>387943</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>331671</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>162082</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>80-84 CHANDOS STREET</AddressLine1Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDIA EARLY TO MID-CAREER SCIENCE ACCELERATOR AWARDS 2021</GrantOrContributionPurposeTxt>
          <Amt>232577</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY AND JDRF CO-FUNDED WORKSHOPS</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JDRF GLOBAL DIABETES ACCESS INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>999800</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HCP T1D EDUCATION PROGRAM (STATE OF AFFAIRS AND PEAK)</GrantOrContributionPurposeTxt>
          <Amt>99699</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JDRF TRAINING PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>750000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY AND JDRF CO-FUNDED WORKSHOPS</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JERUSALEM COLLEGE OF TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>21 HAVAAD HALEUMI ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY FACULTY OF LIFE AND HEALTH SCIENCES BUILDING</GrantOrContributionPurposeTxt>
          <Amt>5465000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOSLIN DIABETES CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE JOSLIN PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02215</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES</GrantOrContributionPurposeTxt>
          <Amt>941354</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOSLIN DIABETES CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE JOSLIN PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02215</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES</GrantOrContributionPurposeTxt>
          <Amt>857270</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JUVENILE DIABETES RESEARCH FOUNDATION CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>235 YORKLAND BLVD SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JDRF CANADA PSYCHOSOCIAL HEALTH INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>36000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JUVENILE DIABETES RESEARCH FOUNDATION CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>235 YORKLAND BLVD SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JDRF CANADA PSYCHOSOCIAL HEALTH INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>19000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT</GrantOrContributionPurposeTxt>
          <Amt>530354</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CD</GrantOrContributionPurposeTxt>
          <Amt>656542</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT</GrantOrContributionPurposeTxt>
          <Amt>246663</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT FOR INNODIA HARVEST ACTIVITIES AT ACADEMIC CONSORTIUM MEMBERS.</GrantOrContributionPurposeTxt>
          <Amt>807155</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CD</GrantOrContributionPurposeTxt>
          <Amt>408046</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT</GrantOrContributionPurposeTxt>
          <Amt>246662</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CD</GrantOrContributionPurposeTxt>
          <Amt>362770</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATE THE BIOLOGICAL, SOCIAL AND ECONOMIC IMPACT OF HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>307779</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T CELL RECEPTOR SEQUENCING IN T1D - BIOMARKER &amp; TECHNOLOGY DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>115097</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1074992</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>288101</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1142151</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>195494</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1325562</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1296483</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>369984</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>778535</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1079926</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KITTSON MEMORIAL HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1010 SOUTH BIRCH AVENUE</AddressLine1Txt>
            <CityNm>HALLOCK</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>56728</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT KITTSON HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>11729</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>FEODOR-LYNEN-STRABE 17</AddressLine1Txt>
            <CityNm>MUCHEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>600891</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>FEODOR-LYNEN-STRABE 17</AddressLine1Txt>
            <CityNm>MUNCHEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>644601</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>FEODOR-LYNEN-STRABE 17</AddressLine1Txt>
            <CityNm>MUNICH</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>606581</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KLINIKUM DER UNIVERSITT MUNCHEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>FEODOR-LYNEN-STRABE 17</AddressLine1Txt>
            <CityNm>MUNCHEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>659714</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KLINIKUM DER UNIVERSITT MUNCHEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>FEODOR-LYNEN-STRABE 17</AddressLine1Txt>
            <CityNm>MUNCHEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>649424</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LAKES REGIONAL HEALTHCARE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>HIGHWAY 71 SOUTH</AddressLine1Txt>
            <CityNm>SPIRIT LAKE</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51360</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE PHARMACY AT LAKES REGIONAL HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>10856</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LINCOLN COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>700 NORTH SPRING STREET</AddressLine1Txt>
            <CityNm>CALIENTE</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89008</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GROVER C. DILS MEDICAL CENTER ULTRASOUND PROJECT</GrantOrContributionPurposeTxt>
          <Amt>36064</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LIVING WATER INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4001 GREENBRIAR DRIVE</AddressLine1Txt>
            <CityNm>STAFFORD</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>77477</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTEGRATED WASH PROGRAM IN CHIPATA DISTRICT, ZAMBIA</GrantOrContributionPurposeTxt>
          <Amt>1369113</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LUCAS COUNTY HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1200 NORTH 7TH STREET</AddressLine1Txt>
            <CityNm>CHARITON</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50049</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AVERA ECARE EMERGENCY VIRTUAL HEALTH AT LUCAS COUNTY HEALTH CENTER</GrantOrContributionPurposeTxt>
          <Amt>45334</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LUCAS COUNTY HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1200 NORTH 7TH STREET</AddressLine1Txt>
            <CityNm>CHARITON</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50049</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AVERA ECARE EMERGENCY VIRTUAL HEALTH AT LUCAS COUNTY HEALTH CENTER</GrantOrContributionPurposeTxt>
          <Amt>17970</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MACCABI HEALTHCARE SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>27 HAMERED ST</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOBILE MAMMOGRAPHY UNIT</GrantOrContributionPurposeTxt>
          <Amt>31500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MACCABI HEALTHCARE SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>27 HAMERED ST</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOBILE MAMMOGRAPHY UNIT</GrantOrContributionPurposeTxt>
          <Amt>31500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MADISON COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 W HUTCHINGS STREET</AddressLine1Txt>
            <CityNm>WINTERSET</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50273</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF EEMERGENCY AT MADISON COUNTY HEALTH CARE SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>37965</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MADISON COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 W HUTCHINGS STREET</AddressLine1Txt>
            <CityNm>WINTERSET</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50273</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF EEMERGENCY AT MADISON COUNTY HEALTH CARE SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>15187</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAINEHEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>22 BRAMHALL STREET</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>ME</StateAbbreviationCd>
            <ZIPCd>04102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMING RURAL DIABETES CARE IN MAINE</GrantOrContributionPurposeTxt>
          <Amt>848894</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAINEHEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>22 BRAMHALL STREET</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>ME</StateAbbreviationCd>
            <ZIPCd>04102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMING RURAL DIABETES CARE IN MAINE</GrantOrContributionPurposeTxt>
          <Amt>596795</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP A DEVICE TO IMPROVE ROUTINE DISEASE MONITORING FOR CD.</GrantOrContributionPurposeTxt>
          <Amt>843986</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHNS DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION</GrantOrContributionPurposeTxt>
          <Amt>350278</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHNS DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION</GrantOrContributionPurposeTxt>
          <Amt>352645</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP A DEVICE TO IMPROVE ROUTINE DISEASE MONITORING FOR CD.</GrantOrContributionPurposeTxt>
          <Amt>752326</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHNS DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION</GrantOrContributionPurposeTxt>
          <Amt>353249</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 FIRST STREET SW</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55905</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>OFF-SITE REMOTE CONTROL ROBOTIC PERCUTANEOUS CORONARY INTERVENTIONS</GrantOrContributionPurposeTxt>
          <Amt>385906</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 FIRST STREET SW</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55905</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>103827</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 FIRST STREET SW</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55905</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD</GrantOrContributionPurposeTxt>
          <Amt>334407</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 FIRST STREET SW</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55905</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD</GrantOrContributionPurposeTxt>
          <Amt>151705</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MCGILL UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>JAMES ADMINISTRATION BUILDING</AddressLine1Txt>
            <CityNm>MONTREAL</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HUMAN CELL ATLAS: ETHICS AND DATA GOVERNANCE</GrantOrContributionPurposeTxt>
          <Amt>189596</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEDSTAR HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3007 TILDEN STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20008</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2022 SUPPORT FOR THE 'MASTERING CLINICAL CHALLENGES IN IBD' SYMPOSIUM</GrantOrContributionPurposeTxt>
          <Amt>35000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEEKER MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>612 S SIBLEY AVE</AddressLine1Txt>
            <CityNm>LITCHFIELD</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55355</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPHARMACY AT MEEKER MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>12269</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MI STATE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>HANNAH ADMINISTRATION BUILDING</AddressLine1Txt>
            <CityNm>EAST LANSING</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>488242601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A C-PEPTIDE COMPLEX FOR IMPROVED GLUCOSE METABOLISM IN PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>382594</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MONROE COUNTY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>6580 165TH STREET</AddressLine1Txt>
            <CityNm>ALBIA</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52531</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPHARMACY AT MONROE COUNTY HOSPITAL &amp; CLINICS</GrantOrContributionPurposeTxt>
          <Amt>17577</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MONROE COUNTY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>6580 165TH STREET</AddressLine1Txt>
            <CityNm>ALBIA</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52531</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPHARMACY AT MONROE COUNTY HOSPITAL CLINICS</GrantOrContributionPurposeTxt>
          <Amt>7031</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MONUMENT HEALTH NETWORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2140 JUNCTION AVE</AddressLine1Txt>
            <CityNm>STURGIS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57785</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT MONUMENT HEALTH STURGIS HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>41418</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MONUMENT HEALTH NETWORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2140 JUNCTION AVE</AddressLine1Txt>
            <CityNm>STURGIS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57785</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT MONUMENT HEALTH STURGIS HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>16568</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL ACADEMY OF SCIENCES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>500 5TH STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING MINORITY SERVING INSTITUTIONS</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL COMMITTEE FOR QUALITY ASSURANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 13TH ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORM HEALTHCARE THROUGH MEASUREMENT, TRANSPARENCY, &amp; ACCOUNTABILITY</GrantOrContributionPurposeTxt>
          <Amt>836732</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL COMMITTEE FOR QUALITY ASSURANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 13TH ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORM HEALTHCARE THROUGH MEASUREMENT, TRANSPARENCY, ACCOUNTABILITY</GrantOrContributionPurposeTxt>
          <Amt>621487</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL COMMITTEE FOR QUALITY ASSURANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 13TH ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORM HEALTHCARE THROUGH MEASUREMENT, TRANSPARENCY, &amp; ACCOUNTABILITY</GrantOrContributionPurposeTxt>
          <Amt>753478</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL PARK FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 K ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BADLANDS NATIONAL PARK CEDAR PASS VISITOR CENTER</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL PARK FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 K ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LITTLE BIGHORN BATTLEFIELD NATIONAL MONUMENT VISITOR CENTER</GrantOrContributionPurposeTxt>
          <Amt>1400000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL PARK FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 K ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BERING LAND BRIDGE VISITOR CENTER</GrantOrContributionPurposeTxt>
          <Amt>2449328</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL PARK FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 K ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LITTLE BIGHORN BATTLEFIELD NATIONAL MONUMENT VISITOR CENTER</GrantOrContributionPurposeTxt>
          <Amt>1750000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL PARK FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 K ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BADLANDS NATIONAL PARK CEDAR PASS VISITOR CENTER</GrantOrContributionPurposeTxt>
          <Amt>750000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL PARK FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 K ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BERING LAND BRIDGE VISITOR CENTER</GrantOrContributionPurposeTxt>
          <Amt>1163270</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEBRASKA DEPARTMENT OF HEALTH &amp; HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>301 CENTENNIAL MALL SOUTH</AddressLine1Txt>
            <CityNm>LINCOLN</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68508</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEBRASKA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>545083</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEBRASKA DEPARTMENT OF HEALTH &amp; HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>301 CENTENNIAL MALL SOUTH</AddressLine1Txt>
            <CityNm>LINCOLN</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68508</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEBRASKA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>309887</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA COMMUNITY FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1980 FESTIVAL PLAZA DRIVE</AddressLine1Txt>
            <CityNm>LAS VEGAS</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89135</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RURAL NEVADA ULTRASOUND CARE INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>1035951</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4150 TECHNOLOGY WAY</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89706</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEVADA VIRTUAL CRISIS CARE</GrantOrContributionPurposeTxt>
          <Amt>1333324</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4150 TECHNOLOGY WAY</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89706</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEVADA VIRTUAL CRISIS CARE</GrantOrContributionPurposeTxt>
          <Amt>1230038</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4150 TECHNOLOGY WAY</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89706</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEVADA VIRTUAL CRISIS CARE</GrantOrContributionPurposeTxt>
          <Amt>1239092</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW DESTINY HOUSING CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>12 W 37TH STREET 7TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AFTERCARE INTERVENTION TO IMPROVE HOUSING &amp; HEALTH STABILITY</GrantOrContributionPurposeTxt>
          <Amt>215030</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW VENTURE FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 CT AVE NW SUITE 300</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024)</GrantOrContributionPurposeTxt>
          <Amt>1435500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW VENTURE FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 CT AVE NW SUITE 300</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024)</GrantOrContributionPurposeTxt>
          <Amt>1468813</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK CITY HEALTH AND HOSPITALS CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 WORTH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10013</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPRESSCARE TELE-BEHAVIORAL SERV. &amp; STRATEGIES (NYC HIGH NEEDS PATIENTS)</GrantOrContributionPurposeTxt>
          <Amt>1457500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK CITY HEALTH AND HOSPITALS CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 WORTH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10013</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPRESSCARE TELE-BEHAVIORAL SERV. &amp; STRATEGIES (NYC HIGH NEEDS PATIENTS)</GrantOrContributionPurposeTxt>
          <Amt>825000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>665 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFYING ENVIRONMENTAL CONTRIBUTORS TO CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1046686</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>665 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF INTERVENTIONS FOR COLLABORATIVE FOR HOMELESS HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>205596</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>665 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANALYSIS OF MEDICAID DATA TO IMPROVE CARE FOR HOMELESS PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>101043</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>665 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANALYSIS OF MEDICAID DATA TO IMPROVE CARE FOR HOMELESS PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>100123</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NORTH DAKOTA DEPARTMENT OF HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>600 E BOULEVARD AVENUE</AddressLine1Txt>
            <CityNm>BISMARCK</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>585050200</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORTH DAKOTA LAW ENFORCEMENT AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>173689</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NORTHERN WESTCHESTER HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>400 EAST MAIN STREET</AddressLine1Txt>
            <CityNm>MOUNT KISCO</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10549</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL CHILD HEALTH UNIT FACILITIES RENOVATION</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OREGON HEALTH &amp; SCIENCE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3181 SW SAM JACKSON PARK RD</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>972393098</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TO EXPAND THE NICH PROGRAM IN THE CALIFORNIA BAY AREA</GrantOrContributionPurposeTxt>
          <Amt>654234</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PALO ALTO VETERANS INSTITUTE FOR RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3801 MIRANDA AVENUE</AddressLine1Txt>
            <CityNm>PALO ALTO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>943040038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CELL ATLAS OF INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>500825</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PALO ALTO VETERANS INSTITUTE FOR RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3801 MIRANDA AVENUE</AddressLine1Txt>
            <CityNm>PALO ALTO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>943040038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CELL ATLAS OF INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>499175</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PANORAMA GLOBAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2101 FOURTH AVENUE SUITE 2100</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND</GrantOrContributionPurposeTxt>
          <Amt>999473</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PANORAMA GLOBAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2101 FOURTH AVENUE SUITE 2100</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND</GrantOrContributionPurposeTxt>
          <Amt>1167087</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 LETTERMAN DRIVE</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94129</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDYING AUTOIMMUNE DIABETES FOLLOWING CERTAIN CANCER IMMUNOTHERAPIES.</GrantOrContributionPurposeTxt>
          <Amt>358140</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PATH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2201 WESTLAKE AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE</GrantOrContributionPurposeTxt>
          <Amt>2004478</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PATH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2201 WESTLAKE AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE</GrantOrContributionPurposeTxt>
          <Amt>1838580</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PAWNEE COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>600 I STREET</AddressLine1Txt>
            <CityNm>PAWNEE CITY</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68420</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE PHARMACY AT PAWNEE COUNTY MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>17845</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PAWNEE COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>600 I STREET</AddressLine1Txt>
            <CityNm>PAWNEE CITY</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68420</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE PHARMACY AT PAWNEE COUNTY MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>7139</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PHILIP HEALTH SERVICES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>503 W PINE STREET</AddressLine1Txt>
            <CityNm>PHILIP</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57567</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF AVERA EEMERGENCY AT PHILIP HEALTH SERVICES</GrantOrContributionPurposeTxt>
          <Amt>12317</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PROJECT NYAME NSA LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>33 WILLETS LANE</AddressLine1Txt>
            <CityNm>MANHASSET</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROJECT NYAME NSA ZAMBIA EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>241600</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PROVIDENCE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1200 PROVIDENCE ROAD</AddressLine1Txt>
            <CityNm>WAYNE</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68787</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPHARMACY AT PROVIDENCE MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>8457</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PUBLIC HEALTH SOLUTIONS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>40 WORTH STREET 5TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10013</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW YORK CITY FUND FOR YOUTH AND FAMILY HOMELESSNESS</GrantOrContributionPurposeTxt>
          <Amt>262335</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PULITZER CENTER ON CRISIS REPORTING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1779 MASSACHUSETTS AVE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING RESILIENCE THROUGH JOURNALISM AND EDUCATION</GrantOrContributionPurposeTxt>
          <Amt>302170</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PULITZER CENTER ON CRISIS REPORTING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1779 MASSACHUSETTS AVE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING RESILIENCE THROUGH JOURNALISM AND EDUCATION</GrantOrContributionPurposeTxt>
          <Amt>310123</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USE NLP FOR EXTRACTION OF CD RELEVANT DATA FROM CLINICAL RECORDS.</GrantOrContributionPurposeTxt>
          <Amt>385780</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS</GrantOrContributionPurposeTxt>
          <Amt>454441</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USE NLP FOR EXTRACTION OF CD RELEVANT DATA FROM CLINICAL RECORDS.</GrantOrContributionPurposeTxt>
          <Amt>369880</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS</GrantOrContributionPurposeTxt>
          <Amt>408267</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55455</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REDEFINING THE FUTURE OF EMERGENCY MEDICINE</GrantOrContributionPurposeTxt>
          <Amt>5026234</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55455</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PHASE 2: ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR T1D</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55455</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECLINICAL DEVELOPMENT OF A MONOCLONAL ANTIBODY TO SERPINB13</GrantOrContributionPurposeTxt>
          <Amt>308267</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55455</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MINNESOTA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>4885390</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55455</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MINNESOTA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1296918</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RENOWN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>245 E LIBERTY ST</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89501</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION LAB AND INNOVATION CENTER</GrantOrContributionPurposeTxt>
          <Amt>3099867</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAFE WATER NETWORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>122 EAST 42ND STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10168</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING AFFORDABLE SAFELY MANAGED WATER SUPPLY</GrantOrContributionPurposeTxt>
          <Amt>1595750</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAFE WATER NETWORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>122 EAST 42ND STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10168</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING AFFORDABLE SAFELY MANAGED WATER SUPPLY</GrantOrContributionPurposeTxt>
          <Amt>1552050</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAGE BIONETWORKS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2901 THIRD AVE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981213014</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXTENSION OF VEOIBD DATA COORDINATION</GrantOrContributionPurposeTxt>
          <Amt>73424</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAGE BIONETWORKS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2901 THIRD AVE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981213014</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXTENSION OF VEOIBD DATA COORDINATION</GrantOrContributionPurposeTxt>
          <Amt>75165</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SANFORD RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2301 E 60TH STREET N</AddressLine1Txt>
            <CityNm>SIOUX FALL</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>571040569</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SANFORD PLEDGE: PHASES 1 AND 2</GrantOrContributionPurposeTxt>
          <Amt>212565</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SCHWARTZREISMAN SCIENCE EDUCATION CENTER REHOVOT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERZL ST 234</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY CAMPUS FOR SCIENCE EDUCATION IN NETIVOT</GrantOrContributionPurposeTxt>
          <Amt>1982305</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SEATTLE CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 5731 M/S S-200</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981455005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF ANTIGEN-SPECIFIC ETREG THERAPY IN T1D - STAGE 3 STUDIES</GrantOrContributionPurposeTxt>
          <Amt>1224949</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREVENTION OF INFLAMMATORY BOWEL DISEASES IN PERSONS AT RISK</GrantOrContributionPurposeTxt>
          <Amt>355916</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>"TASTY &amp; HEALTHY" DIET: A RANDOMIZED CONTROLLED TRIAL FOR INDUCING AND MAINTAINING REMISSION IN CROHN'S DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>527468</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY CANCER CENTER AT SHAARE ZEDEK MEDICAL CENTER JERUSALEM</GrantOrContributionPurposeTxt>
          <Amt>5226272</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHENANDOAH MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 PERSHING AVE</AddressLine1Txt>
            <CityNm>SHENANDOAH</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SHENANDOAH MEDICAL CENTER / AVERA EEMERGENCY IMPLEMENTATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>15320</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIMULATION IN MOTION MONTANA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O MONTANA MEDICAL ASSOCIATION</AddressLine1Txt>
            <CityNm>HELENA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING TOWARD A SUSTAINABLE SIMULATION IN MOTION MONTANA</GrantOrContributionPurposeTxt>
          <Amt>108298</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIOUX VALLEY MEMORIAL HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 SIOUX VALLEY DRIVE</AddressLine1Txt>
            <CityNm>CHEROKEE</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE EMERGENCY AT CHEROKEE REGIONAL MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>13877</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SNV NETHERLANDS DEVELOPMENT ORGANISATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PARKSTRAAT 83</AddressLine1Txt>
            <CityNm>DEN HAAG</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTHY FUTURE FOR ALL IMPROVING WATER, SANITATION, HYGIENE &amp; NUTRITION</GrantOrContributionPurposeTxt>
          <Amt>1207754</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SNV NETHERLANDS DEVELOPMENT ORGANISATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PARKSTRAAT 83</AddressLine1Txt>
            <CityNm>DEN HAAG</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTHY FUTURE FOR ALL IMPROVING WATER, SANITATION, HYGIENE &amp; NUTRITION</GrantOrContributionPurposeTxt>
          <Amt>962857</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOS CHILDREN'S VILLAGES-USA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1620 I STREET NW SUITE 220</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDUCARE 4.0: DEBRE TABOR AND GONDAR CITY, ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>1386577</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTH LINCOLN HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>711 ONYX ST</AddressLine1Txt>
            <CityNm>KEMMERER</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>83101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICE AT SOUTH LINCOLN MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>26976</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTH LINCOLN HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>711 ONYX ST</AddressLine1Txt>
            <CityNm>KEMMERER</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>83101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICE AT SOUTH LINCOLN MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>10791</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTH LINCOLN HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>711 ONYX ST</AddressLine1Txt>
            <CityNm>KEMMERER</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>83101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICE AT SOUTH LINCOLN MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>151487</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTHCENTRAL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4501 DIPLOMACY DR</AddressLine1Txt>
            <CityNm>ANCHORAGE</CityNm>
            <StateAbbreviationCd>AK</StateAbbreviationCd>
            <ZIPCd>99508</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>903283</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTHCENTRAL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4501 DIPLOMACY DR</AddressLine1Txt>
            <CityNm>ANCHORAGE</CityNm>
            <StateAbbreviationCd>AK</StateAbbreviationCd>
            <ZIPCd>99508</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>818171</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABETESWISE-PRO: INCREASING DIABETES DEVICE UPTAKE IN PEOPLE DIABETES</GrantOrContributionPurposeTxt>
          <Amt>817475</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INVESTIGATING THE ROLE OF THE HUMAN EXPOSOME IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>690953</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE EDUCATION AT NEW ONSET OF T1D</GrantOrContributionPurposeTxt>
          <Amt>339811</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION &amp; EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON IIT</GrantOrContributionPurposeTxt>
          <Amt>330000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1009155</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INVESTIGATING THE ROLE OF THE HUMAN EXPOSOME IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>836979</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A CONTINUOUS MULTIANALYTE SENSOR FOR T1D</GrantOrContributionPurposeTxt>
          <Amt>1374460</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A CONTINUOUS MULTIANALYTE SENSOR FOR T1D</GrantOrContributionPurposeTxt>
          <Amt>1374444</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STANFORD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION &amp; EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON IIT</GrantOrContributionPurposeTxt>
          <Amt>1296812</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING ACCESS TO MEDICINE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NARITAWEG 227</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ACCESS TO T1D CARE</GrantOrContributionPurposeTxt>
          <Amt>750000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING ACCESS TO MEDICINE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NARITAWEG 227</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ACCESS TO T1D CARE</GrantOrContributionPurposeTxt>
          <Amt>875000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING HEALTH ACTION INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OVERTOOM 60/II</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLLY</GrantOrContributionPurposeTxt>
          <Amt>1287681</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING HEALTH ACTION INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OVERTOOM 60/II</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLLY</GrantOrContributionPurposeTxt>
          <Amt>1245075</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STIFTELSEN FORSKNING AVSEENDE INFLAMMATORISKA TARMSJUKDOM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEPT OF GASTROENTEROLOGY</AddressLine1Txt>
            <CityNm>OREBRO</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INV CAREERS IN IBD</GrantOrContributionPurposeTxt>
          <Amt>132000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STIFTELSEN UTBILDNING AVSEENDE INFLAMMATORISKA TARMSJUKDOM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEPT OF GASTROENTEROLOGY</AddressLine1Txt>
            <CityNm>OREBRO</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INV CAREERS IN IBD</GrantOrContributionPurposeTxt>
          <Amt>132000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STIFTELSENFORSKNING AVSEENDE INFLAMMATORISKA TARMSJUKDOM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEPT OF GASTROENTEROLOGY</AddressLine1Txt>
            <CityNm>OREBRO</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INV CAREERS IN IBD</GrantOrContributionPurposeTxt>
          <Amt>132000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SYNERGOS INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3 EAST 54TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10022</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING LIVES AND LIVELIHOODS OF SMALLHOLDER FARMERS</GrantOrContributionPurposeTxt>
          <Amt>1063518</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>11 AVENUE DE LAFAYETTE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02111</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>261908</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TECHNISCHE UNIVERSITT DRESDEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZSTR 10</AddressLine1Txt>
            <CityNm>DRESDEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT SCREENING FOR ISLET AUTOANTIBODIES IN CHILDREN.</GrantOrContributionPurposeTxt>
          <Amt>52102</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TECHNISCHE UNIVERSITT DRESDEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZSTR 10</AddressLine1Txt>
            <CityNm>DRESDEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENOMIC INFLUENCE OF MATERNAL T1D - UNDERSTANDING PROTECTION AGAINST T1D</GrantOrContributionPurposeTxt>
          <Amt>210829</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TECHNISCHE UNIVERSITT DRESDEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZSTR 10</AddressLine1Txt>
            <CityNm>DRESDEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT SCREENING FOR ISLET AUTOANTIBODIES IN CHILDREN.</GrantOrContributionPurposeTxt>
          <Amt>60079</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ASPEN INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2300 N STREET</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE ASPEN INSTITUTE IS AN EDUCATIONAL AND POLICY STUDIES ORGANIZATION</GrantOrContributionPurposeTxt>
          <Amt>996251</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ASPEN INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2300 N STREET</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE ASPEN INSTITUTE IS AN EDUCATIONAL AND POLICY STUDIES ORGANIZATION</GrantOrContributionPurposeTxt>
          <Amt>998081</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BARUCH PADEH MEDICAL CENTER PORIYA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE BARUCH PADEH MEDICAL CENTERPORI</AddressLine1Txt>
            <AddressLine2Txt>A</AddressLine2Txt>
            <CityNm>TIBERIAS</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY REHABILITATION CENTER OF THE NORTH</GrantOrContributionPurposeTxt>
          <Amt>4453113</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BARUCH PADEH MEDICAL CENTER PORIYA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE BARUCH PADEH MEDICAL CENTERPORI</AddressLine1Txt>
            <AddressLine2Txt>A</AddressLine2Txt>
            <CityNm>TIBERIAS</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY REHABILITATION CENTER OF THE NORTH</GrantOrContributionPurposeTxt>
          <Amt>5431730</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN COLON AND SMALL INTESTINE CELL ATLAS IN HEALTH AND CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>463751</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN COLON AND SMALL INTESTINE CELL ATLAS IN HEALTH AND CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>463755</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHINESE UNIVERSITY OF HONG KONG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PI CHIU BUILDING</AddressLine1Txt>
            <CityNm>SHATIN</CityNm>
            <CountryCd>HK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL TRANSFER OF SPECIALIZED CELLS FOR TREATMENT OF BOWEL DISEASE</GrantOrContributionPurposeTxt>
          <Amt>492017</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHINESE UNIVERSITY OF HONG KONG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PI CHIU BUILDING</AddressLine1Txt>
            <CityNm>SHATIN</CityNm>
            <CountryCd>HK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN</GrantOrContributionPurposeTxt>
          <Amt>430508</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHINESE UNIVERSITY OF HONG KONG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PI CHIU BUILDING</AddressLine1Txt>
            <CityNm>SHATIN</CityNm>
            <CountryCd>HK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN</GrantOrContributionPurposeTxt>
          <Amt>249337</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHINESE UNIVERSITY OF HONG KONG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PI CHIU BUILDING</AddressLine1Txt>
            <CityNm>SHATIN</CityNm>
            <CountryCd>HK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN</GrantOrContributionPurposeTxt>
          <Amt>251789</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 E DUARTE RD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING GENETIC PROTECTION FROM T1D.</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 E DUARTE RD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING GENETIC PROTECTION FROM T1D.</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS</GrantOrContributionPurposeTxt>
          <Amt>954604</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS</GrantOrContributionPurposeTxt>
          <Amt>1335936</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>155544</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP IUS AND HISTOPATHOLOGY INDICES FOR MONITORING STRICTURING CD</GrantOrContributionPurposeTxt>
          <Amt>348000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD</GrantOrContributionPurposeTxt>
          <Amt>1355310</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP IUS AND HISTOPATHOLOGY INDICES FOR MONITORING STRICTURING CD</GrantOrContributionPurposeTxt>
          <Amt>111750</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD</GrantOrContributionPurposeTxt>
          <Amt>1321210</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE CHANGING EPIDEMIOLOGY OF CROHNS IN THE WESTERN WORLD</GrantOrContributionPurposeTxt>
          <Amt>186777</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VISUALIZATION OF COVID-19 VACCINE SEROLOGY IN CD</GrantOrContributionPurposeTxt>
          <Amt>89047</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY</GrantOrContributionPurposeTxt>
          <Amt>122854</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP PROTEIN PANEL TO IDENTIFY FIBROSTENOTIC CD PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>419010</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE CHANGING EPIDEMIOLOGY OF CROHNS IN THE WESTERN WORLD</GrantOrContributionPurposeTxt>
          <Amt>191883</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VISUALIZATION OF COVID-19 VACCINE SEROLOGY IN CD</GrantOrContributionPurposeTxt>
          <Amt>89047</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY</GrantOrContributionPurposeTxt>
          <Amt>126154</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE CHANGING EPIDEMIOLOGY OF CROHNS IN THE WESTERN WORLD</GrantOrContributionPurposeTxt>
          <Amt>121036</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VISUALIZATION OF COVID-19 VACCINE SEROLOGY IN CD</GrantOrContributionPurposeTxt>
          <Amt>89047</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY</GrantOrContributionPurposeTxt>
          <Amt>137153</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP PROTEIN PANEL TO IDENTIFY FIBROSTENOTIC CD PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>247654</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY</GrantOrContributionPurposeTxt>
          <Amt>127077</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY</GrantOrContributionPurposeTxt>
          <Amt>137417</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY</GrantOrContributionPurposeTxt>
          <Amt>119554</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HOSPITAL FOR SICK CHILDREN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>555 UNIVERSITY AVE</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VEOIBD: PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO</GrantOrContributionPurposeTxt>
          <Amt>548276</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HOSPITAL FOR SICK CHILDREN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>555 UNIVERSITY AVE</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VEOIBD: PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO</GrantOrContributionPurposeTxt>
          <Amt>555480</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE LEGATUM INSTITUTE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>11 CHARLES STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PHASE TWO OF THE UNITED STATES PROSPERITY INDEX</GrantOrContributionPurposeTxt>
          <Amt>50000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE LEGATUM INSTITUTE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>11 CHARLES STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PHASE TWO OF THE UNITED STATES PROSPERITY INDEX</GrantOrContributionPurposeTxt>
          <Amt>50000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>YEZREEL VALLEY</AddressLine1Txt>
            <CityNm>YEZREEL VALLEY</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>OPP. FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS SEEKING NURSING DEG</GrantOrContributionPurposeTxt>
          <Amt>220000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>YEZREEL VALLEY</AddressLine1Txt>
            <CityNm>YEZREEL VALLEY</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>OPP. FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS SEEKING NURSING DEG</GrantOrContributionPurposeTxt>
          <Amt>220000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ONE LOVE FOUNDATION IN HONOR OF YEARDLEY LOVE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>44 PONDFIELD ROAD SUITE 12</AddressLine1Txt>
            <CityNm>BRONXVILLE</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING FOR THE FUTURE: SUPPORT FOR DIGITAL PROGRAMS AND OPERATIONS</GrantOrContributionPurposeTxt>
          <Amt>1023100</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>CHARLOTTESVILLE</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>229044195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS</GrantOrContributionPurposeTxt>
          <Amt>331333</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>CHARLOTTESVILLE</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>229044195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS</GrantOrContributionPurposeTxt>
          <Amt>202177</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>120 THEORY SUITE 200</AddressLine1Txt>
            <CityNm>IRVINE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>926971050</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A MULTI-ANALYTE SENSOR FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>851633</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>120 THEORY SUITE 200</AddressLine1Txt>
            <CityNm>IRVINE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>926971050</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A MULTI-ANALYTE SENSOR FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>837543</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>120 THEORY SUITE 200</AddressLine1Txt>
            <CityNm>IRVINE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>926971050</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A MULTI-ANALYTE SENSOR FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>837542</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FEASIBILITY EVAL OF AID IN PRIMARY CARE AND THROUGH TELEHEALTH</GrantOrContributionPurposeTxt>
          <Amt>705874</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION</GrantOrContributionPurposeTxt>
          <Amt>580677</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR</GrantOrContributionPurposeTxt>
          <Amt>155376</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ASK THE EXPERTS</GrantOrContributionPurposeTxt>
          <Amt>543207</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SINGLE PERSISTENT ISLET AUTOANTIBODY PHENOTYPE: CUSTOMIZED RISK ANALYSIS</GrantOrContributionPurposeTxt>
          <Amt>264341</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FAILED GENETIC PROTECTION: T1D IN THE PRESENCE OF DQB1*06:02</GrantOrContributionPurposeTxt>
          <Amt>266200</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION</GrantOrContributionPurposeTxt>
          <Amt>1111050</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPLEMENT SYSTEM IN INITIATION AND PROGRESSION OF ISLET AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>223818</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D</GrantOrContributionPurposeTxt>
          <Amt>202073</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEEDS PATHWAY: EMPOWERMENT FOR DIABETES TECHNOLOGY EARLY DEVICE SUCCESS</GrantOrContributionPurposeTxt>
          <Amt>905046</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ASK THE EXPERTS</GrantOrContributionPurposeTxt>
          <Amt>575810</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FAILED GENETIC PROTECTION: T1D IN THE PRESENCE OF DQB1*06:02</GrantOrContributionPurposeTxt>
          <Amt>266200</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION</GrantOrContributionPurposeTxt>
          <Amt>1008526</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D</GrantOrContributionPurposeTxt>
          <Amt>178454</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BUILDING 500</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEEDS PATHWAY: EMPOWERMENT FOR DIABETES TECHNOLOGY EARLY DEVICE SUCCESS</GrantOrContributionPurposeTxt>
          <Amt>694245</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF NEW MEXICO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>SPONSORED PROJECTS - PREAWARD</AddressLine1Txt>
            <CityNm>ALBUQUERQUE</CityNm>
            <StateAbbreviationCd>NM</StateAbbreviationCd>
            <ZIPCd>871310001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE ECHO INSTITUTE: REPLICATION OF THE ECHO MODEL</GrantOrContributionPurposeTxt>
          <Amt>1188238</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SDEROT DEVELOPMENT FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>6 BAR LEV STREET</AddressLine1Txt>
            <CityNm>SDEROT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SDEROT MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>1558573</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SDEROT DEVELOPMENT FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>6 BAR LEV STREET</AddressLine1Txt>
            <CityNm>SDEROT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SDEROT RESILIENCE COMPLEX, RESILIENCE CENTER AND PARENTHOOD HOUSE</GrantOrContributionPurposeTxt>
          <Amt>184286</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SDEROT DEVELOPMENT FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>6 BAR LEV STREET</AddressLine1Txt>
            <CityNm>SDEROT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ESTABLISHING A WARM HOME COMPLEX FOR CHILDREN AT RISK IN SDEROT</GrantOrContributionPurposeTxt>
          <Amt>2421222</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SDEROT DEVELOPMENT FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>6 BAR LEV STREET</AddressLine1Txt>
            <CityNm>SDEROT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SDEROT MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>614379</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SONIA NABETA FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 2222</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100082222</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROJECT BODA</GrantOrContributionPurposeTxt>
          <Amt>412944</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TEL AVIV JAFFA ACADEMIC COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RABENU YERUHAM ST 2 POB 8401</AddressLine1Txt>
            <CityNm>TEL AVIV YAFFO</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCHOLARSHIP SUPPORT FOR ULTRA-ORTHODOX MEN PURSUING NURSING DEGREES</GrantOrContributionPurposeTxt>
          <Amt>306724</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TEL AVIV JAFFA ACADEMIC COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RABENU YERUHAM ST 2 POB 8401</AddressLine1Txt>
            <CityNm>TEL AVIV YAFFO</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCHOLARSHIP SUPPORT FOR ULTRA-ORTHODOX MEN PURSUING NURSING DEGREES</GrantOrContributionPurposeTxt>
          <Amt>253818</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNITED NATIONS INSTITUTE FOR TRAINING AND RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNITAR</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING ACCESS: TREATMENT FOR NCDS IN LOW /MIDDLE-INCOME COUNTRIES.</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF ADELAIDE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE UNIVERSITY OF ADELAIDE</AddressLine1Txt>
            <CityNm>ADELAIDE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENVIRONMENTAL DETERMINANTS OF ISLET AUTOIMMUNITY (ENDIA) STUDY</GrantOrContributionPurposeTxt>
          <Amt>794339</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF ADELAIDE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE UNIVERSITY OF ADELAIDE</AddressLine1Txt>
            <CityNm>ADELAIDE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDIA EXPANDED SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>419418</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5801 SOUTH ELLIS AVENUE</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60637</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A CELL ATLAS OF THE ILEAL COLONIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>487806</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5801 SOUTH ELLIS AVENUE</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60637</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNO PHARMACOGENOMICS TO PREDICT RESPONSE TO BIOLOGICS IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>305353</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION</GrantOrContributionPurposeTxt>
          <Amt>708833</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DISCERN ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN T1D</GrantOrContributionPurposeTxt>
          <Amt>230209</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GCA - HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>444247</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GCA - HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>444246</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DISCERN ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN T1D</GrantOrContributionPurposeTxt>
          <Amt>109128</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GCA - HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>553832</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY OFFICES WELLINGTON</AddressLine1Txt>
            <AddressLine2Txt>SQUARE</AddressLine2Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PHARMACOLOGICAL MODULATION TO ADDRESS GLUCAGON SECRETION IN T1D</GrantOrContributionPurposeTxt>
          <Amt>546306</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY OFFICES WELLINGTON</AddressLine1Txt>
            <AddressLine2Txt>SQUARE</AddressLine2Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE</GrantOrContributionPurposeTxt>
          <Amt>244860</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY OFFICES WELLINGTON</AddressLine1Txt>
            <AddressLine2Txt>SQUARE</AddressLine2Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE</GrantOrContributionPurposeTxt>
          <Amt>244860</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF QUEENSLAND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>CUMBRAE STEWART BUILDING 72</AddressLine1Txt>
            <CityNm>BRISBANE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET T1D</GrantOrContributionPurposeTxt>
          <Amt>435713</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF WESTERN AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>35 STIRLING HIGHWAY</AddressLine1Txt>
            <CityNm>CRAWLEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM ASSESSMENTS OF ENDIA CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>166923</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PERSONALIZED NUTRITIONAL, MICROBIOME AND HOST PATTERNS IN CROHNS</GrantOrContributionPurposeTxt>
          <Amt>1720206</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE QUANTUM MATERIALS DEVICES FABRICATION LAB</GrantOrContributionPurposeTxt>
          <Amt>660000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE QUANTUM MATERIALS DEVICES FABRICATION LAB</GrantOrContributionPurposeTxt>
          <Amt>1750000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TOWNSEND HEALTH SYSTEMS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>110 NORTH OAK</AddressLine1Txt>
            <CityNm>TOWNSEND</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59644</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-PHARMACY AT BILLINGS CLINIC BROADWATER</GrantOrContributionPurposeTxt>
          <Amt>35128</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TOWNSEND HEALTH SYSTEMS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>110 NORTH OAK</AddressLine1Txt>
            <CityNm>TOWNSEND</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59644</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-PHARMACY AT BILLINGS CLINIC BROADWATER</GrantOrContributionPurposeTxt>
          <Amt>15112</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF INDIANA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>509 E 3RD ST</AddressLine1Txt>
            <CityNm>BLOOMINGTON</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>474013654</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOLECULAR DESIGN AND TESTING OF GLUCOSE-RESPONSIVE THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>696962</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF INDIANA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>509 E 3RD ST</AddressLine1Txt>
            <CityNm>BLOOMINGTON</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>474013654</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE EFFORT TO VALIDATE MICRORNAS AS BIOMARKERS OF T1D</GrantOrContributionPurposeTxt>
          <Amt>426380</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH SERVICES</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191046205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD</GrantOrContributionPurposeTxt>
          <Amt>285463</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH SERVICES</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191046205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD</GrantOrContributionPurposeTxt>
          <Amt>285463</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH SERVICES</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191046205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD</GrantOrContributionPurposeTxt>
          <Amt>285079</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH SERVICES</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191046205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD</GrantOrContributionPurposeTxt>
          <Amt>293370</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED NATIONS DEVELOPMENT PROGRAMME</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 UNITED NATIONS PLAZA</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNITED NATIONS MULTILATERAL AGENCY</GrantOrContributionPurposeTxt>
          <Amt>377955</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED NATIONS DEVELOPMENT PROGRAMME</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 UNITED NATIONS PLAZA</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNITED NATIONS MULTILATERAL AGENCY</GrantOrContributionPurposeTxt>
          <Amt>339777</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED STATES AFRICAN DEVELOPMENT FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1400 I STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LIVELIHOOD IMPROVEMENT PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>1779762</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED STATES AFRICAN DEVELOPMENT FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1400 I STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LIVELIHOOD IMPROVEMENT PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>1283255</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED STATES FUND FOR UNICEF</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 MAIDEN LANE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>784421</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED STATES FUND FOR UNICEF</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 MAIDEN LANE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>869232</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITAIR MEDISCH CENTRUM UTRECHT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HEIDELBERGLAAN 100</AddressLine1Txt>
            <CityNm>UTRECHT</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPITHELIAL BASED DIAGNOSTICS FOR TARGETED THERAPIES OF VEOIBD</GrantOrContributionPurposeTxt>
          <Amt>173250</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITAIR MEDISCH CENTRUM UTRECHT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HEIDELBERGLAAN 100</AddressLine1Txt>
            <CityNm>UTRECHT</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPITHELIAL BASED DIAGNOSTICS FOR TARGETED THERAPIES OF VEOIBD</GrantOrContributionPurposeTxt>
          <Amt>173250</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE CATHOLIQUE DE LOUVAIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLACE DE LUNIVERSITE 1</AddressLine1Txt>
            <CityNm>LOUVAINLANEUVE</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDY OF THE GLUCAGON RESPONSE TO HYPOGLYCEMIA IN CHILDREN WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>147087</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE CATHOLIQUE DE LOUVAIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLACE DE LUNIVERSITE 1</AddressLine1Txt>
            <CityNm>LOUVAINLANEUVE</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDY OF THE GLUCAGON RESPONSE TO HYPOGLYCEMIA IN CHILDREN WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>62567</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE LIBRE DE BRUXELLES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE FRANKLIN ROOSEVELT 50</AddressLine1Txt>
            <CityNm>BRUSSELS</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP TOOLS FOR QUANTIFICATION OF HUMAN BETA CELL MASS.</GrantOrContributionPurposeTxt>
          <Amt>213582</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE LIBRE DE BRUXELLES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE FRANKLIN ROOSEVELT 50</AddressLine1Txt>
            <CityNm>BRUSSELS</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP TOOLS FOR QUANTIFICATION OF HUMAN BETA CELL MASS.</GrantOrContributionPurposeTxt>
          <Amt>213602</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE LIBRE DE BRUXELLES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE FRANKLIN ROOSEVELT 50</AddressLine1Txt>
            <CityNm>BRUSSELS</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP TOOLS FOR QUANTIFICATION OF HUMAN BETA CELL MASS.</GrantOrContributionPurposeTxt>
          <Amt>295566</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P C</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1001 MAIN STREET</AddressLine1Txt>
            <CityNm>BUFFALO</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>14203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELEHEALTH REIMBURSEMENT STUDY FOR UNDERSERVED T1D PEDIATRIC POPULATIONS</GrantOrContributionPurposeTxt>
          <Amt>576839</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P C</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1001 MAIN STREET</AddressLine1Txt>
            <CityNm>BUFFALO</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>14203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELEHEALTH REIMBURSEMENT STUDY FOR UNDERSERVED T1D PEDIATRIC POPULATIONS</GrantOrContributionPurposeTxt>
          <Amt>233094</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF BIRMINGHAM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INSTITUTE OF IMMUNOLOGY</AddressLine1Txt>
            <CityNm>BIRMINGHAM</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR T1D.</GrantOrContributionPurposeTxt>
          <Amt>322720</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CALIFORNIA LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCLA OFFICE OF CONTRACTS AND GRANTS</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>900951406</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE RESPONSIVE GLUCAGON TO REDUCE HYPOGLYCEMIA IN PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>568851</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CALIFORNIA LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCLA OFFICE OF CONTRACTS AND GRANTS</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>900951406</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE RESPONSIVE GLUCAGON TO REDUCE HYPOGLYCEMIA IN PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>568027</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERING ISLET ANTIGEN-SPECIFIC TREGS FOR T1D</GrantOrContributionPurposeTxt>
          <Amt>537711</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ID ANALYSIS OF EXTREME FORMS OF T1D, ESTABLISHMENT OF PATIENT REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>433333</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE OLD SCHOOLS</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH T1D PART 2</GrantOrContributionPurposeTxt>
          <Amt>496568</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE OLD SCHOOLS</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH T1D PART 2</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE OLD SCHOOLS</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH T1D PART 2</GrantOrContributionPurposeTxt>
          <Amt>353223</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF DUNDEE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NETHERGATE</AddressLine1Txt>
            <CityNm>DUNDEE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HYPO-RESOLVE - UNDERSTANDING ORGAN SPECIFIC CONSEQUENCES OF HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>133804</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STIMULATED GLUCAGON LEVELS BIOMARKER OF HYPOGLYCEMIA RISK IN T1D</GrantOrContributionPurposeTxt>
          <Amt>323139</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STIMULATED GLUCAGON LEVELS BIOMARKER OF HYPOGLYCEMIA RISK IN T1D</GrantOrContributionPurposeTxt>
          <Amt>268565</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING EXTREMELY EARLY-ONSET TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>566086</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING EXTREMELY EARLY-ONSET TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>451469</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN ATLAS NEONATAL DEVELOPMENTAL EARLY LIFE PANCREAS/IMMUNITY CON'T</GrantOrContributionPurposeTxt>
          <Amt>1043638</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE T1D RESEARCH: NETWORK FOR PANCREATIC ORGAN DONORS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>1199692</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF IOWA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>DIVISION OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52442</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION IOWA (SIM-IA)</GrantOrContributionPurposeTxt>
          <Amt>999877</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF IOWA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>DIVISION OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52442</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION IOWA (SIM-IA)</GrantOrContributionPurposeTxt>
          <Amt>748244</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 LAKE AVENUE NORTH</AddressLine1Txt>
            <CityNm>WORCESTER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01655</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS</GrantOrContributionPurposeTxt>
          <Amt>311133</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 LAKE AVENUE NORTH</AddressLine1Txt>
            <CityNm>WORCESTER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01655</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS</GrantOrContributionPurposeTxt>
          <Amt>311131</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 LAKE AVENUE NORTH</AddressLine1Txt>
            <CityNm>WORCESTER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01655</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS</GrantOrContributionPurposeTxt>
          <Amt>286613</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 LAKE AVENUE NORTH</AddressLine1Txt>
            <CityNm>WORCESTER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01655</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS</GrantOrContributionPurposeTxt>
          <Amt>286614</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MELBOURNE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LEVEL 4 ALAN GILBERT BUILDING</AddressLine1Txt>
            <CityNm>VICTORIA</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANIMAL AND CLINICAL EVALUATION OF A NOVEL CONTINUOUS KETONE SENSOR</GrantOrContributionPurposeTxt>
          <Amt>703827</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MIAMI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1320 SOUTH DIXIE HIGHWAY SUITE 650</AddressLine1Txt>
            <CityNm>CORAL GABLES</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33146</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE</GrantOrContributionPurposeTxt>
          <Amt>326055</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MIAMI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1320 SOUTH DIXIE HIGHWAY SUITE 650</AddressLine1Txt>
            <CityNm>CORAL GABLES</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33146</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE</GrantOrContributionPurposeTxt>
          <Amt>328238</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NEBRASKA FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1010 LINCOLN MALL</AddressLine1Txt>
            <CityNm>LINCOLN</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68501</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOBILE RURAL HEALTHCARE PROVIDER TRAINING</GrantOrContributionPurposeTxt>
          <Amt>582072</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MONITORING COVID-19 VACCINE EFFECTIVENESS IN IBD PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>966865</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFYING MOLECULAR PROFILES PREDICTIVE OF POST-OPERATIVE CD OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>585750</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFYING MOLECULAR PROFILES PREDICTIVE OF POST-OPERATIVE CD OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>581625</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NOTRE DAME DU LAC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>940 GRACE HALL</AddressLine1Txt>
            <CityNm>NOTRE DAME</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>465565708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>593043</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NOTRE DAME DU LAC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>940 GRACE HALL</AddressLine1Txt>
            <CityNm>NOTRE DAME</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>465565708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES</GrantOrContributionPurposeTxt>
          <Amt>503082</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NOTRE DAME DU LAC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>940 GRACE HALL</AddressLine1Txt>
            <CityNm>NOTRE DAME</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>465565708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>652642</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NOTRE DAME DU LAC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>940 GRACE HALL</AddressLine1Txt>
            <CityNm>NOTRE DAME</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>465565708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES</GrantOrContributionPurposeTxt>
          <Amt>542672</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF OULU</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PO BOX 8000</AddressLine1Txt>
            <CityNm>OULU</CityNm>
            <CountryCd>FI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL AND PATERNAL T1D - MECHANISMS FOR RECURRENCE RISK IN OFFSPRING</GrantOrContributionPurposeTxt>
          <Amt>284289</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF OULU</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PO BOX 8000</AddressLine1Txt>
            <CityNm>OULU</CityNm>
            <CountryCd>FI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL AND PATERNAL T1D - MECHANISMS FOR RECURRENCE RISK IN OFFSPRING</GrantOrContributionPurposeTxt>
          <Amt>263104</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF PITTSBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3420 FORBES AVENUE</AddressLine1Txt>
            <CityNm>PITTSBURGH</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>15260</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RANDOMIZED CONTROLLED TRIAL: ANALOGUE VS HUMAN INSULIN</GrantOrContributionPurposeTxt>
          <Amt>1338570</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF PITTSBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3420 FORBES AVENUE</AddressLine1Txt>
            <CityNm>PITTSBURGH</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>15260</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RANDOMIZED CONTROLLED TRIAL: ANALOGUE VS HUMAN INSULIN</GrantOrContributionPurposeTxt>
          <Amt>998931</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF TOLEDO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3000 ARLINGTON AVENUE</AddressLine1Txt>
            <CityNm>TOLEDO</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>436142595</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES CAR TREG THERAPEUTIC APPROACH</GrantOrContributionPurposeTxt>
          <Amt>110480</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF UTAH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>201 S PRESIDENTS CIRCLE</AddressLine1Txt>
            <CityNm>SALT LAKE CITY</CityNm>
            <StateAbbreviationCd>UT</StateAbbreviationCd>
            <ZIPCd>84112</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANTI-PHAGE ANTIBODIES: CROHNS DISEASE DIAGNOSIS AND TREATMENT RESPONSE</GrantOrContributionPurposeTxt>
          <Amt>203988</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF ZURICH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEPARTMENT OF IMMUNOLOGY UNIVERSITY</AddressLine1Txt>
            <AddressLine2Txt>OF ZURICH AND UNIVERSITY HOSPITAL Z</AddressLine2Txt>
            <CityNm>ZURICH</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERATE BISPECIFIC INTERLEUKIN-2 IMMUNOTHERAPY TO TREAT T1D MELLITUS</GrantOrContributionPurposeTxt>
          <Amt>126830</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UPPSALA UNIVERSITET</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BOX 256</AddressLine1Txt>
            <CityNm>UPPSALA</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ALPHA-CELL SIGNALING FOR GLUCAGON SECRETION</GrantOrContributionPurposeTxt>
          <Amt>305920</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS</GrantOrContributionPurposeTxt>
          <Amt>656092</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA</GrantOrContributionPurposeTxt>
          <Amt>244200</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS</GrantOrContributionPurposeTxt>
          <Amt>146933</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFY SMALL MOLECULES ENHANCING GLUCAGON SECRETION UNDER HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>330000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA</GrantOrContributionPurposeTxt>
          <Amt>244200</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USE OF MRI OF THE PANCREAS IN T1D</GrantOrContributionPurposeTxt>
          <Amt>373041</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PANCREATLAS DATABASE EXPANSION.</GrantOrContributionPurposeTxt>
          <Amt>659685</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA</GrantOrContributionPurposeTxt>
          <Amt>248256</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA</GrantOrContributionPurposeTxt>
          <Amt>248256</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU FEASIBILITY PILOT</GrantOrContributionPurposeTxt>
          <Amt>146667</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU FEASIBILITY PILOT</GrantOrContributionPurposeTxt>
          <Amt>591068</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU FEASIBILITY PILOT</GrantOrContributionPurposeTxt>
          <Amt>146667</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU FEASIBILITY PILOT</GrantOrContributionPurposeTxt>
          <Amt>700486</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU FEASIBILITY PILOT</GrantOrContributionPurposeTxt>
          <Amt>146666</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU FEASIBILITY PILOT</GrantOrContributionPurposeTxt>
          <Amt>233495</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VETERANS MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>40 1ST STREET SE</AddressLine1Txt>
            <CityNm>WAUKON</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52172</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE PHARMACY AND EMERGENCY SERVICES AT VETERANS MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>74191</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VETERANS MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>40 1ST STREET SE</AddressLine1Txt>
            <CityNm>WAUKON</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52172</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE PHARMACY AND EMERGENCY SERVICES AT VETERANS MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>30504</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VILLAGES OF HOPE AFRICA SOCIETY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2450 MILLTOWER COURT</AddressLine1Txt>
            <CityNm>MISSISSAUGA</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ZAMBIA DEVELOPMENT: FOOD PRODUCTION, WATER SUPPLY, EDUCATION FACILITIES</GrantOrContributionPurposeTxt>
          <Amt>502010</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VIVLI INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>14 STORY STREET SUITE 406</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02138</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PUBLICLY SHARING THE DATA FROM EXERCISE AND T1D STUDIES</GrantOrContributionPurposeTxt>
          <Amt>72174</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VIVLI INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>14 STORY STREET SUITE 406</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02138</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PUBLICLY SHARING THE DATA FROM EXERCISE AND T1D STUDIES</GrantOrContributionPurposeTxt>
          <Amt>72174</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>660 S EUCLID AVE</AddressLine1Txt>
            <CityNm>ST LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>63110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VACCINE SAFETY AND EFFICACY</GrantOrContributionPurposeTxt>
          <Amt>656480</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHOE BARTON MEDICAL CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1107 US HIGHWAY 395 N</AddressLine1Txt>
            <CityNm>GARDNERVILLE</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89410</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RADIOLOGY AND INTERVENTIONAL EQUIPMENT WITH CONSTRUCTION RELATED COSTS.</GrantOrContributionPurposeTxt>
          <Amt>1465248</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WATER4 INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2405 NW 10TH STREET</AddressLine1Txt>
            <CityNm>OKLAHOMA CITY</CityNm>
            <StateAbbreviationCd>OK</StateAbbreviationCd>
            <ZIPCd>73107</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING THE NUMA MODEL TO DELIVER SAFE, SUSTAINABLE WATER</GrantOrContributionPurposeTxt>
          <Amt>1439503</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WATER4 INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2405 NW 10TH STREET</AddressLine1Txt>
            <CityNm>OKLAHOMA CITY</CityNm>
            <StateAbbreviationCd>OK</StateAbbreviationCd>
            <ZIPCd>73107</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING THE NUMA MODEL TO DELIVER SAFE, SUSTAINABLE WATER</GrantOrContributionPurposeTxt>
          <Amt>1673164</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WATERAID AMERICA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>233 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10279</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATING A NEW REALITY FOR WASH IN HEALTHCARE FACILITIES IN ZAMBIA</GrantOrContributionPurposeTxt>
          <Amt>2166773</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WYOMING DEPARTMENT OF HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>6101 YELLOWSTONE RD SUITE 400</AddressLine1Txt>
            <CityNm>CHEYENNE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82009</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>183693</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WYOMING STATE PARKS AND CULTURAL RESOURCES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2301 CENTRAL AVENUE</AddressLine1Txt>
            <CityNm>CHEYENNE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82002</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERPRETIVE CENTER AT FORT PHIL KEARNY STATE HISTORIC SITE</GrantOrContributionPurposeTxt>
          <Amt>30000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROJECTS</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>443827</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROJECTS</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>298606</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YEHUDA ABARBANEL GOVERNMENT HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>15 KEREN KAYEMET ST</AddressLine1Txt>
            <CityNm>BAT YAM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MODERNIZATION OF ABARBANELS INFORMATION TECHNOLOGY AND SECURITY SYSTEMS</GrantOrContributionPurposeTxt>
          <Amt>454960</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YITZHAK SHAMIR MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEER YAAKOV</AddressLine1Txt>
            <CityNm>TZRIFIN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION AND RENOVATION OF SHAMIR MEDICAL CENTER'S CANCER INSTITUTE</GrantOrContributionPurposeTxt>
          <Amt>6082143</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YITZHAK SHAMIR MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEER YAAKOV</AddressLine1Txt>
            <CityNm>TZRIFIN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION AND RENOVATION OF SHAMIR MEDICAL CENTER'S CANCER INSTITUTE</GrantOrContributionPurposeTxt>
          <Amt>1978286</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YOUTH DEVELOPMENT ORGANIZATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15 UNION STREET 563</AddressLine1Txt>
            <CityNm>LAWRENCE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01840</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING PROJECT SUPPORT 2022</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YOUTH DEVELOPMENT ORGANIZATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15 UNION STREET 563</AddressLine1Txt>
            <CityNm>LAWRENCE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01840</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING PROJECT SUPPORT 2022</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <TotalGrantOrContriApprvFutAmt>462030416</TotalGrantOrContriApprvFutAmt>
      </SupplementaryInformationGrp>
      <AnalysisIncomeProducingActyGrp>
        <IntOnSavAndTempCashInvstGrp>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>17175</ExclusionAmt>
        </IntOnSavAndTempCashInvstGrp>
        <DividendsAndInterestFromSecDtl>
          <BusinessCd>901101</BusinessCd>
          <UnrelatedBusinessTaxblIncmAmt>13523625</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>23107617</ExclusionAmt>
        </DividendsAndInterestFromSecDtl>
        <OtherInvestmentIncomeGrp>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>40305895</ExclusionAmt>
        </OtherInvestmentIncomeGrp>
        <GainSalesAstOthThanInvntryGrp>
          <BusinessCd>901101</BusinessCd>
          <UnrelatedBusinessTaxblIncmAmt>7559982</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionCd>18</ExclusionCd>
          <ExclusionAmt>754085920</ExclusionAmt>
        </GainSalesAstOthThanInvntryGrp>
        <OtherRevenueDescribedGrp>
          <Desc>GRANT RECOVERIES</Desc>
          <ExclusionCd>01</ExclusionCd>
          <ExclusionAmt>892513</ExclusionAmt>
        </OtherRevenueDescribedGrp>
        <OtherRevenueDescribedGrp>
          <Desc>OTHER TAXABLE INCOME</Desc>
          <ExclusionCd>01</ExclusionCd>
          <ExclusionAmt>414</ExclusionAmt>
        </OtherRevenueDescribedGrp>
        <OtherRevenueDescribedGrp>
          <Desc>UBI ORDINARY INCOME THROUGH K-1S - NOT ON BOOKS</Desc>
          <BusinessCd>901101</BusinessCd>
          <UnrelatedBusinessTaxblIncmAmt>4651930</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>-4651930</ExclusionAmt>
        </OtherRevenueDescribedGrp>
        <SubtotalsIncmProducingActyGrp>
          <UnrelatedBusinessTaxblIncmAmt>25735537</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionAmt>813757604</ExclusionAmt>
          <RelatedOrExemptFunctionIncmAmt>0</RelatedOrExemptFunctionIncmAmt>
        </SubtotalsIncmProducingActyGrp>
        <TotalIncomeProducingActyAmt>839493141</TotalIncomeProducingActyAmt>
      </AnalysisIncomeProducingActyGrp>
      <TrnsfrTransRlnNonchrtblEOGrp>
        <TrnsfrOfCashToNonchrtblEOInd>1</TrnsfrOfCashToNonchrtblEOInd>
        <TrnsfrOtherAssetNonchrtblEOInd>0</TrnsfrOtherAssetNonchrtblEOInd>
        <SalesOrExchangesOfAssetsInd>0</SalesOrExchangesOfAssetsInd>
        <PurchaseOfAssetsNonchrtblEOInd>0</PurchaseOfAssetsNonchrtblEOInd>
        <RentalOfFacilitiesOthAssetsInd>0</RentalOfFacilitiesOthAssetsInd>
        <ReimbursementArrangementsInd>0</ReimbursementArrangementsInd>
        <LoansOrLoanGuaranteesInd>0</LoansOrLoanGuaranteesInd>
        <PerformanceOfServicesEtcInd>0</PerformanceOfServicesEtcInd>
        <SharingOfFacilitiesEtcInd>0</SharingOfFacilitiesEtcInd>
        <TransferScheduleDetail>
          <LineNumberTxt>1a(1)</LineNumberTxt>
          <InvolvedAmt>616544</InvolvedAmt>
          <NoncharitableExemptOrgName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </NoncharitableExemptOrgName>
          <TransfersTransAndShrArrngmDesc>GRANT IN SUPPORT OF AADE TECHNOLOGY INSTITUTE: DANA - DIABETES ADVANCED NETWORK ACCESS</TransfersTransAndShrArrngmDesc>
        </TransferScheduleDetail>
        <TransferScheduleDetail>
          <LineNumberTxt>1a(1)</LineNumberTxt>
          <InvolvedAmt>4000</InvolvedAmt>
          <NoncharitableExemptOrgName>
            <BusinessNameLine1Txt>INSTITUTIONAL LIMITED PARTNER ASSOCIATION</BusinessNameLine1Txt>
          </NoncharitableExemptOrgName>
          <TransfersTransAndShrArrngmDesc>MEMBERSHIP FEE</TransfersTransAndShrArrngmDesc>
        </TransferScheduleDetail>
        <RelationshipsNonchrtblEOInd>0</RelationshipsNonchrtblEOInd>
      </TrnsfrTransRlnNonchrtblEOGrp>
    </IRS990PF>
    <AccountingFeesSchedule documentId="RetDoc2002200001">
      <AccountingFeesDetail>
        <CategoryTxt>DEMASCO, SENA &amp; JAHELKA LLP (BOOKKEEPING)</CategoryTxt>
        <Amt>30862</Amt>
        <NetInvestmentIncomeAmt>4721</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>24654</DisbursementsCharitablePrpsAmt>
      </AccountingFeesDetail>
      <AccountingFeesDetail>
        <CategoryTxt>PKF O'CONNOR DAVIES, LLP (AUDIT &amp; TAX)</CategoryTxt>
        <Amt>494690</Amt>
        <NetInvestmentIncomeAmt>283800</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>168025</DisbursementsCharitablePrpsAmt>
      </AccountingFeesDetail>
      <AccountingFeesDetail>
        <CategoryTxt>PRICEWATERHOUSECOOPERS ADVISORY LTD. (GRANTS ADMINISTRATION)</CategoryTxt>
        <Amt>92823</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>87761</DisbursementsCharitablePrpsAmt>
      </AccountingFeesDetail>
      <AccountingFeesDetail>
        <CategoryTxt>UKG INC. (DBA ULTIMATE SOFTWARE GROUP)</CategoryTxt>
        <Amt>99</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>99</DisbursementsCharitablePrpsAmt>
      </AccountingFeesDetail>
    </AccountingFeesSchedule>
    <AllOthProgRltdInvestmentsSch documentId="RetDoc2063500001">
      <AllOtherProgramRelatedInvstGrp>
        <Desc>BIORASIS, INC. - EARLY FEASIBILITY STUDIES OF THE GLUCOWIZZARD</Desc>
        <Amt>410000</Amt>
      </AllOtherProgramRelatedInvstGrp>
    </AllOthProgRltdInvestmentsSch>
    <ExpenditureResponsibilityStmt documentId="RetDoc2118100001">
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>A GLIMMER OF HOPE FOUNDATION</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>3600 N CAPITAL OF TEXAS HWY BLDG B</AddressLine1Txt>
          <AddressLine2Txt>SUITE 330</AddressLine2Txt>
          <CityNm>AUSTIN</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>78746</ZIPCd>
        </USAddress>
        <GrantDt>2019-09-09</GrantDt>
        <GrantAmt>7923870</GrantAmt>
        <PurposeOfGrantTxt>INTEGRATED COMMUNITY DEVELOPMENT IN ODA BULTUM, ETHIOPIA</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>4400291</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>1/2020, 7/2020, 1/2021, 3/2021, 7/2021, 1/2022, 7/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>A GLIMMER OF HOPE FOUNDATION</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>3600 N CAPITAL OF TEXAS HWY BLDG B</AddressLine1Txt>
          <AddressLine2Txt>SUITE 330</AddressLine2Txt>
          <CityNm>AUSTIN</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>78746</ZIPCd>
        </USAddress>
        <GrantDt>2018-02-20</GrantDt>
        <GrantAmt>5000000</GrantAmt>
        <PurposeOfGrantTxt>INTEGRATED COMMUNITY DEVELOPMENT IN AMHARA, ETHIOPIA</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>5000000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>1/2019, 1/2020, 2/2021, 1/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>AKSTON BIOSCIENCES CORPORATION</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>100 CUMMINGS CENTER SUITE 454C</AddressLine1Txt>
          <CityNm>BEVERLY</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>01915</ZIPCd>
        </USAddress>
        <GrantDt>2017-03-01</GrantDt>
        <GrantAmt>6194000</GrantAmt>
        <PurposeOfGrantTxt>PRECLINICAL TRIAL OF INSULIN-FUSION TO END AUTOIMMUNITY &amp; IMPROVE T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>5586294</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>10/2018, 1/2019, 4/2019, 8/2019, 10/2019, 3/2020, 10/2020, 2/2021, 6/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ALIMENTIV INC (FKA ROBARTS)</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
          <CityNm>LONDON</CityNm>
          <ProvinceOrStateNm>ON</ProvinceOrStateNm>
          <CountryCd>CA</CountryCd>
          <ForeignPostalCd>N6A5B6</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2022-02-10</GrantDt>
        <GrantAmt>894043</GrantAmt>
        <PurposeOfGrantTxt>DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>0</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PENDING</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ALIMENTIV INC (FKA ROBARTS)</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
          <CityNm>LONDON</CityNm>
          <ProvinceOrStateNm>ON</ProvinceOrStateNm>
          <CountryCd>CA</CountryCd>
          <ForeignPostalCd>N6A5B6</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2018-11-20</GrantDt>
        <GrantAmt>3390428</GrantAmt>
        <PurposeOfGrantTxt>STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1983840</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR + 12/2019, 1/2020, 6/2020, 12/2020, 1/2021, 6/2021, 12/2021, 6/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>125 S WACKER DRIVE SUITE 600</AddressLine1Txt>
          <CityNm>CHICAGO</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>60606</ZIPCd>
        </USAddress>
        <GrantDt>2021-11-20</GrantDt>
        <GrantAmt>2500000</GrantAmt>
        <PurposeOfGrantTxt>EXPANSION OF THE DANATECH PLATFORM</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>195070</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>1/2022, 5/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>125 S WACKER DRIVE SUITE 600</AddressLine1Txt>
          <CityNm>CHICAGO</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>60606</ZIPCd>
        </USAddress>
        <GrantDt>2018-07-11</GrantDt>
        <GrantAmt>2679637</GrantAmt>
        <PurposeOfGrantTxt>AADE TECHNOLOGY INSTITUTE: DANA - DIABETES ADVANCED NETWORK ACCESS</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>2639117</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>2/2019, 8/2019, 1/2020, 8/2020, 1/2021, 6/2021, 1/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ASITY MADAGASCAR</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>LOT IAB 39 TER C ANALAMHINTSY</AddressLine1Txt>
          <CityNm>ANTANANARIVO</CityNm>
          <CountryCd>MA</CountryCd>
          <ForeignPostalCd>101</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2017-03-01</GrantDt>
        <GrantAmt>284790</GrantAmt>
        <PurposeOfGrantTxt>IMPLEMENT SUSTAINABLE MANAGEMENT STRATEGIES FOR WETLAND CONSERVATION</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>284790</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>2/2018, 2/2019, 5/2020, 9/2021</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>LEVEL 2 55 VICTORIA PARADE</AddressLine1Txt>
          <CityNm>FITZROY</CityNm>
          <CountryCd>AS</CountryCd>
          <ForeignPostalCd>3065</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2020-07-23</GrantDt>
        <GrantAmt>2309216</GrantAmt>
        <PurposeOfGrantTxt>FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE: THE MIRO STUDY</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>742482</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>2/2021, 8/2021, 2/2022, 7/2022, 8/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>LEVEL 2 55 VICTORIA PARADE</AddressLine1Txt>
          <CityNm>FITZROY</CityNm>
          <CountryCd>AS</CountryCd>
          <ForeignPostalCd>3065</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2017-02-15</GrantDt>
        <GrantAmt>3719569</GrantAmt>
        <PurposeOfGrantTxt>THE ENIGMA STUDIES - EASTERN INFLAMMATORY BOWEL DISEASE GUT MICROBIOTA</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>3719569</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR + 11/2019, 1/2020, 4/2020, 10/2020, 11/2020, 3/2021, 9/2021, 3/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>BIORASIS INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1392 STORRS RD U4213 ATL ROOM 106</AddressLine1Txt>
          <CityNm>STORRS</CityNm>
          <StateAbbreviationCd>CT</StateAbbreviationCd>
          <ZIPCd>06269</ZIPCd>
        </USAddress>
        <GrantDt>2018-02-06</GrantDt>
        <GrantAmt>3016000</GrantAmt>
        <PurposeOfGrantTxt>EARLY FEASIBILITY STUDIES OF THE GLUCOWIZZARD IN CARE FOR T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1648500</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR + 9/2019, 2/2020, 5/2020, 8/2020, 11/2020, 2/2021, 7/2021, 5/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
          <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
          <CityNm>WILMINGTON</CityNm>
          <StateAbbreviationCd>DE</StateAbbreviationCd>
          <ZIPCd>19801</ZIPCd>
        </USAddress>
        <GrantDt>2021-12-21</GrantDt>
        <GrantAmt>45430130</GrantAmt>
        <PurposeOfGrantTxt>CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>15476957</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>2/2022, 7/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>CAPILLARY BIOMEDICAL INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2 WRIGLEY</AddressLine1Txt>
          <CityNm>IRVINE</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92617</ZIPCd>
        </USAddress>
        <GrantDt>2020-09-02</GrantDt>
        <GrantAmt>1500000</GrantAmt>
        <PurposeOfGrantTxt>ADVANCED EXTENDED INFUSION SET TO IMPROVE CARE IN T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1428325</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>10/2020, 3/2021, 4/2021, 10/2021, 1/2022, 5/2022, 6/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>DIABETOMICS INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2345 NE OVERLOOK DRIVE SUITE 140</AddressLine1Txt>
          <CityNm>HILLSBORO</CityNm>
          <StateAbbreviationCd>OR</StateAbbreviationCd>
          <ZIPCd>97006</ZIPCd>
        </USAddress>
        <GrantDt>2018-01-11</GrantDt>
        <GrantAmt>4031900</GrantAmt>
        <PurposeOfGrantTxt>POINT-OF-CARE RAPID TESTS FOR TID SCREENING AND INTERVENTION</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>3031900</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR +1/2020, 5/2020, 10/2020, 4/2021, 10/2021, 12/2021, 2/2022, 4/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>DREAMED DIABETES LTD</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>5 MOTA GUR ST</AddressLine1Txt>
          <CityNm>PETAH TIKVA</CityNm>
          <CountryCd>IS</CountryCd>
          <ForeignPostalCd>4952701</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2016-02-01</GrantDt>
        <GrantAmt>3585828</GrantAmt>
        <PurposeOfGrantTxt>MD-LOGIC PUMP GUIDE4U - ADVISORY SYSTEM TO IMPROVE CARE OF T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>3546253</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>10/2016, 1/2017, 7/2017, 9/2017, 2/2018, 6/2018, 9/2018, 12/2019</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>FEROX THERAPEUTICS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>111 TOWN SQUARE PLACE SUITE 1203</AddressLine1Txt>
          <AddressLine2Txt>PMB 1034</AddressLine2Txt>
          <CityNm>JERSEY CITY</CityNm>
          <StateAbbreviationCd>NJ</StateAbbreviationCd>
          <ZIPCd>07310</ZIPCd>
        </USAddress>
        <GrantDt>2018-11-20</GrantDt>
        <GrantAmt>872300</GrantAmt>
        <PurposeOfGrantTxt>INSULIN INDUCED HYPOGLYCEMIA PREVENTION PROGRAM</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>872300</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>7/2019, 10/2019, 1/2020, 4/2020, 7/2020, 12/2020, 1/2021, 4/2021, 7/2021</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>GRAND CANYON UNIVERSITY</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>3300 WEST CAMELBACK ROAD</AddressLine1Txt>
          <CityNm>PHOENIX</CityNm>
          <StateAbbreviationCd>AZ</StateAbbreviationCd>
          <ZIPCd>85017</ZIPCd>
        </USAddress>
        <GrantDt>2019-06-26</GrantDt>
        <GrantAmt>2274027</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1410426</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>6/2020, 7/2020, 7/2021, 4/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
          <CityNm>MUNSTER</CityNm>
          <CountryCd>GM</CountryCd>
        </ForeignAddress>
        <GrantDt>2020-10-21</GrantDt>
        <GrantAmt>172967</GrantAmt>
        <PurposeOfGrantTxt>POINT-OF-CARE INTESTINAL ULTRASOUND TRAINING IN THE UNITED STATES</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>0</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PENDING</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>200 VESEY STREET 28TH FLOOR</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10281</ZIPCd>
        </USAddress>
        <GrantDt>2012-05-21</GrantDt>
        <GrantAmt>8200000</GrantAmt>
        <PurposeOfGrantTxt>ORTHOGONALLY REDUNDANT GLUCOSE SENSOR TO IMPROVE CARE OF T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>8200000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>7/2015, 5/2016, 7/2016, 6/2017, 6/2019, 11/2019, 5/2020, 8/2020</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NURU INTERNATIONAL</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2020 PENNSYLVANIA AVE NW</AddressLine1Txt>
          <CityNm>WASHINGTON</CityNm>
          <StateAbbreviationCd>DC</StateAbbreviationCd>
          <ZIPCd>20006</ZIPCd>
        </USAddress>
        <GrantDt>2013-11-25</GrantDt>
        <GrantAmt>4680506</GrantAmt>
        <PurposeOfGrantTxt>CREATING A SELF-SUSTAINING, SCALING, AGRICULTURE-BASED DEVELOPMENT MODEL</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>4680506</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR + 12/2015, 1/2017, 2/2018, 1/2019, 1/2020, 6/2020, 1/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>PACIFIC DIABETES TECHNOLOGIES</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>12154 SW GARDEN PLACE</AddressLine1Txt>
          <CityNm>PORTLAND</CityNm>
          <StateAbbreviationCd>OR</StateAbbreviationCd>
          <ZIPCd>97223</ZIPCd>
        </USAddress>
        <GrantDt>2014-09-08</GrantDt>
        <GrantAmt>2867072</GrantAmt>
        <PurposeOfGrantTxt>DUAL USE CATHETER FOR INSULIN DELIVERY &amp; SENSING TO IMPROVE CARE OF T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>2867072</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>1/2015, 5/2015, 12/2015, 2/2016, 7/2016, 2/2017, 12/2017, 6/2018</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>PERCUSENSE INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>25134 RYE CANYON LOOP</AddressLine1Txt>
          <CityNm>VALENCIA</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>91355</ZIPCd>
        </USAddress>
        <GrantDt>2020-09-02</GrantDt>
        <GrantAmt>2500000</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF CONTINUOUS GLUCOSE AND KETONE METER FOR TREATMENT IN T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>641203</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>7/2021, 8/2021, 5/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>SOUTH DAKOTA BROADCASTERS ASSOCIATION</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>106 WEST CAPITOL AVE</AddressLine1Txt>
          <CityNm>PIERRE</CityNm>
          <StateAbbreviationCd>SD</StateAbbreviationCd>
          <ZIPCd>57501</ZIPCd>
        </USAddress>
        <GrantDt>2020-12-03</GrantDt>
        <GrantAmt>1110000</GrantAmt>
        <PurposeOfGrantTxt>COVID-19 PUBLIC AWARENESS AND BEHAVIOR</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1100000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>5/2021, 1/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>THETIS PHARMACEUTICALS LLC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>54 DANBURY ROAD SUITE 285</AddressLine1Txt>
          <CityNm>RIDGEFIELD</CityNm>
          <StateAbbreviationCd>NJ</StateAbbreviationCd>
          <ZIPCd>06877</ZIPCd>
        </USAddress>
        <GrantDt>2022-02-24</GrantDt>
        <GrantAmt>4166030</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF A NOVEL RESOLVIN E1 THERAPY FOR TREATMENT OF CROHNS DISEASE</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>117079</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>5/2022, 8/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>THE LEGATUM INSTITUTE FOUNDATION</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>11 CHARLES STREET</AddressLine1Txt>
          <CityNm>LONDON</CityNm>
          <CountryCd>UK</CountryCd>
          <ForeignPostalCd>W1J 5DW</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2021-09-21</GrantDt>
        <GrantAmt>150000</GrantAmt>
        <PurposeOfGrantTxt>PHASE TWO OF US PROSPERITY INDEX: EXPANDING COUNTY-LEVEL INDEX TO INCLUDE WYOMING AND DEEPENING IMPACT</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>4050</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>1/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>THE LEGATUM INSTITUTE FOUNDATION</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>11 CHARLES STREET</AddressLine1Txt>
          <CityNm>LONDON</CityNm>
          <CountryCd>UK</CountryCd>
          <ForeignPostalCd>W1J 5DW</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2017-12-04</GrantDt>
        <GrantAmt>1013551</GrantAmt>
        <PurposeOfGrantTxt>UNITED STATES PROSPERITY INDEX</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1013551</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR +7/2019, 8/2019, 1/2020, 7/2020, 12/2020, 1/2021, 11/2021, 1/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ZUCARA THERAPEUTICS</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>1300-661 UNIVERSITY AVENUE</AddressLine1Txt>
          <CityNm>TORONTO</CityNm>
          <ProvinceOrStateNm>ON</ProvinceOrStateNm>
          <CountryCd>CA</CountryCd>
          <ForeignPostalCd>M5G 0B7</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2018-02-06</GrantDt>
        <GrantAmt>3900000</GrantAmt>
        <PurposeOfGrantTxt>PRECLINICAL DEVELOPMENT OF ZT-01 TO PREVENT HYPOGLYCEMIA IN T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>3900000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR + 7/2020, 2/2021, 4/2021, 7/2021, 10/2021, 2/2022, 4/2022, 7/2022</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
    </ExpenditureResponsibilityStmt>
    <GeneralExplanationAttachment documentId="RetDoc2258700001">
      <GeneralExplanationGrp>
        <IdentifierTxt>CONTROLLED ENTITIES</IdentifierTxt>
        <FormAndLineReferenceDesc>FORM 990-PF, PART VI-A, LINE 11:</FormAndLineReferenceDesc>
        <MediumExplanationTxt>THE FOLLOWING CONTROLLED ENTITIES ARE NOT EXCESS BUSINESS HOLDINGS:ACADIAN FRONTIER MARKETS EQUITY FUND260 FRANKLIN STREETBOSTON, MA 02110EIN# 20-5852756CHATHAM CO-INVEST26 MAIN STREET, SUITE 204CHATHAM, NJ 07928EIN# 85-0651355ESTATE OF LEONA M. HELMSLEY230 PARK AVENUE, SUITE 659NEW YORK, NY 10169EIN# 20-7535047HELMSLEY ENTERPRISES, INC.230 PARK AVENUE, SUITE 659NEW YORK, NY 10169EIN# 13-2665914LACM GLOBAL EQUITY FUND, LP11150 SANTA MONICA BLVD., STE. 200LOS ANGELES, CA 90025EIN# 45-3646231 LACM WORLD SMALL CAP EQUITY FUND, L.P.11150 SANTA MONICA BLVD., STE. 200LOS ANGELES, CA 90025EIN# 83-2888004MARATHON-LONDON GLOBAL SELECTORION HOUSE, 5 UPPER ST. MARTIN'S LANELONDON, UK WC2H 9EAEIN# 61-1915057MHR LONGEVITY PARTNERS1345 AVENUE OF THE AMERICAS 42ND FLOORNEW YORK, NY 10105EIN# 98-1471155NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER, L.P.2929 ARCH STREET 17TH FLOORPHILADELPHIA, PA 19104EIN# 98-1142649PITANGO SPVBEIT ACKERSHTEIN - BLDG. B, 11 HAMENOFIM ST. 11TH FL.HERZLIYA, ISRAELEIN# 98-1492234</MediumExplanationTxt>
      </GeneralExplanationGrp>
      <GeneralExplanationGrp>
        <FormAndLineReferenceDesc>FORM 990-PF, PART VII, LINE 1:</FormAndLineReferenceDesc>
        <MediumExplanationTxt>STEPHANIE A. CUSKLEY WAS CHIEF EXECUTIVE OFFICER FROM 4/1/21-10/31/21.SARAH E. PAUL WAS GENERAL COUNSEL 4/1/21-10/31/21 AND FROM 11/1/21-3/31/22 CEO AND GENERAL COUNSEL.</MediumExplanationTxt>
      </GeneralExplanationGrp>
      <GeneralExplanationGrp>
        <FormAndLineReferenceDesc>FORM 990-PF, PART VII, LINE 1 AND 2, COLUMN (C), COMPENSATION:</FormAndLineReferenceDesc>
        <MediumExplanationTxt>ALL REPORTED COMPENSATION AMOUNTS INCLUDE "SALARY, FEES, BONUSES AND SEVERANCE PAYMENTS RECEIVED BY EACH PERSON LISTED," AS WELL AS CURRENT YEAR PAYMENTS OF AMOUNTS REPORTED OR REPORTABLE AS DEFERRED COMPENSATION IN CURRENT OR PRIOR YEARS.</MediumExplanationTxt>
      </GeneralExplanationGrp>
    </GeneralExplanationAttachment>
    <InvestmentsCorpStockSchedule documentId="RetDoc2018900001">
      <InvestmentsCorporateStockGrp>
        <StockNm>ALPHABET INC, 2,862 SHRS</StockNm>
        <EOYBookValueAmt>7993537</EOYBookValueAmt>
        <EOYFMVAmt>7993537</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AMAZON.COM INC, 1,739 SHRS</StockNm>
        <EOYBookValueAmt>5669053</EOYBookValueAmt>
        <EOYFMVAmt>5669053</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AMERICAN TOWER CORP, 15,113 SHRS</StockNm>
        <EOYBookValueAmt>3796688</EOYBookValueAmt>
        <EOYFMVAmt>3796688</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ANSYS INC, 16,010 SHRS</StockNm>
        <EOYBookValueAmt>5085577</EOYBookValueAmt>
        <EOYFMVAmt>5085577</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BIO-TECHNE CORP, 12,546 SHRS</StockNm>
        <EOYBookValueAmt>5432920</EOYBookValueAmt>
        <EOYFMVAmt>5432920</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BLACKLINE INC, 33,880 SHRS</StockNm>
        <EOYBookValueAmt>2480694</EOYBookValueAmt>
        <EOYFMVAmt>2480694</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AZENTA INC, 10,673 SHRS</StockNm>
        <EOYBookValueAmt>884578</EOYBookValueAmt>
        <EOYFMVAmt>884578</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CBRE GROUP INC, 55,720 SHRS</StockNm>
        <EOYBookValueAmt>5099494</EOYBookValueAmt>
        <EOYFMVAmt>5099494</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CABLE ONE INC, 2,855 SHRS</StockNm>
        <EOYBookValueAmt>4180405</EOYBookValueAmt>
        <EOYFMVAmt>4180405</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CARMAX INC, 33,809 SHRS</StockNm>
        <EOYBookValueAmt>3261892</EOYBookValueAmt>
        <EOYFMVAmt>3261892</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>COSTAR GROUP INC, 42,938 SHRS</StockNm>
        <EOYBookValueAmt>2860100</EOYBookValueAmt>
        <EOYFMVAmt>2860100</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CROWDSTRIKE HOLDINGS INC, 9,928 SHRS</StockNm>
        <EOYBookValueAmt>2254450</EOYBookValueAmt>
        <EOYFMVAmt>2254450</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DANAHER CORP, 22,680 SHRS</StockNm>
        <EOYBookValueAmt>6652724</EOYBookValueAmt>
        <EOYFMVAmt>6652724</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DOLLAR GENERAL CORP, 16,258 SHRS</StockNm>
        <EOYBookValueAmt>3619519</EOYBookValueAmt>
        <EOYFMVAmt>3619519</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ECOLAB INC, 20,601 SHRS</StockNm>
        <EOYBookValueAmt>3637313</EOYBookValueAmt>
        <EOYFMVAmt>3637313</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FASTENAL CO, 59,691 SHRS</StockNm>
        <EOYBookValueAmt>3545645</EOYBookValueAmt>
        <EOYFMVAmt>3545645</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>GUIDEWIRE SOFTWARE INC, 23,015 SHRS</StockNm>
        <EOYBookValueAmt>2177679</EOYBookValueAmt>
        <EOYFMVAmt>2177679</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>HEICO CORP, 45,587 SHRS</StockNm>
        <EOYBookValueAmt>5781799</EOYBookValueAmt>
        <EOYFMVAmt>5781799</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>IDEXX LABORATORIES INC, 4,096 SHRS</StockNm>
        <EOYBookValueAmt>2240758</EOYBookValueAmt>
        <EOYFMVAmt>2240758</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ILLUMINA INC, 16,733 SHRS</StockNm>
        <EOYBookValueAmt>5846510</EOYBookValueAmt>
        <EOYFMVAmt>5846510</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>INTUITIVE SURGICAL INC, 21,969 SHRS</StockNm>
        <EOYBookValueAmt>6627608</EOYBookValueAmt>
        <EOYFMVAmt>6627608</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MARKEL CORP, 3,399 SHRS</StockNm>
        <EOYBookValueAmt>5014341</EOYBookValueAmt>
        <EOYFMVAmt>5014341</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MASTERCARD INC, 19,236 SHRS</StockNm>
        <EOYBookValueAmt>6874562</EOYBookValueAmt>
        <EOYFMVAmt>6874562</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MOODY'S CORP, 6,951 SHRS</StockNm>
        <EOYBookValueAmt>2345337</EOYBookValueAmt>
        <EOYFMVAmt>2345337</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>OKTA INC, 7,695 SHRS</StockNm>
        <EOYBookValueAmt>1161637</EOYBookValueAmt>
        <EOYFMVAmt>1161637</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>QUALCOMM INC, 32,515 SHRS</StockNm>
        <EOYBookValueAmt>4968942</EOYBookValueAmt>
        <EOYFMVAmt>4968942</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>S&amp;P GLOBAL INC, 14,521 SHRS</StockNm>
        <EOYBookValueAmt>5956224</EOYBookValueAmt>
        <EOYFMVAmt>5956224</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SBA COMMUNICATIONS CORP, 9,184 SHRS</StockNm>
        <EOYBookValueAmt>3160214</EOYBookValueAmt>
        <EOYFMVAmt>3160214</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SHOPIFY INC, 1,604 SHRS</StockNm>
        <EOYBookValueAmt>1084240</EOYBookValueAmt>
        <EOYFMVAmt>1084240</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SPROUT SOCIAL INC, 8,650 SHRS</StockNm>
        <EOYBookValueAmt>693038</EOYBookValueAmt>
        <EOYFMVAmt>693038</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TELEFLEX INC, 11,542 SHRS</StockNm>
        <EOYBookValueAmt>4095448</EOYBookValueAmt>
        <EOYFMVAmt>4095448</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>THERMO FISHER SCIENTIFIC INC, 11,560 SHRS</StockNm>
        <EOYBookValueAmt>6827914</EOYBookValueAmt>
        <EOYFMVAmt>6827914</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TRANSDIGM GROUP INC, 8,842 SHRS</StockNm>
        <EOYBookValueAmt>5760917</EOYBookValueAmt>
        <EOYFMVAmt>5760917</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TWILIO INC, 6,204 SHRS</StockNm>
        <EOYBookValueAmt>1022481</EOYBookValueAmt>
        <EOYFMVAmt>1022481</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VEEVA SYSTEMS INC, 12,632 SHRS</StockNm>
        <EOYBookValueAmt>2683795</EOYBookValueAmt>
        <EOYFMVAmt>2683795</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VERISK ANALYTICS INC, 18,395 SHRS</StockNm>
        <EOYBookValueAmt>3948119</EOYBookValueAmt>
        <EOYFMVAmt>3948119</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VISA INC, 39,464 SHRS</StockNm>
        <EOYBookValueAmt>8751931</EOYBookValueAmt>
        <EOYFMVAmt>8751931</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VULCAN MATERIALS CO, 20,911 SHRS</StockNm>
        <EOYBookValueAmt>3841351</EOYBookValueAmt>
        <EOYFMVAmt>3841351</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WASTE CONNECTIONS INC, 39,215 SHRS</StockNm>
        <EOYBookValueAmt>5478336</EOYBookValueAmt>
        <EOYFMVAmt>5478336</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WILLSCOT MOBILE MINI HOLDINGS, 43,251 SHRS</StockNm>
        <EOYBookValueAmt>1692412</EOYBookValueAmt>
        <EOYFMVAmt>1692412</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WORKIVA INC, 11,503 SHRS</StockNm>
        <EOYBookValueAmt>1357354</EOYBookValueAmt>
        <EOYFMVAmt>1357354</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ATLASSIAN CORP PLC, 3,724 SHRS</StockNm>
        <EOYBookValueAmt>1094223</EOYBookValueAmt>
        <EOYFMVAmt>1094223</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALPHABET INC, 2,653 SHRS</StockNm>
        <EOYBookValueAmt>7378922</EOYBookValueAmt>
        <EOYFMVAmt>7378922</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AVERY DENNISON CORP, 5,781 SHRS</StockNm>
        <EOYBookValueAmt>1005721</EOYBookValueAmt>
        <EOYFMVAmt>1005721</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BERKSHIRE HATHAWAY INC, 30,799 SHRS</StockNm>
        <EOYBookValueAmt>10869275</EOYBookValueAmt>
        <EOYFMVAmt>10869275</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BOOKING HOLDINGS INC, 2,792 SHRS</StockNm>
        <EOYBookValueAmt>6556872</EOYBookValueAmt>
        <EOYFMVAmt>6556872</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CDW CORP/DE, 8,780 SHRS</StockNm>
        <EOYBookValueAmt>1570654</EOYBookValueAmt>
        <EOYFMVAmt>1570654</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CARLISLE COS INC, 12,678 SHRS</StockNm>
        <EOYBookValueAmt>3117774</EOYBookValueAmt>
        <EOYFMVAmt>3117774</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CARMAX INC, 33,476 SHRS</StockNm>
        <EOYBookValueAmt>3229764</EOYBookValueAmt>
        <EOYFMVAmt>3229764</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>COMCAST CORP, 116,977 SHRS</StockNm>
        <EOYBookValueAmt>5476863</EOYBookValueAmt>
        <EOYFMVAmt>5476863</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DOLLAR GENERAL CORP, 37,840 SHRS</StockNm>
        <EOYBookValueAmt>8424319</EOYBookValueAmt>
        <EOYFMVAmt>8424319</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DOLLAR TREE INC, 44,089 SHRS</StockNm>
        <EOYBookValueAmt>7060853</EOYBookValueAmt>
        <EOYFMVAmt>7060853</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DOVER CORP, 27,994 SHRS</StockNm>
        <EOYBookValueAmt>4392259</EOYBookValueAmt>
        <EOYFMVAmt>4392259</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>META PLATFORMS INC, 14,120 SHRS</StockNm>
        <EOYBookValueAmt>3139723</EOYBookValueAmt>
        <EOYFMVAmt>3139723</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FRESENIUS MEDICAL CARE AG &amp; CO, 129,576 SHRS</StockNm>
        <EOYBookValueAmt>4364120</EOYBookValueAmt>
        <EOYFMVAmt>4364120</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>JPMORGAN CHASE &amp; CO, 37,415 SHRS</StockNm>
        <EOYBookValueAmt>5100413</EOYBookValueAmt>
        <EOYFMVAmt>5100413</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>KONINKLIJKE PHILIPS NV, 145,657 SHRS</StockNm>
        <EOYBookValueAmt>4446908</EOYBookValueAmt>
        <EOYFMVAmt>4446908</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MASCO CORP, 150,820 SHRS</StockNm>
        <EOYBookValueAmt>7691820</EOYBookValueAmt>
        <EOYFMVAmt>7691820</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MICRON TECHNOLOGY INC, 84,147 SHRS</StockNm>
        <EOYBookValueAmt>6554210</EOYBookValueAmt>
        <EOYFMVAmt>6554210</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NORTHERN TRUST CORP, 45,944 SHRS</StockNm>
        <EOYBookValueAmt>5350179</EOYBookValueAmt>
        <EOYFMVAmt>5350179</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>OMNICOM GROUP INC, 62,210 SHRS</StockNm>
        <EOYBookValueAmt>5280385</EOYBookValueAmt>
        <EOYFMVAmt>5280385</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PPG INDUSTRIES INC, 31,507 SHRS</StockNm>
        <EOYBookValueAmt>4129622</EOYBookValueAmt>
        <EOYFMVAmt>4129622</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PACCAR INC, 63,404 SHRS</StockNm>
        <EOYBookValueAmt>5583990</EOYBookValueAmt>
        <EOYFMVAmt>5583990</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PROGRESSIVE CORP/THE, 46,833 SHRS</StockNm>
        <EOYBookValueAmt>5338494</EOYBookValueAmt>
        <EOYFMVAmt>5338494</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>QUEST DIAGNOSTICS INC, 33,976 SHRS</StockNm>
        <EOYBookValueAmt>4649955</EOYBookValueAmt>
        <EOYFMVAmt>4649955</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SAP SE, 31,806 SHRS</StockNm>
        <EOYBookValueAmt>3529194</EOYBookValueAmt>
        <EOYFMVAmt>3529194</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SCHLUMBERGER LTD, 100,410 SHRS</StockNm>
        <EOYBookValueAmt>4147937</EOYBookValueAmt>
        <EOYFMVAmt>4147937</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CHARLES SCHWAB CORP/THE, 81,139 SHRS</StockNm>
        <EOYBookValueAmt>6840829</EOYBookValueAmt>
        <EOYFMVAmt>6840829</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SMITH &amp; NEPHEW PLC, 149,359 SHRS</StockNm>
        <EOYBookValueAmt>4764552</EOYBookValueAmt>
        <EOYFMVAmt>4764552</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SONY GROUP CORP, 66,468 SHRS</StockNm>
        <EOYBookValueAmt>6826928</EOYBookValueAmt>
        <EOYFMVAmt>6826928</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TJX COS INC/THE, 54,941 SHRS</StockNm>
        <EOYBookValueAmt>3328326</EOYBookValueAmt>
        <EOYFMVAmt>3328326</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNILEVER PLC, 118,915 SHRS</StockNm>
        <EOYBookValueAmt>5418957</EOYBookValueAmt>
        <EOYFMVAmt>5418957</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNITEDHEALTH GROUP INC, 12,444 SHRS</StockNm>
        <EOYBookValueAmt>6346067</EOYBookValueAmt>
        <EOYFMVAmt>6346067</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ARCH CAPITAL GROUP LTD, 81,943 SHRS</StockNm>
        <EOYBookValueAmt>3967680</EOYBookValueAmt>
        <EOYFMVAmt>3967680</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>EATON CORP PLC, 21,836 SHRS</StockNm>
        <EOYBookValueAmt>3313831</EOYBookValueAmt>
        <EOYFMVAmt>3313831</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CHUBB LTD, 16,804 SHRS</StockNm>
        <EOYBookValueAmt>3594376</EOYBookValueAmt>
        <EOYFMVAmt>3594376</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNILEVER PLC, 112,629 SHRS</StockNm>
        <EOYBookValueAmt>5131091</EOYBookValueAmt>
        <EOYFMVAmt>5131091</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NINTENDO CO LTD, 15,800 SHRS</StockNm>
        <EOYBookValueAmt>8027897</EOYBookValueAmt>
        <EOYFMVAmt>8027897</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TGS ASA, 64,852 SHRS</StockNm>
        <EOYBookValueAmt>976043</EOYBookValueAmt>
        <EOYFMVAmt>976043</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>GLAXOSMITHKLINE PLC, 349,926 SHRS</StockNm>
        <EOYBookValueAmt>7589146</EOYBookValueAmt>
        <EOYFMVAmt>7589146</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>RECKITT BENCKISER GROUP PLC, 105,210 SHRS</StockNm>
        <EOYBookValueAmt>8078763</EOYBookValueAmt>
        <EOYFMVAmt>8078763</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>INFORMA PLC, 650,658 SHRS</StockNm>
        <EOYBookValueAmt>5155554</EOYBookValueAmt>
        <EOYFMVAmt>5155554</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NOVARTIS AG, 124,594 SHRS</StockNm>
        <EOYBookValueAmt>11000557</EOYBookValueAmt>
        <EOYFMVAmt>11000557</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NESTLE SA, 66,975 SHRS</StockNm>
        <EOYBookValueAmt>8748052</EOYBookValueAmt>
        <EOYFMVAmt>8748052</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CIE FINANCIERE RICHEMONT SA, 64,029 SHRS</StockNm>
        <EOYBookValueAmt>8210184</EOYBookValueAmt>
        <EOYFMVAmt>8210184</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALCON INC, 40,429 SHRS</StockNm>
        <EOYBookValueAmt>3237835</EOYBookValueAmt>
        <EOYFMVAmt>3237835</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALPHABET INC, 2,923 SHRS</StockNm>
        <EOYBookValueAmt>8129886</EOYBookValueAmt>
        <EOYFMVAmt>8129886</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BOOKING HOLDINGS INC, 2,867 SHRS</StockNm>
        <EOYBookValueAmt>6733006</EOYBookValueAmt>
        <EOYFMVAmt>6733006</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BRISTOL-MYERS SQUIBB CO, 175,887 SHRS</StockNm>
        <EOYBookValueAmt>12845028</EOYBookValueAmt>
        <EOYFMVAmt>12845028</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CORTEVA INC, 134,177 SHRS</StockNm>
        <EOYBookValueAmt>7712494</EOYBookValueAmt>
        <EOYFMVAmt>7712494</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>EBAY INC, 136,662 SHRS</StockNm>
        <EOYBookValueAmt>7825266</EOYBookValueAmt>
        <EOYFMVAmt>7825266</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ELECTRONIC ARTS INC, 58,456 SHRS</StockNm>
        <EOYBookValueAmt>7395269</EOYBookValueAmt>
        <EOYFMVAmt>7395269</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FOX CORP, 243,582 SHRS</StockNm>
        <EOYBookValueAmt>9609310</EOYBookValueAmt>
        <EOYFMVAmt>9609310</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>INTERCONTINENTAL EXCHANGE INC, 63,295 SHRS</StockNm>
        <EOYBookValueAmt>8362535</EOYBookValueAmt>
        <EOYFMVAmt>8362535</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>JOHNSON &amp; JOHNSON, 39,431 SHRS</StockNm>
        <EOYBookValueAmt>6988356</EOYBookValueAmt>
        <EOYFMVAmt>6988356</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MICROSOFT CORP, 20,632 SHRS</StockNm>
        <EOYBookValueAmt>6361052</EOYBookValueAmt>
        <EOYFMVAmt>6361052</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NEWS CORP, 369,723 SHRS</StockNm>
        <EOYBookValueAmt>8189364</EOYBookValueAmt>
        <EOYFMVAmt>8189364</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NEWS CORP, 163,588 SHRS</StockNm>
        <EOYBookValueAmt>3684002</EOYBookValueAmt>
        <EOYFMVAmt>3684002</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ORACLE CORP, 83,656 SHRS</StockNm>
        <EOYBookValueAmt>6920861</EOYBookValueAmt>
        <EOYFMVAmt>6920861</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>S&amp;P GLOBAL INC, 14,641 SHRS</StockNm>
        <EOYBookValueAmt>6005445</EOYBookValueAmt>
        <EOYFMVAmt>6005445</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SALESFORCE INC, 20,882 SHRS</StockNm>
        <EOYBookValueAmt>4433666</EOYBookValueAmt>
        <EOYFMVAmt>4433666</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TRANSUNION, 46,201 SHRS</StockNm>
        <EOYBookValueAmt>4774411</EOYBookValueAmt>
        <EOYFMVAmt>4774411</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WESTERN UNION CO/THE, 220,210 SHRS</StockNm>
        <EOYBookValueAmt>4126735</EOYBookValueAmt>
        <EOYFMVAmt>4126735</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ZILLOW GROUP INC, 21,460 SHRS</StockNm>
        <EOYBookValueAmt>1035016</EOYBookValueAmt>
        <EOYFMVAmt>1035016</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ZILLOW GROUP INC, 120,087 SHRS</StockNm>
        <EOYBookValueAmt>5919088</EOYBookValueAmt>
        <EOYFMVAmt>5919088</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AON PLC, 27,075 SHRS</StockNm>
        <EOYBookValueAmt>8816432</EOYBookValueAmt>
        <EOYFMVAmt>8816432</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ACCENTURE PLC, 56 SHRS</StockNm>
        <EOYBookValueAmt>18885</EOYBookValueAmt>
        <EOYFMVAmt>18885</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ACCENTURE PLC, 11,632 SHRS</StockNm>
        <EOYBookValueAmt>3922659</EOYBookValueAmt>
        <EOYFMVAmt>3922659</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CHINA RENAISSANCE HOLDINGS LTD, 127,556 SHRS</StockNm>
        <EOYBookValueAmt>157768</EOYBookValueAmt>
        <EOYFMVAmt>157768</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MEITUAN, 183,364 SHRS</StockNm>
        <EOYBookValueAmt>3643210</EOYBookValueAmt>
        <EOYFMVAmt>3643210</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>JW CAYMAN THERAPEUTICS CO LTD, 7,143 SHRS</StockNm>
        <EOYBookValueAmt>7406</EOYBookValueAmt>
        <EOYFMVAmt>7406</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BRII BIOSCIENCES LTD, 80,115 SHRS</StockNm>
        <EOYBookValueAmt>113553</EOYBookValueAmt>
        <EOYFMVAmt>113553</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AFFIRM HOLDINGS INC, 90,830 SHRS</StockNm>
        <EOYBookValueAmt>4203612</EOYBookValueAmt>
        <EOYFMVAmt>4203612</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AIRBNB INC, 12,774 SHRS</StockNm>
        <EOYBookValueAmt>2194062</EOYBookValueAmt>
        <EOYFMVAmt>2194062</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BERKELEY LIGHTS INC, 2,018 SHRS</StockNm>
        <EOYBookValueAmt>14348</EOYBookValueAmt>
        <EOYFMVAmt>14348</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BILL.COM HOLDINGS INC, 6,110 SHRS</StockNm>
        <EOYBookValueAmt>1385687</EOYBookValueAmt>
        <EOYFMVAmt>1385687</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CROWDSTRIKE HOLDINGS INC, 5,806 SHRS</StockNm>
        <EOYBookValueAmt>1318426</EOYBookValueAmt>
        <EOYFMVAmt>1318426</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DADA NEXUS LTD, 16,164 SHRS</StockNm>
        <EOYBookValueAmt>147577</EOYBookValueAmt>
        <EOYFMVAmt>147577</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DIGITALOCEAN HOLDINGS INC, 79,471 SHRS</StockNm>
        <EOYBookValueAmt>4597397</EOYBookValueAmt>
        <EOYFMVAmt>4597397</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DOORDASH INC, 22,663 SHRS</StockNm>
        <EOYBookValueAmt>2655877</EOYBookValueAmt>
        <EOYFMVAmt>2655877</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>META PLATFORMS INC, 10,000 SHRS</StockNm>
        <EOYBookValueAmt>2223600</EOYBookValueAmt>
        <EOYFMVAmt>2223600</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FUTU HOLDINGS LTD, 5,962 SHRS</StockNm>
        <EOYBookValueAmt>194123</EOYBookValueAmt>
        <EOYFMVAmt>194123</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>GUARDANT HEALTH INC, 4,000 SHRS</StockNm>
        <EOYBookValueAmt>264960</EOYBookValueAmt>
        <EOYFMVAmt>264960</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>LYFT INC, 17,155 SHRS</StockNm>
        <EOYBookValueAmt>658752</EOYBookValueAmt>
        <EOYFMVAmt>658752</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>OSCAR HEALTH INC, 22,936 SHRS</StockNm>
        <EOYBookValueAmt>228672</EOYBookValueAmt>
        <EOYFMVAmt>228672</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PINDUODUO INC, 146,148 SHRS</StockNm>
        <EOYBookValueAmt>5861996</EOYBookValueAmt>
        <EOYFMVAmt>5861996</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ROBLOX CORP, 72,000 SHRS</StockNm>
        <EOYBookValueAmt>3329280</EOYBookValueAmt>
        <EOYFMVAmt>3329280</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SENTINELONE INC, 23,937 SHRS</StockNm>
        <EOYBookValueAmt>927319</EOYBookValueAmt>
        <EOYFMVAmt>927319</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SNOWFLAKE INC, 11,358 SHRS</StockNm>
        <EOYBookValueAmt>2602459</EOYBookValueAmt>
        <EOYFMVAmt>2602459</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SUMO LOGIC INC, 55,907 SHRS</StockNm>
        <EOYBookValueAmt>652435</EOYBookValueAmt>
        <EOYFMVAmt>652435</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TWILIO INC, 10,000 SHRS</StockNm>
        <EOYBookValueAmt>1648100</EOYBookValueAmt>
        <EOYFMVAmt>1648100</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UIPATH INC, 133,883 SHRS</StockNm>
        <EOYBookValueAmt>2890534</EOYBookValueAmt>
        <EOYFMVAmt>2890534</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNITY SOFTWARE INC, 30,651 SHRS</StockNm>
        <EOYBookValueAmt>3040886</EOYBookValueAmt>
        <EOYFMVAmt>3040886</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ZOOM VIDEO COMMUNICATIONS INC, 11,000 SHRS</StockNm>
        <EOYBookValueAmt>1289530</EOYBookValueAmt>
        <EOYFMVAmt>1289530</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
    </InvestmentsCorpStockSchedule>
    <InvestmentsOtherSchedule2 documentId="RetDoc2018100001">
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>JPM US LARGE CAP</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>125183266</BookValueAmt>
        <EOYFMVAmt>125183266</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SPDR TRUST SERIES I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>124358622</BookValueAmt>
        <EOYFMVAmt>124358622</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>JPM CORE BOND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1255541161</BookValueAmt>
        <EOYFMVAmt>1255541161</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>JPM SHORT DURATION BOND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>326609332</BookValueAmt>
        <EOYFMVAmt>326609332</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CHATHAM</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>108419200</BookValueAmt>
        <EOYFMVAmt>108419200</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CHATHAM CO INVEST</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>70062390</BookValueAmt>
        <EOYFMVAmt>70062390</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CHATHAM OFFSHORE</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>107383116</BookValueAmt>
        <EOYFMVAmt>107383116</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>BRILLIANT PARTNERS</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>75250122</BookValueAmt>
        <EOYFMVAmt>75250122</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CAMBER</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>140373678</BookValueAmt>
        <EOYFMVAmt>140373678</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED GENESIS FUND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>17968765</BookValueAmt>
        <EOYFMVAmt>17968765</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>JERICHO</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>187120249</BookValueAmt>
        <EOYFMVAmt>187120249</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA CAP GLOBAL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>218057635</BookValueAmt>
        <EOYFMVAmt>218057635</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACADIAN FRONTIER</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>104404213</BookValueAmt>
        <EOYFMVAmt>104404213</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIGHCLERE INTL SC</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>151927907</BookValueAmt>
        <EOYFMVAmt>151927907</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIGHCLERE INTL SMID</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>82124194</BookValueAmt>
        <EOYFMVAmt>82124194</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>LA CAPITAL GLOBAL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>111532600</BookValueAmt>
        <EOYFMVAmt>111532600</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>LACM WORLD SMALL CAP</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>110390023</BookValueAmt>
        <EOYFMVAmt>110390023</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>MARATHON GLOBAL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>105854074</BookValueAmt>
        <EOYFMVAmt>105854074</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SILCHESTER INTL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>141761870</BookValueAmt>
        <EOYFMVAmt>141761870</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>BLACKROCK US DEBT</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>231439336</BookValueAmt>
        <EOYFMVAmt>231439336</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH FUND IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>30645594</BookValueAmt>
        <EOYFMVAmt>30645594</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>14875787</BookValueAmt>
        <EOYFMVAmt>14875787</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19128215</BookValueAmt>
        <EOYFMVAmt>19128215</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>38337112</BookValueAmt>
        <EOYFMVAmt>38337112</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11625605</BookValueAmt>
        <EOYFMVAmt>11625605</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL INDIA V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>15744558</BookValueAmt>
        <EOYFMVAmt>15744558</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL INDIA VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8221624</BookValueAmt>
        <EOYFMVAmt>8221624</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL INDIA VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>640000</BookValueAmt>
        <EOYFMVAmt>640000</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL LEADERS FUND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12870376</BookValueAmt>
        <EOYFMVAmt>12870376</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL LEADERS II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11190585</BookValueAmt>
        <EOYFMVAmt>11190585</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL LEADERS III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>25535297</BookValueAmt>
        <EOYFMVAmt>25535297</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7610255</BookValueAmt>
        <EOYFMVAmt>7610255</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>28131818</BookValueAmt>
        <EOYFMVAmt>28131818</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19705081</BookValueAmt>
        <EOYFMVAmt>19705081</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XIV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11574672</BookValueAmt>
        <EOYFMVAmt>11574672</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3872286</BookValueAmt>
        <EOYFMVAmt>3872286</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH BIO FUND I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9110573</BookValueAmt>
        <EOYFMVAmt>9110573</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH BIO FUND II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19043732</BookValueAmt>
        <EOYFMVAmt>19043732</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH BIO III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>14243936</BookValueAmt>
        <EOYFMVAmt>14243936</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH BIO IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1046617</BookValueAmt>
        <EOYFMVAmt>1046617</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH CNK IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2000000</BookValueAmt>
        <EOYFMVAmt>2000000</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH CNK SEED I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1250000</BookValueAmt>
        <EOYFMVAmt>1250000</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH FUND VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11938432</BookValueAmt>
        <EOYFMVAmt>11938432</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH FUND VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1326986</BookValueAmt>
        <EOYFMVAmt>1326986</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>63683169</BookValueAmt>
        <EOYFMVAmt>63683169</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH III PARALLEL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12003088</BookValueAmt>
        <EOYFMVAmt>12003088</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>50068896</BookValueAmt>
        <EOYFMVAmt>50068896</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH IV PARALLEL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>21653467</BookValueAmt>
        <EOYFMVAmt>21653467</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH LSV FUND II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>21569100</BookValueAmt>
        <EOYFMVAmt>21569100</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH LSV FUND III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5641070</BookValueAmt>
        <EOYFMVAmt>5641070</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH LSV I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22356136</BookValueAmt>
        <EOYFMVAmt>22356136</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>55628188</BookValueAmt>
        <EOYFMVAmt>55628188</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH V PARALLEL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>31505964</BookValueAmt>
        <EOYFMVAmt>31505964</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>29989545</BookValueAmt>
        <EOYFMVAmt>29989545</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ANGELENO INV III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16814435</BookValueAmt>
        <EOYFMVAmt>16814435</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ARBORETUM III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6292132</BookValueAmt>
        <EOYFMVAmt>6292132</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ARBORETUM IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>38759884</BookValueAmt>
        <EOYFMVAmt>38759884</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ARBORETUM V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>15421213</BookValueAmt>
        <EOYFMVAmt>15421213</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>BAYVIEW</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>61702904</BookValueAmt>
        <EOYFMVAmt>61702904</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>COLLER VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7988854</BookValueAmt>
        <EOYFMVAmt>7988854</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>COLLER VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>41152855</BookValueAmt>
        <EOYFMVAmt>41152855</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>COLLER VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>20280774</BookValueAmt>
        <EOYFMVAmt>20280774</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CRESTVIEW ELO</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7213977</BookValueAmt>
        <EOYFMVAmt>7213977</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CRESTVIEW III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>44406113</BookValueAmt>
        <EOYFMVAmt>44406113</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CRESTVIEW IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>21758970</BookValueAmt>
        <EOYFMVAmt>21758970</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EIG ENERGY FUND XVI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>50259711</BookValueAmt>
        <EOYFMVAmt>50259711</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EIG ENERGY XV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8117949</BookValueAmt>
        <EOYFMVAmt>8117949</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EIG ENERGY XVII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11222263</BookValueAmt>
        <EOYFMVAmt>11222263</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>87147420</BookValueAmt>
        <EOYFMVAmt>87147420</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>49692754</BookValueAmt>
        <EOYFMVAmt>49692754</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE OPP I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5987177</BookValueAmt>
        <EOYFMVAmt>5987177</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>35174100</BookValueAmt>
        <EOYFMVAmt>35174100</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2347654</BookValueAmt>
        <EOYFMVAmt>2347654</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EPIRIS II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>20029076</BookValueAmt>
        <EOYFMVAmt>20029076</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FORTISSIMO</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>24365576</BookValueAmt>
        <EOYFMVAmt>24365576</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FORTISSIMO V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16714172</BookValueAmt>
        <EOYFMVAmt>16714172</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER GTH BUYOUT X</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4187317</BookValueAmt>
        <EOYFMVAmt>4187317</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8040922</BookValueAmt>
        <EOYFMVAmt>8040922</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER PUBLIC FUND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>10041196</BookValueAmt>
        <EOYFMVAmt>10041196</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER SUNMD CO INV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6000000</BookValueAmt>
        <EOYFMVAmt>6000000</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER X</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9849046</BookValueAmt>
        <EOYFMVAmt>9849046</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GAVEA IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1423455</BookValueAmt>
        <EOYFMVAmt>1423455</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GAVEA V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8901233</BookValueAmt>
        <EOYFMVAmt>8901233</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GAVEA V PLUS</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2202473</BookValueAmt>
        <EOYFMVAmt>2202473</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GENERL ATLANTIC 2013</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>96361826</BookValueAmt>
        <EOYFMVAmt>96361826</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GENERL ATLANTIC 2018</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>108629521</BookValueAmt>
        <EOYFMVAmt>108629521</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GSO CAP SOLUTION III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3348966</BookValueAmt>
        <EOYFMVAmt>3348966</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GSO CAPITAL SOLS II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3475632</BookValueAmt>
        <EOYFMVAmt>3475632</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GSO CAPITAL SOLUTION</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>417946</BookValueAmt>
        <EOYFMVAmt>417946</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HARBOUR ENERGY</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>244087504</BookValueAmt>
        <EOYFMVAmt>244087504</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG BAYSIDE III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3904650</BookValueAmt>
        <EOYFMVAmt>3904650</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG BIOVENTURE II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>18420605</BookValueAmt>
        <EOYFMVAmt>18420605</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG BRAZIL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3808092</BookValueAmt>
        <EOYFMVAmt>3808092</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG BRAZIL LATAM B</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>20121078</BookValueAmt>
        <EOYFMVAmt>20121078</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG BRAZIL LATAM C</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>20121078</BookValueAmt>
        <EOYFMVAmt>20121078</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG CAPITAL V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>17693596</BookValueAmt>
        <EOYFMVAmt>17693596</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG GROWTH B&amp;E F II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>30934699</BookValueAmt>
        <EOYFMVAmt>30934699</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG GROWTH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3936960</BookValueAmt>
        <EOYFMVAmt>3936960</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG MID MARKET II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>21131884</BookValueAmt>
        <EOYFMVAmt>21131884</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG MID MARKET III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5892715</BookValueAmt>
        <EOYFMVAmt>5892715</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG BREYER</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3622962</BookValueAmt>
        <EOYFMVAmt>3622962</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG CHINA CAP III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>33453637</BookValueAmt>
        <EOYFMVAmt>33453637</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG CHINA VTR IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>40828775</BookValueAmt>
        <EOYFMVAmt>40828775</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG CHINA VTR V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>45266218</BookValueAmt>
        <EOYFMVAmt>45266218</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG-ACCEL CHINA CAP</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19941265</BookValueAmt>
        <EOYFMVAmt>19941265</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG-ACCEL CHINA GWTH</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>17001054</BookValueAmt>
        <EOYFMVAmt>17001054</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IRON POINT IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19326121</BookValueAmt>
        <EOYFMVAmt>19326121</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>JPM PEG SECONDRY III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7398507</BookValueAmt>
        <EOYFMVAmt>7398507</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>MHR AXIOM</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>130163165</BookValueAmt>
        <EOYFMVAmt>130163165</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>MHR INST PARTNERS IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>53702525</BookValueAmt>
        <EOYFMVAmt>53702525</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>NEWMARKET IIFC</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>28151533</BookValueAmt>
        <EOYFMVAmt>28151533</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ASIA III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>46543663</BookValueAmt>
        <EOYFMVAmt>46543663</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ASIA IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>14622698</BookValueAmt>
        <EOYFMVAmt>14622698</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ISRAEL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8495791</BookValueAmt>
        <EOYFMVAmt>8495791</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ISRAEL II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19994911</BookValueAmt>
        <EOYFMVAmt>19994911</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED PI VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>13579228</BookValueAmt>
        <EOYFMVAmt>13579228</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED PI VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>25075044</BookValueAmt>
        <EOYFMVAmt>25075044</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED PI VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>13269232</BookValueAmt>
        <EOYFMVAmt>13269232</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ROYALTY II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2700553</BookValueAmt>
        <EOYFMVAmt>2700553</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEP IV CORE</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>24547</BookValueAmt>
        <EOYFMVAmt>24547</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEP IV SUPPL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6620</BookValueAmt>
        <EOYFMVAmt>6620</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEP VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>10582867</BookValueAmt>
        <EOYFMVAmt>10582867</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO GROWTH</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>58909417</BookValueAmt>
        <EOYFMVAmt>58909417</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO GROWTH II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16020456</BookValueAmt>
        <EOYFMVAmt>16020456</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO HEALTHTECH I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8483389</BookValueAmt>
        <EOYFMVAmt>8483389</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO SPV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22465094</BookValueAmt>
        <EOYFMVAmt>22465094</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO VI, LP</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>32581826</BookValueAmt>
        <EOYFMVAmt>32581826</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO VTR VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>39038518</BookValueAmt>
        <EOYFMVAmt>39038518</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO VTR VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9600875</BookValueAmt>
        <EOYFMVAmt>9600875</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>RIDGEWOOD III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>47262943</BookValueAmt>
        <EOYFMVAmt>47262943</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>RIDGEWOOD IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>20839295</BookValueAmt>
        <EOYFMVAmt>20839295</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>S CAPITAL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>28861155</BookValueAmt>
        <EOYFMVAmt>28861155</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>S CAPITAL II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8110693</BookValueAmt>
        <EOYFMVAmt>8110693</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA CAPITAL FUND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>14513399</BookValueAmt>
        <EOYFMVAmt>14513399</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA CH GWTH VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>17764152</BookValueAmt>
        <EOYFMVAmt>17764152</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA CH VTR VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4007521</BookValueAmt>
        <EOYFMVAmt>4007521</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA CHINA GR III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>64873538</BookValueAmt>
        <EOYFMVAmt>64873538</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA CHINA GR IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22456554</BookValueAmt>
        <EOYFMVAmt>22456554</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA CHINA GRTH V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>31877099</BookValueAmt>
        <EOYFMVAmt>31877099</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA CHINA VE VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6961358</BookValueAmt>
        <EOYFMVAmt>6961358</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA CHINA VTR IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12117192</BookValueAmt>
        <EOYFMVAmt>12117192</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA CHINA VTR V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9516172</BookValueAmt>
        <EOYFMVAmt>9516172</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA CHINA VTR VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8435406</BookValueAmt>
        <EOYFMVAmt>8435406</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA GBL GRTH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>126509054</BookValueAmt>
        <EOYFMVAmt>126509054</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA GG 3 CH ANX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8055631</BookValueAmt>
        <EOYFMVAmt>8055631</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA GLB GROWTH</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>58737501</BookValueAmt>
        <EOYFMVAmt>58737501</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA GLB GRWTH II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>46203352</BookValueAmt>
        <EOYFMVAmt>46203352</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA IND GWTH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>10112804</BookValueAmt>
        <EOYFMVAmt>10112804</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA IND VTR VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2976104</BookValueAmt>
        <EOYFMVAmt>2976104</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA INDIA V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16011246</BookValueAmt>
        <EOYFMVAmt>16011246</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA INDIA VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12021946</BookValueAmt>
        <EOYFMVAmt>12021946</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA ISRAEL V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8061256</BookValueAmt>
        <EOYFMVAmt>8061256</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA SCOUT III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2319529</BookValueAmt>
        <EOYFMVAmt>2319529</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA SCOUT IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>383454</BookValueAmt>
        <EOYFMVAmt>383454</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GROWTH V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3644549</BookValueAmt>
        <EOYFMVAmt>3644549</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GRTH VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>14487067</BookValueAmt>
        <EOYFMVAmt>14487067</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GRWTH VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>17899869</BookValueAmt>
        <EOYFMVAmt>17899869</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GWTH IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8210652</BookValueAmt>
        <EOYFMVAmt>8210652</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GWTH VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>13536477</BookValueAmt>
        <EOYFMVAmt>13536477</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US VENT XVI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7127542</BookValueAmt>
        <EOYFMVAmt>7127542</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US VTR XIV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>33485268</BookValueAmt>
        <EOYFMVAmt>33485268</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US VTR XV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8007347</BookValueAmt>
        <EOYFMVAmt>8007347</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US VTR XVII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2734071</BookValueAmt>
        <EOYFMVAmt>2734071</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SQUOIA GG 3 US IN AX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12398506</BookValueAmt>
        <EOYFMVAmt>12398506</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>STARWOOD X</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>27691411</BookValueAmt>
        <EOYFMVAmt>27691411</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>STARWOOD XI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>46862402</BookValueAmt>
        <EOYFMVAmt>46862402</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>STARWOOD XII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6883036</BookValueAmt>
        <EOYFMVAmt>6883036</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>TAURUS RESOURCES II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>32766833</BookValueAmt>
        <EOYFMVAmt>32766833</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>WTI VLL IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16144368</BookValueAmt>
        <EOYFMVAmt>16144368</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>WTI VLL VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11404600</BookValueAmt>
        <EOYFMVAmt>11404600</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>WTI VLL VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>21471065</BookValueAmt>
        <EOYFMVAmt>21471065</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>WTI VLL X</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1869752</BookValueAmt>
        <EOYFMVAmt>1869752</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>YORK CO INVEST 1</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1745106</BookValueAmt>
        <EOYFMVAmt>1745106</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>YORK DISTRESSED III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>50404072</BookValueAmt>
        <EOYFMVAmt>50404072</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>YORK DISTRESSED IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>24545279</BookValueAmt>
        <EOYFMVAmt>24545279</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>YORK EUROPEAN</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2094171</BookValueAmt>
        <EOYFMVAmt>2094171</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>YORK EUROPEAN II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>35947200</BookValueAmt>
        <EOYFMVAmt>35947200</EOYFMVAmt>
      </InvestmentsOtherGrp>
    </InvestmentsOtherSchedule2>
    <LandEtcSchedule2 documentId="RetDoc2059000001">
      <LandEtcGrp>
        <CategoryOrItemTxt>FURNITURE, FIXTURES AND EQUIPMENT</CategoryOrItemTxt>
        <CostOrOtherBasisAmt>2533661</CostOrOtherBasisAmt>
        <AccumulatedDepreciationAmt>1473077</AccumulatedDepreciationAmt>
        <BookValueAmt>1060584</BookValueAmt>
        <EOYFMVAmt>1060584</EOYFMVAmt>
      </LandEtcGrp>
      <LandEtcGrp>
        <CategoryOrItemTxt>LEASEHOLD IMPROVEMENTS</CategoryOrItemTxt>
        <CostOrOtherBasisAmt>6857003</CostOrOtherBasisAmt>
        <AccumulatedDepreciationAmt>865085</AccumulatedDepreciationAmt>
        <BookValueAmt>5991918</BookValueAmt>
        <EOYFMVAmt>5991918</EOYFMVAmt>
      </LandEtcGrp>
      <LandEtcGrp>
        <CategoryOrItemTxt>WORK IN PROGRESS</CategoryOrItemTxt>
        <CostOrOtherBasisAmt>246869</CostOrOtherBasisAmt>
        <AccumulatedDepreciationAmt>0</AccumulatedDepreciationAmt>
        <BookValueAmt>246869</BookValueAmt>
        <EOYFMVAmt>246869</EOYFMVAmt>
      </LandEtcGrp>
    </LandEtcSchedule2>
    <LegalFeesSchedule documentId="RetDoc2002100001">
      <LegalFeesGrp>
        <CategoryTxt>HAROLD A MERIAM III (INVESTMENT RELATED)</CategoryTxt>
        <LegalFeesAmt>34176</LegalFeesAmt>
        <NetInvestmentIncomeAmt>34176</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
      <LegalFeesGrp>
        <CategoryTxt>LOEB &amp; LOEB LLP (GENERAL AND ADMINISTRATIVE)</CategoryTxt>
        <LegalFeesAmt>114796</LegalFeesAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>105257</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
      <LegalFeesGrp>
        <CategoryTxt>ROPES &amp; GRAY LLP (INVESTMENT RELATED)</CategoryTxt>
        <LegalFeesAmt>206358</LegalFeesAmt>
        <NetInvestmentIncomeAmt>206358</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
      <LegalFeesGrp>
        <CategoryTxt>PATTERSON BELKNAP WEBB &amp; TYLER LLP (GENERAL &amp; ADMINISTRATIVE)</CategoryTxt>
        <LegalFeesAmt>62644</LegalFeesAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>35011</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
      <LegalFeesGrp>
        <CategoryTxt>PROSKAUER ROSE LLP (GENERAL &amp; ADMINISTRATIVE)</CategoryTxt>
        <LegalFeesAmt>13675</LegalFeesAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>13675</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
      <LegalFeesGrp>
        <CategoryTxt>OTHER LEGAL FEES</CategoryTxt>
        <LegalFeesAmt>15220</LegalFeesAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>17165</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
    </LegalFeesSchedule>
    <OtherAssetsSchedule documentId="RetDoc2046600001">
      <OtherAssetsScheduleGrp>
        <Desc>ACCRUED INCOME RECEIVABLE</Desc>
        <BOYBookValueAmt>1758404</BOYBookValueAmt>
        <EOYBookValueAmt>1399923</EOYBookValueAmt>
        <EOYFMVAmt>1399923</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>DUE FROM BROKER</Desc>
        <BOYBookValueAmt>10708909</BOYBookValueAmt>
        <EOYBookValueAmt>107058082</EOYBookValueAmt>
        <EOYFMVAmt>107058082</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>RETIREMENT PLAN ASSET</Desc>
        <BOYBookValueAmt>1725098</BOYBookValueAmt>
        <EOYBookValueAmt>1898891</EOYBookValueAmt>
        <EOYFMVAmt>1898891</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>ADVANCES AND OTHER RECEIVABLES</Desc>
        <BOYBookValueAmt>13</BOYBookValueAmt>
        <EOYBookValueAmt>22058</EOYBookValueAmt>
        <EOYFMVAmt>22058</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>PREPAID FEDERAL EXCISE TAX</Desc>
        <BOYBookValueAmt>9454455</BOYBookValueAmt>
        <EOYBookValueAmt>2228391</EOYBookValueAmt>
        <EOYFMVAmt>2228391</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>PROGRAM RELATED INVESTMENTS</Desc>
        <BOYBookValueAmt>16614400</BOYBookValueAmt>
        <EOYBookValueAmt>20909674</EOYBookValueAmt>
        <EOYFMVAmt>20909674</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
    </OtherAssetsSchedule>
    <OtherDecreasesSchedule documentId="RetDoc2049800001">
      <OtherDecreasesDetail>
        <Desc>UNREALIZED LOSS ON INVESTMENTS</Desc>
        <Amt>468837509</Amt>
      </OtherDecreasesDetail>
    </OtherDecreasesSchedule>
    <OtherExpensesSchedule documentId="RetDoc2003200001">
      <OtherExpensesScheduleGrp>
        <Desc>AMERICAN DEPOSITARY RECEIPT FEE</Desc>
        <RevenueAndExpensesPerBooksAmt>16890</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>16890</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>CONSULTING REIMBURSEMENTS</Desc>
        <RevenueAndExpensesPerBooksAmt>19042</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>19391</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>CUSTODY, BANK, &amp; PERFORMANCE REPORTING FEES</Desc>
        <RevenueAndExpensesPerBooksAmt>830104</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>829889</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>215</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>FILING FEES AND PENALTIES</Desc>
        <RevenueAndExpensesPerBooksAmt>51276</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>1625</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>INFORMATION TECHNOLOGY/COMPUTERS</Desc>
        <RevenueAndExpensesPerBooksAmt>1554580</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>241219</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>1289674</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>INSURANCE</Desc>
        <RevenueAndExpensesPerBooksAmt>336673</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>39538</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>319924</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>OFFICE EXPENSES</Desc>
        <RevenueAndExpensesPerBooksAmt>791818</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>300793</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>470551</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>PORTFOLIO DEDUCTIONS</Desc>
        <RevenueAndExpensesPerBooksAmt>19483419</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>51341400</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
    </OtherExpensesSchedule>
    <OtherIncomeSchedule2 documentId="RetDoc2001500001">
      <OtherIncomeDetail>
        <Desc>FX TRANSACTION NET GAIN</Desc>
        <RevenueAndExpensesPerBooksAmt>1538224</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>1521732</NetInvestmentIncomeAmt>
        <AdjustedNetIncomeAmt>1538224</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>CLASS ACTION PROCEEDS, NET</Desc>
        <RevenueAndExpensesPerBooksAmt>26593</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>26593</NetInvestmentIncomeAmt>
        <AdjustedNetIncomeAmt>26593</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>OTHER PARTNERSHIP INCOME</Desc>
        <RevenueAndExpensesPerBooksAmt>38741078</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>44425949</NetInvestmentIncomeAmt>
        <AdjustedNetIncomeAmt>38741078</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>SECTION 951(A) INCOME INCLUSION</Desc>
        <NetInvestmentIncomeAmt>233106429</NetInvestmentIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>GRANT RECOVERIES</Desc>
        <RevenueAndExpensesPerBooksAmt>892513</RevenueAndExpensesPerBooksAmt>
        <AdjustedNetIncomeAmt>892513</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>OTHER TAXABLE INCOME</Desc>
        <RevenueAndExpensesPerBooksAmt>414</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>414</NetInvestmentIncomeAmt>
        <AdjustedNetIncomeAmt>414</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
    </OtherIncomeSchedule2>
    <OtherIncreasesSchedule documentId="RetDoc2049700001">
      <OtherIncreasesDetail>
        <Desc>DEFERRED FEDERAL EXCISE TAX BENEFIT</Desc>
        <Amt>6516842</Amt>
      </OtherIncreasesDetail>
    </OtherIncreasesSchedule>
    <OtherLiabilitiesSchedule documentId="RetDoc2065700001">
      <OtherLiabilitiesDetail>
        <Desc>DEFERRED FEDERAL EXCISE TAX</Desc>
        <BOYBookValueAmt>43954729</BOYBookValueAmt>
        <EOYBookValueAmt>37437887</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>RETIREMENT PLAN LIABILITY</Desc>
        <BOYBookValueAmt>2389093</BOYBookValueAmt>
        <EOYBookValueAmt>2509260</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>ACCRUED VACATION</Desc>
        <BOYBookValueAmt>934558</BOYBookValueAmt>
        <EOYBookValueAmt>1452558</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>DEFERRED RENT EXPENSE</Desc>
        <BOYBookValueAmt>586204</BOYBookValueAmt>
        <EOYBookValueAmt>560586</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>REFUNDABLE DEPOSITS</Desc>
        <BOYBookValueAmt>317</BOYBookValueAmt>
        <EOYBookValueAmt>319</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>GRANT REFUNDS PENDING MODIFICATION</Desc>
        <BOYBookValueAmt>1103455</BOYBookValueAmt>
        <EOYBookValueAmt>1005850</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
    </OtherLiabilitiesSchedule>
    <OtherProfessionalFeesSchedule documentId="RetDoc2002300001">
      <OtherProfessionalFeesDetail>
        <CategoryTxt>COLLER VI (INVESTMENT MANAGEMENT)</CategoryTxt>
        <Amt>826179</Amt>
        <NetInvestmentIncomeAmt>826179</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>COLLER VII (INVESTMENT MANAGEMENT)</CategoryTxt>
        <Amt>514686</Amt>
        <NetInvestmentIncomeAmt>514686</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>COLLER VIII (INVESTMENT MANAGEMENT)</CategoryTxt>
        <Amt>260342</Amt>
        <NetInvestmentIncomeAmt>260342</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>DF DENT &amp; COMPANY, INC. (INVESTMENT MANAGEMENT)</CategoryTxt>
        <Amt>896140</Amt>
        <NetInvestmentIncomeAmt>896140</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>EDWARD GILLEN (PROGRAM CONSULTING)</CategoryTxt>
        <Amt>125020</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>125020</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>FIDUCIARY MANAGEMENT, INC. (INVESTMENT MANAGEMENT)</CategoryTxt>
        <Amt>772776</Amt>
        <NetInvestmentIncomeAmt>772776</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>GAVEA INVESTMENT FUND V B L.P.</CategoryTxt>
        <Amt>538219</Amt>
        <NetInvestmentIncomeAmt>538219</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>GENESIS ANALYTICS (PROGRAM CONSULTING)</CategoryTxt>
        <Amt>135605</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>85605</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>GLOBAL HEALTH STRATEGIES (PROGRAM CONSULTING)</CategoryTxt>
        <Amt>423023</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>512839</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>GLOBAL STRATEGY GROUP LLC (PUBLIC RELATIONS)</CategoryTxt>
        <Amt>324670</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>327170</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>IFP GLOBAL EQUITY LP (INVESTMENT MANAGEMENT)</CategoryTxt>
        <Amt>1516006</Amt>
        <NetInvestmentIncomeAmt>1516006</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>OTHER CONSULTING FEES - GENERAL MANAGEMENT</CategoryTxt>
        <Amt>60982</Amt>
        <NetInvestmentIncomeAmt>4086</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>47321</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>OTHER CONSULTING FEES - GRANTS MANAGEMENT</CategoryTxt>
        <Amt>111105</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>107745</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>OTHER CONSULTING FEES - HUMAN RESOURCES</CategoryTxt>
        <Amt>12330</Amt>
        <NetInvestmentIncomeAmt>4000</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>8330</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>OTHER CONSULTING FEES - INFORMATION TECHNOLOGY</CategoryTxt>
        <Amt>44545</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>38985</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>OTHER INVESTMENT MANAGEMENT &amp; CONSULTING FEES</CategoryTxt>
        <Amt>42937</Amt>
        <NetInvestmentIncomeAmt>42937</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>OTHER PROGRAM RELATED CONSULTING FEES</CategoryTxt>
        <Amt>508285</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>513251</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>OTHER PUBLIC RELATIONS CONSULTING FEES</CategoryTxt>
        <Amt>115331</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>130835</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>OTHER RECRUITMENT FEES</CategoryTxt>
        <Amt>50838</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>73947</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>PRECISION ADVISORS, LLC DBA PRECISION FOR VALUE, LLC (PROGRAM CONSULTING)</CategoryTxt>
        <Amt>178684</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>188381</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>SCOTT KAHN (PROGRAM CONSULTING)</CategoryTxt>
        <Amt>194890</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>207265</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>SOLUTION SIMPLE (INFORMATION TECHNOLOGY)</CategoryTxt>
        <Amt>246425</Amt>
        <NetInvestmentIncomeAmt>29416</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>210297</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>T. ROWE PRICE ASSOCIATES INC. (INVESTMENT MANAGEMENT)</CategoryTxt>
        <Amt>694426</Amt>
        <NetInvestmentIncomeAmt>694426</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>WILSHIRE ASSOCIATES INCORPORATED (INVESTMENT ADVISORY)</CategoryTxt>
        <Amt>438320</Amt>
        <NetInvestmentIncomeAmt>438320</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
    </OtherProfessionalFeesSchedule>
    <TaxesSchedule documentId="RetDoc2002500001">
      <TaxesDetail>
        <CategoryTxt>STATE UNRELATED BUSINESS INCOME TAX</CategoryTxt>
        <Amt>1777255</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
      <TaxesDetail>
        <CategoryTxt>FOREIGN TAXES WITHHELD</CategoryTxt>
        <Amt>530184</Amt>
        <NetInvestmentIncomeAmt>3095765</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
      <TaxesDetail>
        <CategoryTxt>FEDERAL EXCISE TAX</CategoryTxt>
        <Amt>13726064</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
    </TaxesSchedule>
    <TransfersFrmControlledEntities documentId="RetDoc2204900001">
      <TransfersFromControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ACADIAN FRONTIER MARKETS EQUITY FUND</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>260 FRANKLIN STREET</AddressLine1Txt>
          <CityNm>BOSTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02110</ZIPCd>
        </USAddress>
        <EIN>205852756</EIN>
        <Desc>DISTRIBUTION FROM PARTNERSHIP</Desc>
        <Amt>1204747</Amt>
      </TransfersFromControlledEntGrp>
      <TransfersFromControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>CHATHAM CO-INVEST</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>26 MAIN STREET SUITE 204</AddressLine1Txt>
          <CityNm>CHATHAM</CityNm>
          <StateAbbreviationCd>NJ</StateAbbreviationCd>
          <ZIPCd>07928</ZIPCd>
        </USAddress>
        <EIN>850651355</EIN>
        <Desc>DISTRIBUTION FROM PARTNERSHIP</Desc>
        <Amt>0</Amt>
      </TransfersFromControlledEntGrp>
      <TransfersFromControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>LACM GLOBAL EQUITY FUND LP</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>11150 SANTA MONICA BLVD STE 200</AddressLine1Txt>
          <CityNm>LOS ANGELES</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>90025</ZIPCd>
        </USAddress>
        <EIN>453646231</EIN>
        <Desc>DISTRIBUTION FROM PARTNERSHIP</Desc>
        <Amt>0</Amt>
      </TransfersFromControlledEntGrp>
      <TransfersFromControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>LACM WORLD SMALL CAP EQUITY FUND LP</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>11150 SANTA MONICA BLVD STE 200</AddressLine1Txt>
          <CityNm>LOS ANGELES</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>90025</ZIPCd>
        </USAddress>
        <EIN>832888004</EIN>
        <Desc>DISTRIBUTION FROM PARTNERSHIP</Desc>
        <Amt>0</Amt>
      </TransfersFromControlledEntGrp>
      <TransfersFromControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>ORION HOUSE 5 UPPER ST MARTINS LANE</AddressLine1Txt>
          <CityNm>LONDON</CityNm>
          <CountryCd>UK</CountryCd>
          <ForeignPostalCd>WC2H 9EA</ForeignPostalCd>
        </ForeignAddress>
        <EIN>611915057</EIN>
        <Desc>DISTRIBUTION FROM PARTNERSHIP</Desc>
        <Amt>0</Amt>
      </TransfersFromControlledEntGrp>
      <TransfersFromControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>MHR LONGEVITY PARTNERS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1345 AVENUE OF THE AMERICAS 42ND</AddressLine1Txt>
          <AddressLine2Txt>FLOOR</AddressLine2Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10105</ZIPCd>
        </USAddress>
        <EIN>981471155</EIN>
        <Desc>DISTRIBUTION FROM PARTNERSHIP</Desc>
        <Amt>55474168</Amt>
      </TransfersFromControlledEntGrp>
      <TransfersFromControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER LP</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2929 ARCH STREET 17TH FLOOR</AddressLine1Txt>
          <CityNm>PHILADELPHIA</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>19104</ZIPCd>
        </USAddress>
        <EIN>981142649</EIN>
        <Desc>DISTRIBUTION</Desc>
        <Amt>0</Amt>
      </TransfersFromControlledEntGrp>
      <TotalAmt>315126035</TotalAmt>
    </TransfersFrmControlledEntities>
    <TransfersToControlledEntities documentId="RetDoc2205000001">
      <TransfersToControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ACADIAN FRONTIER MARKETS EQUITY FUND</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>260 FRANKLIN STREET</AddressLine1Txt>
          <CityNm>BOSTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02110</ZIPCd>
        </USAddress>
        <EIN>205852756</EIN>
        <Desc>MANAGEMENT FEE</Desc>
        <Amt>1204747</Amt>
      </TransfersToControlledEntGrp>
      <TransfersToControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>MHR LONGEVITY PARTNERS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1345 AVENUE OF THE AMERICAS 42ND</AddressLine1Txt>
          <AddressLine2Txt>FLOOR</AddressLine2Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10105</ZIPCd>
        </USAddress>
        <EIN>981471155</EIN>
        <Desc>CONTRIBUTION OF CAPITAL</Desc>
        <Amt>55474168</Amt>
      </TransfersToControlledEntGrp>
      <TransfersToControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>PITANGO SPV</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>BEIT ACKERSHTEIN - BLDG B 11</AddressLine1Txt>
          <AddressLine2Txt>HAMENOFIM ST 11TH FL</AddressLine2Txt>
          <CityNm>HERZLIYA</CityNm>
          <CountryCd>IS</CountryCd>
        </ForeignAddress>
        <EIN>981492234</EIN>
        <Desc>CONTRIBUTION OF CAPITAL</Desc>
        <Amt>1065000</Amt>
      </TransfersToControlledEntGrp>
      <TotalAmt>57743915</TotalAmt>
    </TransfersToControlledEntities>
  </ReturnData>
</Return>
